var title_f31_22_32096="Iridodialysis I";
var content_f31_22_32096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Iridodialysis I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of a patient following blunt trauma. There is a hyphema in the form of a blood clot in the anterior chamber. A small iridodialysis is at 3:00 at the iris insertion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Kathryn A. Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32096=[""].join("\n");
var outline_f31_22_32096=null;
var title_f31_22_32097="Technique for deep suture";
var content_f31_22_32097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Technique for placing a dermal suture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Absorbable suture material should be used for dermal sutures. The knot is buried by placing the suture using an inverted technique in which the suture loop begins in the dermis. The needle is directed toward the skin surface, exiting near the dermal-epidermal junction. It is then inserted into the opposite side of the wound directly across from the point of exit. The loop is completed in the dermis at the level where the needle was initially placed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32097=[""].join("\n");
var outline_f31_22_32097=null;
var title_f31_22_32098="Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)";
var content_f31_22_32098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/3/31793\">",
"         Patient information: Evaluating memory and thinking problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/24/1411\">",
"         Patient information: Time to stop driving? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/37/14934\">",
"         Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tips-for-caregivers-of-people-with-alzheimer-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H23375932\">",
"      <span class=\"h1\">",
"       What plans should we make for the future?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After your family member is diagnosed with Alzheimer disease, you will need to make plans for his or her:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Living situation &ndash; If he or she lives alone, you need to make sure he or she is safe. If he or she can&rsquo;t live alone, you need to make a plan. You might have him or her live at home with help, or move to a nursing home. &nbsp;",
"       </li>",
"       <li>",
"        Decision-making &ndash; Early on, your family member should choose a &ldquo;power of attorney.&rdquo; A power of attorney is someone who can make decisions for him or her when he or she is no longer able to.",
"       </li>",
"       <li>",
"        Money &ndash; People have trouble understanding how to manage their money as their disease gets worse. If your family member takes care of his or her own money, you need to check that he or she does it correctly.",
"       </li>",
"       <li>",
"        Driving &ndash; If your family member still drives, talk with the doctor about when he or she should stop. The right time to stop is different for each person.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23375947\">",
"      <span class=\"h1\">",
"       How can I make the home safe?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help keep your family member from getting hurt around the house, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keep walkways clear of clutter. If you have loose rugs, remove them or tack them down.",
"       </li>",
"       <li>",
"        Put a handrail and nonslip mat in the bathtub or shower.",
"       </li>",
"       <li>",
"        Put child-proof locks on cabinets with dangerous items (such as matches or medicines). You can also put child-proof covers on the stove.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23375962\">",
"      <span class=\"h1\">",
"       How can I keep my family member from wandering away?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To keep him or her from wandering away or getting lost, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lock the outside door. If your family member can unlock the door, put another lock on the door that he or she can&rsquo;t reach.",
"       </li>",
"       <li>",
"        Have him or her wear or carry identification at all times.",
"       </li>",
"       <li>",
"        Put a system in your home that lets you know when people enter or leave.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23375977\">",
"      <span class=\"h1\">",
"       How can I make daily activities easier?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To make your daily activities easier, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Schedule appointments, visits, and activities for times of the day when your family member is at his or her best.",
"       </li>",
"       <li>",
"        Do activities he or she enjoys or can still help with.",
"       </li>",
"       <li>",
"        Allow extra time for activities or to get where you are going.",
"       </li>",
"       <li>",
"        Stick to a routine, and avoid new or crowded places.",
"       </li>",
"       <li>",
"        Use simple words, short sentences, and a calm voice (but don&rsquo;t use &ldquo;baby talk&rdquo;). When you give directions, give only 1 direction at a time.",
"       </li>",
"       <li>",
"        Not give him or her too many choices. For example, offer only 2 choices for lunch.",
"       </li>",
"       <li>",
"        Buy clothes and shoes that are easy to put on and take off.",
"       </li>",
"       <li>",
"        Remember that it doesn&rsquo;t help to argue. Try to move on to something else.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23375992\">",
"      <span class=\"h1\">",
"       How can I avoid bladder or bowel accidents?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can avoid accidents by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having your family member use the toilet every few hours.",
"       </li>",
"       <li>",
"        Not giving him or her drinks before bedtime.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23376007\">",
"      <span class=\"h1\">",
"       What if my family member isn&rsquo;t eating enough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To get him or her to eat more, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Give him or her many small meals each day, instead of 3 large ones.",
"       </li>",
"       <li>",
"        Give him or her high-protein or high-calorie drinks, such as shakes.",
"       </li>",
"       <li>",
"        Make food easier to eat by putting it in a bowl or cutting it up.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23376022\">",
"      <span class=\"h1\">",
"       How can I help my family member sleep better at night?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help him or her sleep better at night, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not let him or her nap during the day.",
"       </li>",
"       <li>",
"        Make sure he or she gets enough exercise during the day (but not right before bedtime).",
"       </li>",
"       <li>",
"        Move bedtime to a later time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23376037\">",
"      <span class=\"h1\">",
"       What if my family member&rsquo;s behavior changes suddenly?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If his or her behavior changes suddenly, call the doctor or nurse. It could mean that your family member has an infection. That&rsquo;s because symptoms of Alzheimer disease often get worse when people get infections, especially bladder or lung infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23376052\">",
"      <span class=\"h1\">",
"       What if I am having a hard time?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are having a hard time, let the doctor or nurse know so that he or she can find ways to get you help. Taking care of a person with Alzheimer disease is a tough job, and it usually gets harder as the disease gets worse. Don&rsquo;t feel bad or guilty about asking for help. Also, make sure to ask for help if your family member hurts or threatens you.",
"     </p>",
"     <p>",
"      One way to get help is to take a break from caregiving. You can hire an aide to help you bathe, dress, or feed your family member. You can also find an adult day care program for your family member to go to during the day.",
"     </p>",
"     <p>",
"      Another way to get help is to join a support group for caregivers of people with Alzheimer disease.",
"     </p>",
"     <p>",
"      The Alzheimer&rsquo;s Association has a lot of information for caregivers. Their website is",
"      <a class=\"external\" href=\"file://www.alz.org/\">",
"       www.alz.org",
"      </a>",
"      . Their toll-free phone number in the US is 1-800-272-3900.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23376067\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/3/31793?source=see_link\">",
"       Patient information: Evaluating memory and thinking problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/24/1411?source=see_link\">",
"       Patient information: Time to stop driving? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/22/32098?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16421 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32098=[""].join("\n");
var outline_f31_22_32098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23375932\">",
"      What plans should we make for the future?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23375947\">",
"      How can I make the home safe?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23375962\">",
"      How can I keep my family member from wandering away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23375977\">",
"      How can I make daily activities easier?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23375992\">",
"      How can I avoid bladder or bowel accidents?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23376007\">",
"      What if my family member isn&rsquo;t eating enough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23376022\">",
"      How can I help my family member sleep better at night?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23376037\">",
"      What if my family member&rsquo;s behavior changes suddenly?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23376052\">",
"      What if I am having a hard time?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23376067\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/3/31793?source=related_link\">",
"      Patient information: Evaluating memory and thinking problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/24/1411?source=related_link\">",
"      Patient information: Time to stop driving? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_22_32099="Etomidate: Patient drug information";
var content_f31_22_32099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Etomidate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"     see \"Etomidate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"     see \"Etomidate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amidate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amidate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put you to sleep for surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702089",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to etomidate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12170 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-85B74C0F79-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32099=[""].join("\n");
var outline_f31_22_32099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169137\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011845\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011844\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011848\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011849\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011851\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011847\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011852\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011853\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=related_link\">",
"      Etomidate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=related_link\">",
"      Etomidate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_22_32100="Distal pancreatectomy with splenectomy";
var content_f31_22_32100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Distal pancreatectomy with splenectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Operative bed following distal pancreatectomy and splenectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32100=[""].join("\n");
var outline_f31_22_32100=null;
var title_f31_22_32101="FNH trichrome";
var content_f31_22_32101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal nodular hyperplasia of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy specimen showing the fibrous septae and a large, thick-walled artery at the edge of the stellate scare (arrow). (Klatskin trichrome stain X 10).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frank A Mitros, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32101=[""].join("\n");
var outline_f31_22_32101=null;
var title_f31_22_32102="Prenatal ultrasound image of first trimester umbilical cord cyst";
var content_f31_22_32102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of first trimester umbilical cord cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 511px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH/AUoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6F8c+LrXwfYWVzd2V9em7uhaRRWYj3l/LeTJ8x0UDbG3f04rzzxB+0J4e8PC3OseH/EluJ93l/u7V92MZ+7OcdR1rT/aCbbpHhc/9Rn/2zuq+W/ju++LQ/bzv/Za4pYiaxUaFtGr+fU7IYeLw0qz3Tt+R9BRftN+E5rOa7i0DxY9pCQJZls4SiE9AzebgZ96rH9qrwQOuleJf/AeD/wCPV8YJczpA8KTSLC5BeMMQrEeo71FXacZ9qf8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+CP+gV4k/8AAeD/AOPUqftT+CXdUTSfEpZjgAW8HJ/7/V8VCuw+Genx3PiBby6l8i2sgJTMTwr/AMH6/wAqipNU4Ob6GlKm6k1BdT7Aj+P+gySLGnh7xGXYbgoS1zj/AL/1Inx50Z4GmHhvxKEXO7clqpGPUG4zXg8waG+cPqtv+/5idIcge+f51m3xku7jbdhZlVcLJCGHXjLD0ryVmFVvRL8f8z1Xl1JLd/18j6Hf4/6BG2JND15CcY3NZjOfT/SKS6+P2iWrwLL4Y8VFp8+WEt7d92PTbOa+fJLKOJ4VsrJpYY0wRIoAY9ypPPPpUfmWBvLW4htLtIEJ3Llg35VazCb6IUsuh0bPd5/2l/C1vOYJvD3i1JgcFGsoc5+nm1Vb9qjwUjlH0jxMrA4INtACD/3+rzO81jT7qaC3jJtY1jLNLITnP8IHekXUwszpaQW8rlM+aVVHkPbGetKOaP7UPxJeWLpL8D1H/hqDwftDf2J4p2ngH7JDg/8AkarMP7SXhmeN5IfDvi10T7xFnDx/5GrwZp7nUmaWeQ2wDGN/MwfLI6MAO9ZLSrJN9nX7T5jZQThiu8d2wetbLHN7L8SP7PS3Z9KXX7Rfhq1VWn0PxGAwyAEtWJ/AT0Wv7Rnhq6GYNC8SN148u2B/Iz5r550/w3ZR2Ukl3M0MI4ARwWdv89qjs7CdIGubZfs43fv3lHlggehPT6VH9oX+EtZcu7PpKL4/6HLMYo/DniYyAZK+VbZ/9H9fapl+O2kNs2+GvE3zHA+S16+h/f8AH418/wClCBIo7qWO9+1plwI+Qc/xZpguLZblrmZ7m4QnKQQuFVCe3XJPvWX9o1b2SX4/5mn9m0rXu/w/yPoSP466RJM8S+G/EnmJ1Ui0BH53FUh+0T4caMuNB8SFA+wny7XGf+//AOtfPcX9oNcqml20v2NiSyE7zk9Ru7mtdNOubWXyxaNJbJEDu42Rc8/U03mFRdF/XzBZdTls3/XyPa/+Gi/DhKY8P+JzvztxDbndj0/f05/2iPDiyKh0HxGSeBtS1Iz6ZE+M+1eLSWKwWLyR3kLR3C5BuPv4PUADoKvfZLXULfTI9EtHlntZQxEK7YosDktn271DzSXZDWWU+7/r5HtB+Ouki2muG8M+JkhhGXZ0tVx9Mz8/QU1vjxootopz4d8R+VL9w4tOfw+0ZryWZCPst3e3CmPc2LdE3FvcAVzUq6ct7MtvbTzbgc7nxGnOcAD9cVMc0qy6L8f8xvLKS6v+vke7D9oXw8Z1hXw/4lMjdAI7U/8Atfipz8etFUTsfDfiYLAMyHy7XC+2fP6+1eBabcT3Orxy3kCw2MIyGiTavTg+tWbmeWWO4FrElnCHAiikOXYnq7574q3mNVO1l/XzJWXUrbv+vke7H476MsUUr+HPEipKMpuW0Un8DcZFOPx00gWZuz4a8SC3H8ZW0A/9KK8Ot9Xsrif7PMAlvCQRM5BaU45I9qo6leQLIPISdNPkkDuudwHpgdtxpf2jXvblX4/5jeW0V1f4f5Hv8vxz0qK3knfwx4m2JH5rAJaltvrtE+4/lXOH9qnwQODpXiXP/XvB/wDHq8d1TUkS5WK2llijzlnfh5n+p6Y/KuX8R+F7TUIhNpWVulP7yRidlwx7Aeue/Q104fHuWlVWOavgOVXpO59Ff8NV+CP+gV4l/wDAeD/49R/w1X4H/wCgV4k/8B4P/j1fGV3bT2lw8FzE8UyHDI4wQagxXpb7Hmn2p/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfav/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxVRQB+gvwv+Nfhz4j6/caRodlq8FzBatds15FGqFFdFIBWRjnLjt616fXxX+xT/yVPVf+wLL/AOj4K+1KAPJv2izt0Hwyf+oyP/SS5r5V+ND700b283+a19S/tKtt8NeGz/1GR/6SXNfKHxZcPHpXfHmf+y1501/t0X5f5no03/sUl5/5HnJpKU9BSV6J5wUUUUAFFFFADlr2zwn4ftNN8OxW2pWbC6uYxcO5RgylgMD04GMfjXnnwz0D/hIvGdhZMf3Kt58pxn5U5x+JAH419V3L2+oyWsJtA1zOSuHQqQR1G6vFzbF+z5aUd3qetllDmvUkecWljp0dkRcRsJsBIpweGPYEdvqKr3Xh/Y8b3k5ZZBsSMDDAnnkjqPrXSaho9xoupzRRb7m12+a1vLHvaIjuMdRWdBNN/aRe5sZI0mGI5o/lCj/dNeQqkr3TPY5Y2sjMk082WmR/ary18+PP3SGY+2OxxVOx8sXW+CW8tYfLyHCBlZ++RVubTYYZpG0+2bUYpGAkmkIYA/0NaGmabe2O69jki+wMMNbCUOWbPcHqa0U0k9Rct2Yl5Y3lxawvEpM8bF944dvz6CmrCtuWh1NXaaSPcMHzSD6gjoRXSajNe6hFFNDJ/ZqofmE0QKyexXrVEyl7WSzmvLdkzl0ig2s3pjPIoVR2VyXG17GRpqX0LBTGzsy5cSuCHXsc44x6VYmtJ1drWEQx718x7mLLgD0y3ApNMvYLZXhkW4e9Z9kUAUrGoz1DH730rSGnTWcs1wyX9xAF/wBXKipFn/Y/wpuVnd6Akc7otu8PiFViNvJuXMeDlc+p45roYXkmN3HqcVpPLCNsKkEopPqKig+wWzRXlrFi5umPyOwAi9yOwqugNnO2oC9gu/M/dh4YmPlt6kHr9aJPndwSsStdanY6e8dgzyyv80qRwgkL3IPYVDc6e6WtrMtqsaHErs8gBK9wwXqTV201CS9M0cl+0kzAJJ8pWMD8uT+lTXugC0slS3Tzc/OwaTazHsfp7VPPbRlcvYwbTXtRlup7aOFLe0+8XiTPkofQev1rbN9d6QtsNMSa7t3wMTnqx4AA6+/NKtrFp8CtPbW/mON7mJdqr6Es3Ws37Xe26iSbV4Ui+8oADzS+2egHvRLlqbISTitSxbabd3mp3Ut1ParIVxMx6o3dR/XFT3EjWFq4026axkmG0s65Mo/3f8ahEmnXWoxLEZlvDxvRNyEd8/411j6Dc3VrbXOnIrRI+5hOBmXtuJ9uwrOVSzVyraHE6FPDbxrYxCea6bJPmHaB6t64o1S5bTpTbaZKvmsh80iP19K2rPRF1HXbidZ2hmIERkkwMY/hHrXUax4ft9J0b7QNr3kxCLI2GbcTjj39qbrQUroVtLSPPPDDizx58Mkks7E7CCxGONzk/d9hXQwaE+u3HlxL5VimXnl2/NKT2ya6z+wdE8P6Eryt9quPvEM+S7+/c1zL6vrjzJFbQSPMT+7ijj2xoP72O+B3NTKTlJuIR+Ez/EXhBWCW2nW8CTcM3PCgD5Rn9T+VZWn+FRZoUkne4u4/3uR0HoTn1/QVravdamrTQCZPtC42xgFs9zuI/lS6fBqd/PLZyb4mmXzpZJVx8gH/AI6g/WqjUqKNrg4Rvcq2vhj+1mF1qV2r28KnIVcbs9gaZYaNcT3klvYMIr2eYxQDG7YgHLH0GOMVq6FBdXt08On/AOkrE4wZOAxPfjjA7Ustre6fql81tqKGaBTEEUfflbrgeg9aXtZPRsdlbQ5Hx14WtNU1T7DHNPcT2iFZLlF3FTjhfcZ7fWvJfE3h++8Oaj9k1GNQzKHjkQ7kkU91P6exFfRvgHw7Ne/bEurj5Y5SZDnmR8d/YV0uteF9DvNBkstWgMtmwIijztkllxw6t1UL27eua78PmLoNQl70TgxWCjV1jpI+NaSu18d+Br3w3m7gLXeiSSmOG8xjn+6w7H36HtXFkc19BTqRqx5oO6PDnCVN8slZiUUUVZB9AfsU/wDJU9V/7Asv/o+CvtSviv8AYp/5Knqv/YFl/wDR8FfalAHjn7T52+E/DxHbWV/9Jbmvkv4myb000enmf0r6v/aoO3wboB/6jSf+k1zXyN4/felh9X/pXHJf7VF+X+Z3Qf8Askl5/wCRxppKtl7YWO3ypDdeZkS+YNuzH3duOuec5/CqtdhwiUUUUAFOH0ptTWsYlmRCcBmAJ9B3NGw0r6I+hf2evDNmmgXWp3wmjvb1sQSxn/VxLxkr3y2T9FFdwrarDrZsJ7n7QAN0csICO6/Q9CK890PxdHILPTpSLjTrZBHbrGGjMSqPlANb974hC+V9mI8yIb1aZvnb/YH+NfI4z2lStKclvt5H0+GhGnTUE/U2dbu9Ym1WDzZXUxAiOR8IzfiO/wBas2fiOJreZZtHtbmcqRJIAA6t6MP8K5+fU/t8cU019diQkM8O1WVB6yd8D1Fab2keoBYrJornf87vaA7eOxOevtXK/d+I6LJ6IyZZhJGLeCUwzNIPNtxGPlX+8GHGKu3ejIlxbSyWrzyxfdVUzHJn3HT61aXTU8qcafcyGcDMlqi/xe+elPsor2zlLXJlu5pFx9kHysq+3OKTl/KVYoX2ktcXCGe0u7EcFQriXJ9R6Vo3OhwXOmB3vHedeBKVUMPxHNaGoanfnSJRYweU+3Coy75E9avaHqS3GkqLDS1lmTAdc7TnvzS5m9bkvTocP/ZjNexSNbveSx/declRn/ZHrVrULK5Ko01tJLEp3GKaXbCmO+TXU6vptpepuukurZz9+N33onvx0p0HlQaZ9hS6gvwF/dPJFnaPf1odRvdh02OF1GxhKpeRwGRIiJGaIgoSOgz6VJBLJcXUk17LAiORsjhYFiOw2elb8ctnBFJHq8flPkhWELMT7pjjHtioptRWwkTyYre5EjbAwRUf6n3p+0drMLFWO3vdReSKXT2kP3TEoyVXtuI4H0pn2NbSOSO3kCXyYJilYgfgTzWza6hNp9tJNBJejzDtMaxjYpP+1VqwkfTbNSLXzLh2Pzy4kZs+57VPMBjaRpGqsd98sH2Wb5wjt5q5/r9KtXmi2ca7r9ZLq/nUiK3SIIkY7A4pLy6vb3UBbWt8Vm2lpPs6bViA7Htmqvl3iXLRXmsTIbj5YxCRJIT3B+v6U7tu47dze8KWdlpllJb3jWR1S4JIijUBkT+gpuoRtdO8MtwsMKDYfKYsBnsvqfftUlh4MP2fz/KW1vUX5pvO3uw/usx7mrJ0WKzt5NRuYhEkK/6l7nr7nsM0TUm0ZxlFXdzn5Lm2RWt9I05vItxseVun/fXrVpdImuYoILq8s5QmZFWOTCo3ueuAP1rTl8Q6Vp9uG1O+svJwF+zwD5IQe/qWPTNc5rHjDSrK3mtNKtLZYJ1zhjh2HoPaqUJPZBz+R1lnZWps1/siCO4gtxiW+I+XI67Sev4VUuo5NM02W/uC+ZiEihX/AFsnt+P8q8+1r4jalJp1tYRi3gCcLFFwiKOn41jS+MNdjltby7AJhBEEbNwTj7x/wrb6q5bIzjOy95noiatLHJBbnQzBLKcspYZJ9D3/ABqPXHnur0aY06h7gg3jK3lpFH2j9TXkNn421JNckvEneS8k4eRl5Yf3E9B71fm8c3Uc5LJapcBsvIx3Ffb61pLA1E9BqvBo950C1stKsJAZEQIhCAAA7fXHbPam3VvYW+mS3tnYxy3rLxjBIHYZ968BufGGo7mWK7hk8z5pWA+6Pr3OK6m58bSrYaXb2QbYjb33HljjgtUywtWOjRKlGTumej6PbT2F0PtuySXYZ7lUOVV/4Ux3AFSa7cB5bWYWwlkmcRFHPzNn27D19K8nl8byxq6RagEZz5krRruc+wrNsfHlzFqTvcMyzsNiM/PkKTyfqe9SsLVcdtCnUjzJtnq11Zvr5+xusYhV/LkLKNhjXluOm3sBXiHxP+G8Frqd3d+DoppLBQXe0kYGRB3Kd2X0HJ4716yfGWl6XYoifPLLhUjxzIffH51n6D4gtvt32uNGmkVt5nbux757AdAKvC162E96K07dycRh4Yj4t+58ukU2voD4j+BrHxPBda7pbQ2esM43W6BUhn7c44WQ+o4PfnmvCb+yuLG8mtbuB4LiFikkbjBUj1r6fDYqGJjeO/Y+fr4adB2ktO57t+xT/wAlT1X/ALAsv/o+CvtSviv9ioY+Kmq/9gaX/wBHwV9qV0HOeJ/tYHb4H0E+mtJ/6TXFfIPjN962XqN/9K+uv2uG2+AdDP8A1GU/9JrivjzxQ+5bXPbd/SuaS/fp+X+Z1xf+ztef+RgHpTacelNrpOQKKKKAFFa/h8rDc+dLC0i/dUjsfWsitaO7NtZosMinI5HcH3FRUV42XU1pWUrvodPp2pWiBrf7VLbqW+4eMH2q4XvYRzdtdRqdwBPQVx9vdR3MJSeElv70fJ+uKn2NGoMEt3x/eBA/+tXDOgup6MK/Nsd7omqzxoXMdo4PBdGPA9K0dM8Q2un3LLYPc2tyQRiNt0f1GP5V5jFei0vUntyZyw+dQTk+9ba3ulTIbhxHE7dQ+chvfFYVMIlrbRm1PFXVj1bSfHUNvFFHO6+Sh/fgAh5j2JNa7+NdA+0eZZ2c8bsOZ0O5lPpzXjmlXQaKRI7mCTGcMv8AgaS2uks0kaW8iEjNl2I4auGWBhdo6ViXa57vo/ibw7qG77SrwXbcl5GKu3vWVd+KLXSZL0RPbmEnMe1iXJPc148ZbW8uBLPIlwwGAFl4ANNFz5E3kQx3UNtjI8oAhj7k9KSy+PcFib6HqFn4y3xo95FezR4JVYiDn6ite1+I9ugSEWMlnP1a4ljBAX0AFePyXlw42288Nu46AN8/4moHmntyJZrrOD8xdy2apYCDfn8wddnuS/EfQtR229xDJcXEbbUnYkRn15HSmalq/htdVtG02yZZRlpWlPDn/Gvn+GYzXUptrlk3HAWIfLXZ+G7DWbwvFEl7cDGFVIWx9elKrgYQW4Uq3M72PX08c6bDp8sdrpok1GQlViDFkjH949q5f/hYWh2cju1ghmabHEhIUjsfaq+leAfGVzEYjbXEML9DMFj4pkvwguLfJvdbsLRVOQoIkYn3rFUqS0myud39wn1f4pWy3UKaRbwbpPklVEwqr68d/rWInjy8g82KztY4l3fJMMFge5JNaB8LeEdBtSk/iJZbsklyu0Bv9kD0rj9Zu9FicCSOSfnLvnYpA6L7D+dXCnRlK0Ytg5SSu3Y6PV/iVqd/o9rCjwM0coLtG+Eb3NUrvxHq2rQXKXV1E0DAbRACMH+tchfa9ZsPl022SEnCKrYCfh3qCLWnYlLGLZgYyFwM/U11/VFb3YmCrq+rNFROkf7+KeWWdidkzbVJ7E+1Q3cECbleTzLjbueZmO1PZR2FYTXV3bTveXV0rOflChvMYD0FGo6ss9ttykYUZ8vqS3qfU/yrqVCV1YxdeNnckjv1sLsSWSfaig3OWJIJ9qvwXN7rryXd6pQD5UQNj8AKyodbjXTlgjhSPu8x6k+wpbHU3uLhUti8a5y0hGSf8K0lTe9vmZxqq9uY0rK1lt7uTdIizOOW/uD0rNvlVmC2SNL5bZkmkGFJ9KvTSxWzEecXbO6Vj0PtnvVG+1JmlQko7dUjAwqjtmlBSbvYc+VKyInuTCyxW5EwY7nkb5VJ9B/jWtbQS3K7DIxyu+Rlb5VA7ZrGgt3nZpJX3MBg7R8qL6D3NbU1tI+lqkhFraYywHUqOmfc1VS10kKnzWbZDa3cEVz54GwKCAU9PWltxFLdGTdI07fOUTpEPc+tcvM6mUR2jPsHdj1rSt5poLfEMgSNm/eyk8tnrVOjbZkQruWjR01pNdl90RElw7EFmfPlqevPqau/bLibV4IDOwt4lG0IcKD3471x9pqEemRuwV3MhJUZ4Uds/Wtbw7ciaSW/vTk9FUcD6D2rnq0Wk30N6dZN26noF1ryARw2aMbezXcvOMv6+5q74i8P6f4v0SDzY1ttRVRtvVXLqP7sn95fryK4G8uI/J3TSHe5xFDEetalnq80MFvDeTbY4wXeNOjD/a9TXD7GVNqdJ2Z0ucZrlnqjt/2TNDvdB+MOqW1/HtJ0SVkdTuSRfPg5U/5I719f18z/ALOuojUPiLG+/n+yLxvL6bAZ7TH8q+mK93D1HVpqclqeFiKap1HGOx4Z+1+cfDzRT/1GY/8A0nuK+ONffcIPbNfYf7Yx2/DbRz/1Go//AEnuK+NNVcOIsHPWm1+8TGn+6a8zOpK0bbR7+50q61KC2d7G1ZVmmGMIW6A1nng1qYCUUUooAltmVJVeRSVHpUi4lkLM6jnPzd6j2FEUlhsfqFOTUjwIAHjk3p3HQiky43HSPF5o42j+8vapYrne3lzzSeX0DA9Kqs3zYPzKOm4UjFCeV2/SlZPcpSa1RYkdLabNqdxx97/D0oeIOPOW4SSQ8sDwc1WAYHKE4HepHjj4Af5sZJPQ0Cvc1rCexjJabdE2PugZBqzLf2gUpNGzI3Tco4rBSAyjMSNgdT1/OtSw0Ca6y8r/AGeIfxScZ+lYzjBPmkzohObVoxL8lpZTWSyRRvGF5yH6iq8MdzM4j05p2i/ijL8mpGjsbHCyXyzKvGMHn2IFSHxGiRGO1jhhC8owTkfjWPvfZV/U3vD7Tsb+leH7/VwHjgitAhw0spFd7o3hXwtYru8S67HeYH+piXb+g614pL4gv7lnV7pkhY7ti8A1csriZIG8iArIzZErZfNYVsPVktZWNqeIp7KJ9Eaf4o+H+hJ5ejaJbM6Dh5Y8kn8eaW9+LN/LCy2MUNlGPukAA14PbFnMh1C7jikP918EirUN9pkb+XGJ5wBywPy/ma45YTzubKcex6Hq3xE1W6U772V26YGcVyM+p6leeY15M53dADiktb8up+yWkQ9C3OKq30usucyS28MRGOoFFOjFPY0c7bGFqU0qT7AtsJVGQxB3fWqUt5JHJC13cecf7nVQP60XtlGJHMl1GX6/M/A/xrNS7WESqwLSHhXxgYr1acE4qx5tSo09S3d6n5k4kghEQj6NsGPqapTahPdbluJndT07AVVeVjJuLbzn+LkUxnJJycg88DFdMYJbHJKo2WbeM7g6SAMDwDUU775yxALZ596VpBs/dxhPVs5zTbeQxuWGN3Y4z+VMltbA0jSS5baCfwAp6TtGFVWOAfXqfWoJCS5LZyeeabxina5Kk1qX5biMKMq0svdmbj6D2rc8KmxlYJdqAFPmSE9W9AB6VywPQnpT1PzgkkD29KznTUouJrTquMrvU9DeFL+Z5IFSCyRhsROhI7k1X12CSSFY53MNsfmd3PzN+HasPS9TmUGONnkk6Rg8LGPX61O1617IsV4hdYhyq87j71xKlOEtdkeiqsJx03MG9ZDclrYERD5V+lWrgCS0j25SFOOeCzVcgiYyTzrbAoOMvwF9gO9U9RE1yQXwkaAYXofy9a61K7scbg4psS+KNbxRW7bwnLHtmmRXsmEgdSUTkKDjn3qKeM20iwq5Zxy2319BSPC8Z5GXbkoOcfWq5VaxDlK90acOoosv+sUSOu0y/wBwdwPetDQpfNllj81zETwB/rJPb2rN0vSmuJFYSAsOW44Ue9bl+YNItlaB993L8uRya5arj8Ed2dVJSfvT2Pef2a/LX4jLHGqJt0a7yichf39r1Pc19QV8lfsoxzJ8SpTO6knRLjCD+D9/bf419a10YZctNL1/M5cW71W/T8jwP9s5tvwx0k/9RqL/ANET18X3L7tvoK+zf21f+SWaV/2Gov8A0RPXxWTnrW1tbmHNpYM80lFFMkKeoBcAkAHv6UypVjdhlVJFA0riuhjbDYI7Y6GhRl8hSV9jSkZHrj07VYtIgZdjRySgjO1OoqW7FqLbsis7nlTk+m7tSsN0YdmJPQCtBLfFwGjt2kXH+rk61s6Zokmo3yNZ2LGMAErux9eTWc60YK7NYYeU3Yz9K0LUL2Nfs9mzBv4gCciuo07wHqc0AhlRxEzcAAAr9c133gzw9LKrS2iTAKMNal9j5/2WHWukXUZnujaiwkje3bbKJ4S+4fyJrxMRmVTmcYI9ejgaainPc5PTPh1oKxAaq97A/G540O0/XbkVW8S+AtImtimk6zdMpyqeZnZu9CcV6FHLpNi4ewnvopjw8cMJ2E+6niojZTXFzLLChu1dSGeVdgA+g4/GuBY2spczkdTw9NrlsfNGq6DfabPJFNAJRHwXTkfnWQQygkjjpX0nJpV7cK0aIbyEbg6wYVIvbnmvP/EHhXSWcwsLq0vTkgMQfM/pXt4fMozdpI8vEZdy+9BnlaOUbI7VeEkse12uMBuynP6VY1PQbqxyWjYoD97qKySMHk8e1ekpRqK6Z5zjOk9UabyWqlTmS5c+vGKswanLEu1IoYsd3PWscrgKSy7T0IpYNvmEyDcB6HFJ009ylVlfQ3JNcvgm2OZHc9AgPFZk1zqDybp5JCT2Y1ImptDxFFF+C4o/tRzINlvCueDlc5/OoULbRRpKae8mVdxaXLFmkPTb0zT7mAbgFJLkZIAzTbu7adgzgCRehXjioPNdSdjtzWiT3MXJbbjGGCRSUE5ApKsyHnJHUmk+ZDnoaNx27c8elC7c/MTj2oADljnOfrSUUlAD3cvjOOOwpoPTJpKWgCSORo87HZc+neum8OXkUdsVOFI+Z264/wDr1ywwBz1qW1kCToXYqmecVnVhzxsbUanJK50l/K81v52WTJ2xx4wB9B71ltDLb3A3SAyr87bjkIT6+9aFzci+CpYo4weCPvMaq39kbUmOQg3Djc/PCj3rCm+XRnXNc2qK/nQ2yl1/eztyrN0Ge9PtfMljKSMIIj8zvjlqSzsvNPnTnKZwqjq1attp8mpX4tTsghUAzSk8Ko7f/Wq5SS0M4Qk9SC1ZJYJIoSywL0UHBdvUn0HpUtlAkL/ab5t0cYwijlnP07UuutYi7S0sNyW0a4LbeXPrit3StMh8qGSZ/wB51VSc7fdvesJzUY83c6KcHJ8vY9g/ZZMjfEHfJEIVbR7oqh+9jz7Xk19WV82fs+LBF8RbeK3xldFuy2epzPacn0r6TrbCS5qSfr+bOPGK1Zr0/I8A/bW/5JZpX/Yai/8ARE9fFVfav7a3/JLNK/7DUX/oieviquk5gpaMGgCgByIXYKoJJ6AVaUIkhVXlQ49P50y1h3o7hiHUgIB3NXFE08ZDJlxwGA+YH3qJOxrTi2Vp0ygkWVHI6gcMKt2M/lXkJiRvNbg724/A1nTIyMVdCCOtT2iiRwfJkaIcHaeh9aGlYcZPmOu0mJtZ1hYrvdEsWMjPAOete36VpcGlaM8kDQSAr0VhlvqD3rx3wGIjdBJ4ZZnJ2h4+SPY13GqNc6IhlUiSCQgFZAN6nPYHrXz2OvOagme9hvdjzGto99qz6jHOHt0MII8lV8pmB7+ma6BfHd7pF7K99HLHA4GQY9xB9c9xXFT6kYbRGuhvlY4UsPLb2x2q/vnFis0BvZC3JhBDE+3NccoO92dDtax1Gu6vBrumM8TIz9fubSR/SuW0m+nNxLHp9/cwCIYIKFxWdFc39xIVlstQWJCGUSIqkfiOtbGmakEvEljFxb7zhmZGTkevGKn2fs01uVdSLb/2hezJ5Nw8pGQRGPLL/pXO+INHv5LjyZtI3GH94v7zb/31616RBJrV7dRPZst1atw3lIg/M1g+LrKSa48u5Z4LhP7s5KhT2PvU0qjjJNoJxTVjmbCa3vNOa2t7C3SXGGiK7mB78GuJ8QeBWeKS4hvbdmBP7uNCNvsRXdRwSxPm0tbibyxwspXafoetRXSGRkiurSG2DHdiPcMn36k110a0qMrwehjUoxqK0jwS4ge1uGjlAJU/gajL9dowD2r0XxvoqCNpjNBGo5AWPb+GTXnBr6LD1lWhzI+fxFF0ZcoA896XBYMRnAqZ5x5QRY0HqcdahyT9K3MAUAtyQooZVydp4A796QdaDnNAhtFLg0EUAJRRSjrz0oASlFOk2cbM++aZQA/+HHHFNzxikpRjFACU5cbhnp3ptKKAOs0zUoo4FhtEUSH+Lv8AX2qteRMyvP8AehB/1jdGb29TWfooEk6xyY8vOSPU/wBa6TWEMqRq5OF4SNTgj/AVxStTqWPRg3Up6mKy3FsiTzN5Zccc5cj+lOR0Cfv3aOJTnywclj6tVq7ijRkWRi9w3JSIZPtz2pLezmkbJh2xDkKBwW+tNyVrsaTvZEcaPPGWjYRqxyz45x7V1PhuEuI7eICJMb2mk647tisO10+6OIETajHMjjk/iegFdp4EFq+rxoV80gjCYyZWHr7Vx4mpaDsdWHh73mew/AbS/sHxJgnKuoudGvCofrtE9pgn3OSa+ja8V+G8ksvxN09pjGCdGvsIvJX9/Z9f89q9qrqy2Tlhot+f5s8/Hq2IkvT8keAftrf8ks0r/sNRf+iJ6+Kq+1f21v8Aklmlf9hqL/0RPXxVXccZaE0A08wm2BuPM3efvOQuMbNvTrznrVYdaSp7WNpJPkKhlG4bu9AEiMY41aKQhh1HQmp7aSaWQtaswmI5XPJpJZVmlC3cQRuhdBj9KPJMOWjUyIOVkTgioZtFWdyWXfIMySS+aOGDDpUunz3Wn3BaAqVbGSBkD8KjF214QkyGdwPvZCtj696YytA+2FJYmYcnJOahp2szS6vdHY6JeXo1eA7YlVjlmVeG/CvYZ7y1NnANSgV7NhjzvJLlPwrxHw/qbR3MMssLMinbluB+B7V7fpW/UNHZN9vAjp8oaY818/mMbSTeh7mElzR0KmseFrW7S3k03UVdGHAAA/DB/wD11yVzo+p6LdPPbTXFyyn7hfCgfSvStA0DFn9nuL6BZB9xmG0j6E9ax9d0qS1nk3Kl3MR/rbZSxJ9SBxXJSryi7bo3lBN36mfoOsWU0sJ1KNvP7rA53j3rtJ9N0W5EM0OqXstwTmO3lYsN3pgcD8a5fSNPuIomk1TTLiPP/LWKIY+uR0q9bzPcOp0d1vRG2GicKD9CeorOo1zOxS1WpvwNrenTedZWlpaJ1YFgC/4A4p+q+J7qW3zeGztyOCHi+99DSBdNmtZG1PS5LeQL8ytKCo+lcEbCbULqSTTbWMWysQhdC7H3A6VnTimrN6A0r3tqdHNe2SxI93EOecQsct+tMttWtXlL6TZRbyOswKyD8TxUD/DXUtVQTvOtrPgYlcDC/QA1i6h4VGjb4JM6hPnMki3OC34dq1UKbW+onNt2Mnx7puo6hG800MG4chZHDivGNTtGgnbe0W7PKoeBXr+uwqtv/o9qIwBypn3A/rXk2vyE3m0qiMvVUIIH5V72WuSjy9DycwjG3N1MzleRT0Wa4faqs7HoAKHAwCzEsfyrQ00xxgE+aMnl4+or05Ssro8uFPmdjqvBvwx1PxCyvNcQafbcEyTNzj2Fd5dfCzwbo1qzX2uTXtwP4I8Kua8mn8Q3lqTFZ3d1s/2ziobi41TUE3l5Ag5yWI/WuCpTxNSWs+WPkd8J4eC0hdmtf+HrGe7lGnS+REDgGRv6Vz+r6Z9gcBZBKO7Cqkksyt80rEjuDT4Lp1bBwzHjcwyR9K64QnDeVzmnOnPRRsVDSVrto91KhljjL5G4gdhWW6lGKnqK1UlLYwlBx3EVS33Rmm0oJFJVECig47UlFADguQTSCgZNKAc0Aa2hS+XOixIWmY/e6bR7V0OtwNHaoylUweXJwPw7msvwpbxvcEtEzyrzg9PyrbvrCW/vgsihygG55GwqD0/zzXBWkva+h6mHi/ZD9JtltrPzUAlnk+ZnI4rPe5mvJgolkijBwMLgH/GtCecxTlPMBtUXaWUcH2FWBp8l60Mxt2RMgRx/xue3A6Vz8/K3KR0ct0lEsxQNLaR2VrE7mYgOwPUDrk12XgzThHdutvJEgcbPMX+FB2B9M9TVrwn4HvdUvIxKrbcAFAcKvouB1PrXoF9pOmeFYI7aGSJrxzukAOQv1PYfSvLxGIumoHZTilJJ7mp8MFiT4nWKW6OEGi3v71+Gk/f2fOOw9K9wrwz4X3Nzc/Fa2eeIpF/Yt55TNwzjz7TJx2HTFe517eV/7rC/n+bPDzD/AHiXy/JHgH7a3/JLNK/7DUX/AKInr4qr7V/bW/5JZpX/AGGov/RE9fFVegcYoq1ZW7zyNsKZUbsM2M1VFdD4NewF/OuqRl4Hi2hh/A2RzUzlyxbNKUeaaRlpMkbMskWfTnOKiSZo33QkqfatXX7KCO432jxvbnoyH+dY5iI+6QfoamDUlcucZQdibz1kcGZBj1Xip5pBFHhJnKn7q9qqIrKSrFV9mHWmOwJIJyO2OlVykqdjRsbiZ5DKzhwg5jJIyPavS/B3iv7PaiGWdYtx+Q7Pu/XPWvLbK6W3fcof0IyOlaCSQmSJw8m0nIPXafpXJicPGqrSR2YWu4apn0fpGsR69D9hvHuXYcLIpVkb+orVtdFj0FzcLd+WTyUIO0/jXkXw/wBUYMFuHKMOkkJAI+or1rQIzeA/bPO1BBzmR8D6YFfM4ii6Mmlse7Sn7SNyDVvFlxbzpGu/bgltsbMoFW9Imh1NpJ5bW1gjI+S5KbS/171o3V5p8ULWlsixt08tmyv5ms28F9b6fI1/FFc2pGFSBgoUe/euW8Xoi7dWYer3c8UNxbT3C3dsm75wu0+yrkcmrGiapHFFALV54XAGYyAWI9DWdYFry4iin1Nobct8kDN932LDrWtNoUtvM39nJZ3RPJYS75B9c/0rZ2tysSlqauqToYHnhF/ZSsPvMdyn8OmK8/1JZmv1e4W4uQ38UUWfxIro/P1ezYRahJcuc8CELtA981ga3rszGZIZLuKVerow/p0q6MZcwnZI5vxNZwSlX2XEqEneWXYy/Ra818Rw2UZUWaFSDg7s5Ndjq/ikRgpHcXDzL97zW+b9a4LWL+TUbnzGJKjoPSvoMFTnHfRHj42pBppblRIizgZAyOpPSum0+Mw6cwg8ktzufBOa5UZLAE/nXY6XE89kIhIjqBjg4ArrxDtFHLhdWzk5pHE7EtuOepFK8s8y4aRmHpu/pWvcafBBcMIvMncdQg4H41UgsLnULwQWkKhycAKa0U42uZypSTsZvFN565r2rwh8HLZolvPF2rQ2cBGfIjOXI+tbOvaL8PtBtTHYWhuZyB+8nfk/Qdq5JZlRT5YXl6G8cvqSV5aHjuk3ULxbby4k2/8APJQTmodYsNoaYxNAh+4h+8fc12MPhqLULsT2zrEobcghXhB7mqfiPQXuHWLSy91Kp+ZweBSjiIc+jsbSw8/ZtPU8/YbfrTa19W0O90zH21Njt/DnJrKKkHmu+MlJXTPMnCUHZqw2iinLwemaogBnBxVm3ZYXWRlEh6he341ECF56n0HSr2kQvcXqKNoY8Bcf0qZSsrmkItuyOt8KefICIY1SeXJLkH5R7mr+tWEdsgW4uGMrHcE3YOP72P8AGtTTrG5s4hNcsC2P3cY4A/AdTVY6HdXl+l3LEryE/dJHP17YrxJVU6jleyPcjTkqaijKtbWe8uYktLaR1XAVtvy/8B9T717V4U8FXEEMdzfSRxyYH3fmaNfQerH17VY8K6ElvbxSMRcXbYA2dFH90V3ISMGKKS5bdCcm2teWJ9GPavNrYl1nyx0RuoeyV+pNBbQaXYh7mc2sZGAgOCB7nqSa59rbTYJp9TuUXy41/cwyn757O47Adq37uciQCG1E+ovwgb/V2/59T9KxtR8OrJAVumNxOzbyo+6W9TXPPTSJVNp3ch/wvjkm+LEGpykk3mjXu302rPZ4wPTmvdK8U+HOmNp3xTsjI8sjy6NfEs544ns+AOwGa9rr6jLP91j8/wA2eFj/APeJfL8keAftrf8AJLNK/wCw1F/6Inr4qr7V/bW/5JZpX/Yai/8ARE9fFVd5xl+30uefTri+ja38i3YK4adFfJ6bUJ3N+AOKgt3VJG35KkY4NQVZswpdt5wAueRmk9io7mjZSWEsBjmtmMnZ0bBP1qIWUTlwZBHj7oI6/Wp7zTL/AEu9WK7spIJWiSdUZeGjddysPUEEYIqBoxncoaM/3C3Q1jaz0Z0xtJaoqLGVUs0YZQcdcUs5t2QGKN0f3ORWlbrCQTcNsQ8FoznP4VGIreG4CQzRzxycZkGMU1O4vZmUY2ChtpA9ccVNbOVx5bFW/nU9w0ltM0ZYCM/wj5l/Kq4lfaRnAPTAq73RnZRejNRbsqEZuX6ZXt78Vu6H4gvba5ia2vZ96nLIDt31zNhPcW5Jt5UBbqHH+NT3VxfFQ80URUfxAD+YrnqUYz0Z1QruKPfPCfi3QLi7V9cgn3sAMEkBD3Ndw+jeFtecG01Oe2A+6FbePwr5S0/VpUlUNJMhB+6p4rs9G1O7WdZlJRcdXfav6V49fAOm7xPRpYn2q1Z71o3gaGa9nlTUkltIm2qk8Q5I71jeLYho1wRZRWCMOsiZDN+FcZc+PdXtrcRW9xC27oN3X8a4rXvE16ZhNevs3ddnPP1rlp4SdVpm8qyp6t3NbV9cmYvPBcXDorHKOCefYntXG614l1G6tz8oijJwMHGaS71hpkMhYsvoCCax7i58597ldg7MeTXs4fDKOriefXr82zKzQ3FyBLcMdvZmOagMhQFFfKewpZrkyEgHavoBUGDjgGvRSfU8yTXQ09MsvNUvJgJ/tCrMCul0kdkocjkoMgfiazIJ3QYILj+6ScVesLxo3LRwL5gHUnFZzi3ds3puOiPSvB+gwavKf7XjnmhX/lna/KrfUmvQDpuhaPFjT7GyspxwAjGeb8xwK4TwHFqM6h5LGa4EnZZsGvR9VvJNH0x1NvFZADoIgx/FjXzeLnN1OW/yPeoxjyXPFfFmp3S6q4jaQZ5BbOR+Fc5JFdGU3NxLkYzmY4z+FaHi/VPtmpyN9r83sMLtCj3rnWmRe6yN/eYk4/Cvbw9JxgtDya9W8nqdjoXiRkjEBbEeMtgYH0ru/D2qQGM/Z/s9uT/GfmJrxRJmkBViVT1HFdN4TS8uiIrRJWC/ekRMkfj0ArDFYWNuZaG2GxMm0rHX+JvJjR5IfLuJm6yT9T9BXkuqvI923nqAR2UYFevNpoMDeSm6b+KSbnH515n4ktPs9wzeW5BPMj8ZPsKrASSfKLH03KPMYFKop21mPAqaBI1OZjx6CvUbPIiri26l32Iqg/3m7V0WiaZfC5RldbdWP+uPJP071UtLTHltHbEzOflyM4+g6fnXoWg+GHZRJdSyCQ9fnGVHoT2rgxWJjCO56WFw7kyOW1lkiSHTRcSOpAe7mOMn0A9Pc16P4M8PW1zFFNcxy3Gz7pJ2qx9T7V0fgr4eRXVql9flks0X5FZsBh/eOa172SxE6Qqrvp8Rx+74EjDt9K+fxFVuKWyPWpuKdlqyxBcx2FuYdOtAWK43xjCg/wB1fU+9W7YnQtDaeYRQSyEvI687QfU+tZtpeXOoXavBElppdv8AeYDl/YE/0q9PNaalatPqEinTovmIH3W/xrCPkTJdDOg1C41OFZdPka1tHYgzuMMV7tk+tS6n4ts7Pba6fFJMqjL3GOGx2U1X1rUra/sf9HiAtYlyP4IkHbJ7n2FcYiy3srPNfxlDztjAARewx2pRdrq5oqalq0d58NL2bUPiraXNyxDPot7ti7Ivn2mPzr2+vBPhHazx/FOC6mDiOfRrxYt3HyrPadB26/jXvdfVZb/u0fn+bPn8f/vEvl+SPAP21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+Kq7jjFFWLTBLqc/MuMjtVcVZsFBlOW24GRxnNJ7FR1Z3XjrxxqHiu20GA20NtYaPYR2NuiBXc7VVWd2xk5K5C9F7c5J5HbDMOZ3ilPXd0NVpmYSHkfVeKtR3qmDy7iOOQEcN3FZ26nRFr4SrLayQ8uVYHurVHFGcbsAr6Zq1HATnbHvU/3WFTw+SmFuIsjsJVK/qKHIFTV9CjKYWAMbOr/wB1v8aBbyYLED86tX6Wfym2RkfuGbcp+hqvGOqM67c5IzjP0NNO60Ias9RsPmSMUDrj0akzICUZGbnoCammSKMBoCXA6q3amidiy+U5Qjt6fjQPyZLaqyuDM7xJ7iuksvJMG5Z5mHXlQRWQRdTxhd0cuRxggmonSS3Qb4HUdxux+orCpHnOinLk2N1EubgrJNdCS3B4XG3j6CuittG/tSAfY4oi3pMK4RcrCJN0G3rh2LH9Ks2GoTLuaRHx/C65IrnqUZ7xZvCrBuzRva14f1OwhO2xiBx96LBAriNQtp45M3KbXP4V2OneJ7u3OyUNdRH+HoVFbaPperKAmlRiZushfjP40oVqlH41cc6NOsvddjydsbRgcjqfWnRsoP7wMfocV3WteCrkgvaeQFz90NXH3mlXtm+2eBh2zjOa7aVenUWjOCph6lN7FYMg+YDBB6Zq/wD2jmNFSNFI6kr/AFqlJE8SfOoHt3qHPGK0cVIzU5QPQvDfiy+hhCQXa2sYONy8sf8ACtPXnvNWtxKbyS59d+W/+tXl0E8kDboiQfWuv0G8aeILevJIp9ThfpivPr4VU37SJ6NDFOpH2cjm9SjKzMnl4Yd85NVEhY9PvdlHJr0i7srW4tXa1tyY16sq7UH/AAI1ysWh3MkzSODbwk4DkdfpXRTxMWtdDGrhXe61M+xhVnL3G6QjjyujE17N4JgvLrTUSRotJsB/APvN7n/GuT8NeBr64YXBtZ5IUOQWPlhvfJ611upay2kWP2eKC2WTp9/zMfjXm46uqv7unqztwlF0lzSJfEGtaFoULxJeS3tw4xlVwo/GvH9X1AahftKYz5XbeSxrU1SZ768M9xKsjHgdlHviqC6e0lyIYCzyPzsjHOPUntXRhaEKCu9zPEVJVXyx2MqO1kmLmJCIxwTWrp2jG4jDJGwKn5nPUV0ml+Eri6mEF00sadSsXb6+9ej+F/Ctqu2O3jbyk4JI3nP+NTicwhBe69RUME5ayRy3gzSJtWuTZQWyhscSMDhR6n1r17w/4V07RWEM2LiSMh5WkIUKfpWzodmNPs7gWMJslAzJdSgeY34nhRWTo17cXGoGCC3tfK3nzJpm3FvceteFXxEqjuj1KcFFM6Kf7Vq1wvzm5gjHyx4K26ehY/xVeOmI9uDeTwsgP3EOFb2PoPYVW1m7jtrcW6gz3bL8qk4A/DsKTRJbe0hVY4pNS1EjJ/hjj+pPCgfiamKV7S19TKV0uZaDNajeeCO2RmjhP3yq4Yr/ALI7CsC5kl1S0ljSBrbTbY7UWUYDkfxMO49q1/EWoX0GPMaDfKwAggGSfXk8mpf7RMVkILS0DXAGGmn+WKM+/r9BWbtdmsbxirmDaoLiKKKW3nvpwMqh+SNB6nsBTrfToDevPFBHcvH8oC/JAG9P9qnvZXt8z20ExkXO65uX+RPoB2HtVuSZtLSEWv79kIAG3kj1Re31NRtqaN9Ebngq3vYfihpkmoSo0kmi32EjXCoBPZ8D16167Xi/gDVbrUvizaC5iWJYtFvQgLZc5ntMk/kK9or6/LbfVo28/wA2fNY66ry5t9PyPAP21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+Kq7jkHbTVmwLiRmjOCF5HrTRdP9hNpti8vzPN3eWN+cYxuxnHtnFRwlhJlCQ3Yik9io7ouyukjBoxtYdQD/Som2sMggHvkVK6HIeUNkc5GKVfs0+FeQxue5TIrNaG71GW8safKzbT/eFTXMkhTbJcs6HkbRUDWhVwUkRl/vA4FTPCVTf5J4H3o2yPypaXuhq9tSvDEHbBVnz/AHTirEzxRIE8t1YdPMUGoYwXGRIFP+0afM8jKBIqkAdQcmnvuC0WhHvMh27EOfbFOW1Ib5kTB7BxUlqbRVJnSTnpxxVyCa2jbdHAjL67trUpSa2QRinq2RQWW1/njWMdmYmrMdlECT50Muewkx+lI+szhwIjIYs/cbBqRN92m9IrWFj13LWT5t5Gy5fslaZo1fatkrdsrmltXuY3K20bKT2yQBU8bW1rlpJRLN6DK0y5ZbjDn7REQvY5/Wi99HsPXe4XDXUzbJ3twwBOC2MVXt3aI/JdMrDv/CPpT7DTopnEslyACcgMeT9a1v7Oti265lQxpyBG3NKU4x939AjCU/e2Lek+ILqDYEZCB/FLnB/CuktPFonPlXboFHXy41QfhxmudjuoY4sRYUDo0gBFUFuftFxvkuFkA44PlqfwrklRjN3sdcasoK1ztYR4Q1B33w3k0x/iZDiqN54L0u+uwmmv5JPYncfyFY9rqRmYRwwJGE6urElvYVvWfiu9gAgaFoYO22LJce+KwlGrTf7uT+82XJP40UW+Gc1xMkFndxM2fnYg/L+ArptM+BepG38+fU5I1AyAsZX+ddVpfxDi0zTV8vT7mMAcFU25/DFMufiLqWtW5it4DkDP+kZ/lXO8Zimt/wAgeGo3ukcq3gC4tLlTNqoZIzlS53BffHTNdBFo9taKsou5LicD5XZQ2PoKrLo3jjxIvlQaXMLfOfNjTYD+eKv6V8NPE73P7yCWN0+9O0gZR7fWom6klepI2jKnB2Whl6pJ4lmBgs7RrvPCmQ7nH4dAKqw/DXxdqLRedbWySydFkfJHvgdK9e0jwHqVlEst5rMdowHAADP/AIVqaLpltHePPHfXOozL8rSyuQo9gBWSqzp7RSJlKE9b3OJ8L/s42cRFx4i1SaW5b5mS2G1V9s1ev/BHhrQNR+zWMbmTGBbwnfM59Se1dxf6reTXUdk1ybe3cdISFZ/bPWootU0HRFmTTrN3uv4p15JJ7bj3q62IVbTmt6mNKE6bu1fyOa0/wJfyodtgum20h5Qvvmcf0rqL62t9A0sRpPZWBjXkBfMfHoB/WpYtcdbJYvPdp3UnYjb2X/efoDWVZWlq8csl00aWwJOd4Lue+Sa5nKmlaOrNV7SWs9vIdpNzDqUG66Y3bf3cF/0+6KrX5aCbzYobPTI0HyswEs7H0Vei1fs50S2kMUkNpbYJG1T0Hck9aw2S3uWBsbY30rMB503yJz3+n61lJ2SRrFK90RadFaWclzqGp3pnnkOREH3t7fifQVo6bLdXMm662WkR+YRDnaO249M1LBpVrLcqgWF2tuXKgLFG3u3r9KL290tJPLMn2q4PAAQ7V/3R/Wps0rstyT0RTuPsa6x58d4GnI2EA7pGH90dlFZmsahLBqMZuTvRTkQxDhFPbPTcfWruo2kzRqukWW13x5lwcblHt6VnXsP2JVWaVPtZOEULvK/XPc1L7lxSaOps5RJZJLeKkUQ5jtIzwPdz3NYV/c3FxcPJCvkWScNJt+aU+gHXHvUE+pPYRRC7jaSeQDCytgIPXbW/ptwI7MXl2qrIwwhmO0D6Ci99LEqPJ7xH8NFtl+KNmYFnNwdGvjNJKuN37+zwB7Dmvbq8j8GKG+KWmz5Zml0a/JkbjcPPssYHYV65X12Wf7rD5/mz5zHO9eT9PyPAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqu85BRU1uzK5Kgk47VCK7/wCD3gm78c6zqNjYSQrNbWZudshID4dVxnt96pnJRi5MumrySOMbe5wC2D1z0p6xQOAAzI4656V6nrnwl8VaXKTJpV40Y4JjAkX9OtcPqnh/VbG4IuLOdR/eMZwPY1ywxMJaJ2O2WHktWrmHMu0LiUN685pjrJ99Rj3HFaE+n3CplkiBPqNpqK3jaJWEpAGOUYdfoa2Ula6MZQadhlrJDsxODu7ZXNTvfIgKiJHHTjiqboTkgMAegPOKlWyYx7o8SE8Gk+XdjTk9EOt51DFU+QN1WX5lP+FXYYoJDt2wjf6ScH6UxNFvJIg6bEUDoTyK2dF8KatqMsSQ2zTRnq6rx9KyqVIJX5janTm3sZkllYwsuXkVs8NvBAqeXTru5VXWaJ0xgHaSa9K0v4favFGy3mk24g7O0ZzWxofgm0gnBvY2cK3KwTiMHn0rgnmMIdbnZDCN+R5Fp+hanOSiTRqvYY3H+Va9t4K1WVwsLXbv/uYFe4m38L6WhEOk3IuTwM8kn2NVIJbONpGn/tRDuyqFgABXJPM6kvhR0QwUOpwmjfBPW9RbcIcMRktMw2j8K6K1+AGoyOv2m/tIwn8JXA/nzXX6ZrUMmCJrxFUfdUnj61q2eruWfyWv7lT/ANMQwFYf2jVekrjeESfumJpPwn8JWjiLVryNp0IyIwMCunh8C/DmxTzXtEuSB1cE1zGuC/e5+0WtnNHP/eMWzP1zWXJea7dMls120JI+Y5+XNRHEzev53KeHvrc7K/1fwTpPy2Hh+2kKD7xQCsoeNLW4niWw0RLSM8+Z5CkN7ciqWm6E7v8AvdSWWfuPKOP/AK9dEuiw2MRuZIX1K47buAp/Csp1XLcv2VOG1/vNQapFNagmzWU46LEFz+J4FR6ZeeHFnL3mlRQTp82RH5mT659ahMF1dQC5ns7cY+6hLKqn6dzUFtFNOrnUltVXPyqZxkDtwKzjUlDUXJCS10Nm68SvfzEWkzQ2KnG6ZhGp9gByazNQ1fWLy4SK3u7sWyDk21vsX/vpqyLZILfVxJIJI4wcJth3rIfQZrtLSSAyK93NcsvGIgvA+tUpyqP3pWIlCNJaRuUra9SG1It9Jlu7nHMlw5Iz7msHXNd1SzYJJLZQ7zxDboWI9hXdalJcPAqW0sdpGegKbn/IVy11HFYXCMzyXM553hRlff0FXVutL3JouLd7FSGC+ig+139pBCxAxJdT5P4KB1qaW8itdOz9gM8zHICphM+pJq2IIJmBtmWKYnmaR/Mc/QdBVu7ju3PkQ3/lj+5FEGYn1Lms1G+qNHPoZmnRXcliZL1be0jbogG78Ao6/jVaKws7KWS6lR4lZt7yzDlvoOij6Vr2qyWd15c19vlPIwoLAVJrl7FHCRsE02Mqbk7gPogo5Eo3YOcnKyOc1rxJY20MZEMc8ZxsDDy4vY88vUVvevesLlpppZyNkaxRkpH9FGBmrEOlrqb/ANo6lLaM6Z2TToGWMeiqeAKcItSuZvLsLmRrAAbpnURrj0XHJqGrrQ10iaOj2jXCGGB5pmBy+8cA+pxxn60ybS7exmZhK0t033tvQD0z2FLfX1/YRQafpUcMZbpGqcsO5/8Armquoi7sLVJtVaOe4c4SANsUe+OrVTS5djOLlzXuXvtMgtDmXEK8FlAVPoP7x964e7urmPWfMtYlAPV3OW9sZrool1C/VWiELTLwAw2xxfRe59zVSfSbKzaObWbwXmouDstrY8D3Yj0qY6mq5Y6dWZN7C0Obu5uFExbIRRlmPuato95cvBLJD9ruM7o/tHEUJ9dvc+9Y1/czveL9ggaQA/KEOAW9CfT6VdS6u4HAneJpl+ZyxxHDnpn1ND2Lsju/AccyfFLTjd3ZuJ20W+LALhU/f2eAK9jrxX4bwBPiZp0xllmll0a+LyPwDiez6DsK9qr6zLP91h8/zZ8zj/8AeJfL8jwD9tb/AJJZpX/Yai/9ET18VV9q/trf8ks0r/sNRf8Aoieviqu84xRXtv7KVxNa+NdYmgSVtumNu8sZwPNj5I9K8itbS0k0y5uJdRjhuoyBFamJy0wPUhgNox7kV6t+zBdtY+MtWeNHlZtNZQqYz/rE7Vz4uXLQk12NsOuarFH1jbeJo3cQ3MLIP76ng/nUt9pWlavbkSeRKrdSQDXOw3ujzA75Y0cjDK3RT9O1UJrbTrKeS8inaQOMbYptq+2B618v9Y/ntI9pUEpe5dMz9Y+Gum3SyoxtruPPCKArJ7e/1rlZvgzYiPNlaPIOcpvAb8Aa19Qu1kvFnjudirnCXSk4+jCti11+eSDZOZPKA4ltnV8e/qKyWIs/dul6nT7OfXX1PKtU+D9i0xQ350+UHO24iIH4Hoakg+F0VtbgLfpMq/xQ8ivVj4lhurR7dpPtm0EYK/P+IPWsHTNA+0lbo74FY7mSNwrD6g1UsXVa5VIcKMV70oo5jRdDhsmaJ0u5I0I+d0R0P5811vh8LbTf6LBZGM9cPt/Db/hWrLbwyQeTZ3d3KR1jyGI+uRUVv9qsbUwvp9wkeeHcrz+YrCUpN3bNVJWsjTubu+gAFtanyz/HBJuAPoVPb3rnNTh1G/ztS38zuIoyGP4VctrcSzDdCkbE8edKQT9Cta0kbWsPzxxqg7tPvJH4il8Qvg06nEtpLWkgmvLfUUf++ELD/wCtVextFvpJWN+YtpKhbiMMxHtmu5giN9b+dZXckLHojjA4+hxXNXWlXqXhad47g5yHSLzOPzpu61RUZp6GZp1m9hqEhuL9EgJxkR53fgK7G01TQYkVfMxKf4lRkz+OKfZWtxaxrcW5kbA5ie2CE/ielX2v5tRj+zS6ZGUcbWy46flTjJ3u2ROV9jG1i6iuIlitJ9wfrgM2B9RVfR7WCG4SKKZ5ZEGC0sI2J+fWuzstGe1tdriSOHHG+VcKPaq8Ph7T7y5Egmurp0OVAOIwfw61XsJtmP1iCVmQG6vBEILaO41FzwXihVEX8aNKsRZF2uLOQTNzulkyB9KsX9vcWcwZ7ciBRhSJ8Y/CufvLq/1Ofy4rdY4R/E8rHP4CiTUXZ7ijFzWmxa1fT31GdhHfvHngrDuc/l0qTTrSDRQBPb3UrtwPMQDn2XqaisbBtPcmbWruPePlggTH6nmrbfYLJhLOl7vkz87yb5PxPYU7deo+Zv3VsRX6avPdeeLVDBt2rBv2596LW206KVZL1J1uRyIzcjH5D+tR6y2ivbI01yIQcfLGWklOe2Aatypptvpn+gQmOMjmQAGRvp70Jcrbugk20lYspffapPLuIE+zDoxY/h9aq3MCQShzaWEa4/d/aHKZ/wCA9T+NWtNtIRYxuWlsww3fvTukx/IVr2drYDDRMrsersod2/E9K1jTdRe8zGU1D4UUNEtHuF+0P9ljAGN0MeOPbNN1C5hln+x2djPM38Usj+Wij19avatqVlYIhvb1IEHCwx8kn3NZEN7a+Y7W8M00jfMWmOAB/KqnamuRMiF5vmaIF0idA7QXKW6nqyJgD8Tyaxj4fAuPMjuBJk5eWfLA/RelWdWv7ydfMEsYt05LKTtH4/xfhVax1OZYWnjsTM2f9ZK21APXJ6fQVyScb2SO2Cna99SW5sYN6/abu5mI+6kSD+Z4FOuJvsQQCVbZ3+VDOxmlP0UcCsXVNVM7gzzuiryfKiIB+meT9au6TZ28lu0zxXpaTnazhXb8f4RU6X0LUbK8ma9hdxWpkGmwSXV+/wB+WY4x9T6D0qjDPe3E8pCxXk7Ehp1Ukk/3U7DHrVK8sLmAIp+zWlmzf8e8UheWQHrlq3rK8vRbR21jZpBGFAL/AHRj8eapO7tIza5feiV59Ku57cW8sn2WI/6wg5fB7KB39657xFpqaZZhdPijtbduHkYlppfbI6CuxjmgtlZdzXd1/FtUsqn0964rxRdS3M+Lmb7NGOdseHlb244WqajHQdOUmxdEvLZI1QRM0oGGO3aq+w9vetLVbRH0/fBbREA5JYfKvv6san0TSbez01Lp7ZpJAu9EuG5Hu3p+NZ99Nd39tLNdXWYR9zYuxP8A9VZNGvxPQ1/hneR3PxRsoo8sYdFvQzdjmez4/T9a9vrwT4QSlvidbRqy+THo96FCrgA+fZ5P8q97r67LP91h8/zZ85mH+8S+X5I8A/bW/wCSWaV/2Gov/RE9fFVfav7a3/JLNK/7DUX/AKInr4qrvOIcvWvTPgSZB4h1RoVYuLI8r1H7xORXmS9a9i/Zmnlt/GGqPAYd39nMCspADDzE4rkx/wDu0/Q6cH/Gj6nvWkaeNVtw0d5bm5AwwYYJ9nU9frVDXtCltyqxSLayZ3GPcdr/AO7mt6O50m9kY31iiTjlmjyG+oI61j3/ANkmvUg0e6naUMMpJk8eg3V8g0lG8T6SNSXNqXdD1xYoFtRbLO6jBjkjyM1oSTWu7zJ9Hgi9WiYKR+FNNlfJGsgDAD+Iwrn8xWRcm8up4nlvES1jJ3lyjK31HUUuaS0/QlxhJ3X5lTW5PDOpXEaLqMlpeKcgbMHPcGpoLI+SHsobe7kXvISN3v16mtRYUCLNAun3luPvFVwRUEGo6ZJcur2psHU4ErKVD/j6U2rlKVloZ8c0zP5f2E6fOeCFfBB/rTX+2lmgaSeWXPyg3BGf+AnitCe40q7l8mPWpDOB92KVWU9u9YN7pmpfaCkkd5ewD7k4faR9QDUtPuUndbHUaLol3NBi/V45CMnB3D8KsweH/sN79pk1OQ7cgCRRgD6HrWTo82qrA1vfWTCMYCP5xJb60+K+u7W5MdzEl1aHou7Lqfx7VSlBWViJKo29Tcvtchii2wXq5XPAgDZ+gFc1qmoTXajy7a7twMZkWNlLe2AK1niguZIpzFd2qIc7Y0+9VnVptYhgiGkC6eMsAQ8YJA9at3krsiPLB2SOdhe6uodtp5lu3/PSe6Jz9QapxNqkE5huNRt5EL5LxTZK+3FddJDei3EjXB34+5PZA8/hS22mxzwF7pIkOPmMUOyoUH0RaqRRWszY+dFi6vCfd2dSfxrp5Hf7IBayXYwOsYCj+VcXb3WlafeNDZyzCTv5iswNadxNqeoQ7LCCR1PV5T5afl1Na058qaMalPms9kNujrOo28kVrc7T082ZRgVRt7i6sJNjzWUaj70kz4ye+KPNls5hFqFmZZgCQkUvy/lVKW4uNRmaFrKCxT+82WbH16Vi5d3qbqOllsX7zXNNdC1zfWsresUWSPxJp2gXiXUchsYHeIdZrgBFP09qetvp1rAomNuTjkhF3GoZltrhVSCG6nQnGyMiNfx70Xd9CeVWsWmbSwztdyi5OOY7K3wv4t3qay1OKSYxaVorqq/8tJwFGfxrOu5761aKG32RqeBGxHX04o8q9jvkuLu7t3AX/j2jUk5+gqlNp6aCdPTV3Ny4ivbtsagv7r/nnApJNR3VpAIGSKWeIkYAEh3H2wvSszUdV8QNbF0tra1tl6m4kIJHrtHNZ2i65aXNwTc3VxPOP+WFqjYH1PSrbV9NyVB2uzSsNPFreF9Q1AyyOcRRLCGkUemT/OtK9FuB5cMDXUp52mTPPvjgfjWcbu9uZtml6atuh+9LL94in3srmL7It95UnBZbaLcx/DoKlNLRA4tu7ZZEiXQ2v5EdvGMHjP4DtisK/hvDe+dDPElkowscpwi89fetE+YY9vkwxIOkt5KCzD12LwPxrOLRT3ixR5vZV7JgIv1IqJXZpBW1NK2vYHiJMT3jf3IIti/99Goxbm6u0mmjSER/chifdg/7RFLqcSqkf9qXZReNtrAOT9cVlSy3wfFtb3LRk4EYxEh/qaVwSvrcuX135OoBmJwBy+B8v+yB1NbdpMFtRNeAICPkic4J+veuW1DTNWuIQxUwPwR5Z5HsKktF1LTLVrjVDGZGb935zbnI9AtOLcdWOUVJWTNm71OMy+SN8jtwI4lKqPriqN9ottPGzEiNyQxkA5B9B/h1rT8PWct1bfbL4rGW5CFsCm6pBFayia8vdg/5Zpjkf7q9/qarllbmIU0nyxMq5juSx+0TLFaIQR5rZMnHUisjWLp7m3SKFz+8+WPAyzD0UdvrUOtXrXk8cFnE625Pz3MrfMfYf/Wp+rSrY2O2NfKlkG1QBmR/oOuKztqdEV3N74UtAnxNsbSAKGg0W98zByQTPZ8E/hXutfPHwQsZLT4mwyTQSwtNo96f3h5bE9p2/Gvoevr8tSWGjbz/ADZ8zj/94l8vyR4B+2t/ySzSv+w1F/6Inr4qr7V/bW/5JZpX/Yai/wDRE9fFVdxxjlr074CFh4n1DZAk/wDoRyjDJI3r0968xAxXpvwGl8jxJqUmI2ZbFiodtuTvTofWuTH/AO7T9DqwX8eHqfRlgjWq/aEs7iJf4gqZIrUNzZ6hHmV7dyv/AD2haN1/EViWWrarcQAWhs3YD/V+eA4+nrUml3NxBet9uuby1mc52Ou5D9D0r5CL5T6ScXLU0p7i8jiK2F04A6EOJRj6dRWYl1fWibmsnmkOSWeEFW/HFaeqsXUSQeXM3cRIFf61XshNbTGeO5eeA/6yNHIdT/unrSbuyY2Udh/22+vLPbZ21vBORyAoBB9Np60xZb+GExXNtdXO4/deMbR9MZrdtpbK6U41EFD0juV2n8zWZq+dPPm28luISPmfaXI+mOtVKFlzExmm+VIqwabapma6020t1xklkxj6kVZudCsLq3EqoAuOJLa4I/ToakivI/sfmSahDOjD7uw4OawbjUbG3lZ3tZVGesROw/8AAaV0tioxlLUvC60KOMQzPdyDoCCRn6kVaaW3iCmws2lTPOJwG/XrVXSry0uYDNZ22nwZz8xY5/EVYS60qWYebewy3ERzshG0KaNwtbobdndo0Ko+m3zexAYH8RWhEJFQmO0ngH4gVzb+IprVgIPN8r1jwxH4Vv2mqLqEOF1RA2OR0I/CuqjUhLRPX5HHVpzTvbQrXdycMX1GSJRyVx/jUUEpliBGLmA/xK4U/maztY0u1+1ia5uWu3Y4C+ZtCH19q3dNk063sVhmls+mAJJQx/SpinKVmXLljHQzby301YiUhFtKRw2S3P1FUbRZLYMQ0s4Hvj+daV5YQsS9tqy20ROfKtyTn8ayzdams5jtoo/KH/LWYHJPpisqmkrv8DSn70bfmTfYYNRcyziOylHCyn5mA+tXJdGspIhi8MjL/GG2gVm3c+pm3PmQ2E0hGAqjJP4VQtrq4Yqt5ZKzjory/Kv0UcUuaC6FqE3sy/Jaw2ziESi8nbgKvJX3zWo8Qs7MgqkJxkk84/Os+yuZFDNM8Ac8Dy124Hoap6rFc3IEktzGsSHKhcnJ989qSkkrpEqLvZszplsUu/tN9dXMrHuchT9AKtXHiI2duGsNPZIjgGVo9ufoDzWvoE813agy28ZC5BcqFH6803U4LSNyTNYRzH++d7D8KSi0ro0c1zcrRQhZdT2tLaT3jE8B5dq/kK6m0sHhtfLjjtbBCOiYBP41h2N40beVBe2zMeu0qv48VqRX+jlhDeXkdxcnqkeX/PHStaNuphWunpsRDT1WORbfVGkLE5kzuC/QCqDQQLIYLKSJpVGXeVd34+lW9TiYp5Wn7oogP9VEm3d9TWXJDdxxCMPbWEA5JQB5PwHr9aio1flSLhe3M2U9ZVFHElpPddAWTdj8OlJ9ol0+zG518x+FSBAGJ9M9Kt6XJbNcsPIu2Ef/AC1nQAyH1AHSpr+eK5nVPJ8mJTnBHzk+vHSsvM2T1SSM+0hvrZBMsaiRskiSTey/U96qR6jrCzM0UiSSu2FYRcgeijv9anvr1bi8SM3ExgjHzxxjZH+JpY7prufZppe1wNpuQmTj0BNK5a22N+0tdS8tJNRuFWYrxCmC2fUk8CqDDSLa5ebUbv7ddkcR5LBR6Zqhe6tZ6VCscbtd3B6tNITuPqf8Ks2SS3ln5upmO2hfsg25HsOtat2WiMOV9SSS6ub6TNtMltEOFIG6T8F7fWuf1G1na6K2n+sb/W3dw+5gPQf/AFquanqcNnGtlocYErcEouSP6k0troN5cQ+bq1xJbwkfdj5lf+i1FmzVNRKVjLHazmG1KXV6Rw0nb3x2FS7oba4z+91HVpesgX5IvZa1LW30+0VrfT7dYMn5yTmRvdmPSpJ/LjjaKz2mRuCy8AfVjU7FX62J/hrDLH8UrN55A0j6NfblzkqRPZ9fz6V7bXj3gONYviVpSRvGyjRr/wD1S4UHz7LPPc+pr2Gvr8sVsLBev5s+ax7viJP0/I8A/bW/5JZpX/Yai/8ARE9fFVfav7a3/JLNK/7DUX/oien+KPGt/wCEvgT8OrTQdQtNO1vWLPT7W3urooI7dBDGZJGLgqFAwCSDjd64rvOM+MlvZ/sBsvM/0Yy+dswMb8Yznr0Ner/s0KG8W6vmBJiumuQrAf8APROlew+NPGMnjj9kPU9VvJEk1JPs9telMAGZLqIE4Xgbhtbjj5uK8e/ZkGfGepDyy4Ont0baR+8TmuTH/wC7T9Dowv8AGj6nsWpyadcSP5uk7ChyZI2AP5cVZ0q7M+LeHVnSE4Hk3UXQezHpWx4i8N297Ak+yVWH8aJkgfhUEWgKLIGyu2aMjlXGD+Rr49xkuh9KpRa3Oh0/To7a1VXbzkA+8zZx+NOm0rTbmQOsZSVTwyOM5rnLfQ0kVkWe4gk9I5Dg/hV+3jvbA4aG1kjP/LXyCW/HFaxmtnExlB/EpD9YuIrBNt8Ld4TgbpSRn8RWGbKziDXNm1xGpOcwTiVQfoeRXVRLBfQlLi4t8tnhVK4/Bqox6XPp0Q+yXsMqknIlQYP5UpQe/QqnNL1Odis5LiPzbu5mWPOAy7c/XiknhsBCA811qGDxhgrj/GtuWK8kUhLd4pj1a3AZKyFTWNMuHkujHNbtggSDayj2wOtYtWNlK5LDJI1swsiAcfcuIwD+eKdpdjp03mPcy2xnz86DBwfqKJr+C7Cma8a3HdZ4WK/nTyLuGEyadFpV4McGKPDfXPrTSBtyVkWUuPDtlKBc3FvHg4yuVP61oyTeH51Bhu2C+ofj+Vcvp1ybi5zqOmNNcjIWNol2mupspb0xhW8OpHEBkbWUk/hWkGmrNfgYTjZqz/EJJ2ihH2Gytr6M8FpJVHH4/wAqoSQyXE6j7Ha25HULHx+eKTVbeOKdblLHY2Ruzzgd+K0dP8U+G0/dSzyeZ/dZG/lTh+8dm7CleCvFXHPb2S25DNbRSDuZiMViRwzySyJYyT3vP3hIVRfbNaOta5oDLuSCFm/hzGMn6Z71y0Wr2NvLKw+0MZGyqSy7FH0AqaqSdkXRUrNyVjUSzu7G4JuIY8kZLGXA/Pqavwz28kSi71I2w/uW6YB/4ERzWNFd3M+HhubO2hJzshQs/wD30a1Le605dq3kF3dseSx+6P6VnGyZpLmsasUUdtH5ovImhxwZn5/+vVTULw3ERjimWFGONyw/e9hnrUYudGvnZ9NsnEynBkdgAPz/AKUSW4vJkFxqC2zE/KEfLnHtWkn9lGMVb3pFFbBrJHe/uJEtySTuXGfwFL/YcWpQj7Dst4m5aUL+8P4Guki0KDy1d5ri+kHTzzxmmx6TrsrMlqtjp0R6yLl3qlQknqhPEJrc59fCUenyLLFA9zKR8qSuFVvfbW9ptnJZxZne2hduscahMf41m6roq6IhnvdUu7qZz8yrJtZs9h3/ACrYttEtJLIG0zDI648yRizDP1qow96yWopzvFNu6fkNv5IxEVur5kQ8bLcBCfx61lmW3tNsWl2Bed+QSSce7N2qIeGbKwnMr6hNcTg/wnLfmelZ9zqE8NyIIbQyq3/LCOTcT7saicmnqi4QT+En1a/t0U25u5577gm3sux9C1N0+zvWgxcGb5zkRKQmP95+p/Ct+yFta2/mXRgtHIyUJCn8cc5qiupW63LSbg6D5QWRguPYdTScVa7ZUZvZIhjtGiBV7KKKMdNvzEn1/wD11UkgTUbg2Vizo+PnaMcL9TWxJfyXvyQJJJu4GAF/IdfzqCPw5bLCyrb+VIxJYLIep7k+tJwv8Iue3xaMSHStJ0cIJJEkuyMBnId8/wBKr3ttBO2+V3lPcKdwH9KIPC1jDOZbm5x/shjk/jWdrmq2UF1Fai9WK0Xhoohl3PoMU53sODu7p3Iba8isbs/2fpMjMvBkcgA/jWncXd/NEZLqRLaLHEcS7nalV4riONiFtLdR/wAtm25HqRWrai1MW63ia7JHyuflT86la9Ryls7HJ2lxHc3bWtlaONv+snny3PsB1NbFnZael1Gs3+l3ZOFWVsgewUcD6VynjT4h+G9Alkg1PUmuboA/6DpWDgj+F5Ogzx05FeE+LvihrGtB7fTYodE045HkWZIdx/tyH5mP5D2rvw2W1quqVl3f6HLXx1Onpe77L9T668L6jY3Pxb0+ztr62nu7XRL7z7eFgfs4aez2hgOATtbjrxzivWK+Lf2LGz8U9V9f7Gm/9HwV9pV9PQpKjBU10PAqTdSTkzwD9tb/AJJZpX/Yai/9ET1xfhb43/DexsPB1xq+g6/ca/4e0yKwhuURDHGREEkKKZgDnB5K5xjpX0H8UNW8G6NoFvcfEOOxk0lrpY4heWRu084o5GECNg7Q/OPUZ5rzD/hPP2ef+fPw3/4Tj/8AxitSDzH4i/Fn4fat8P8AxZovhHRNbsNR1+5iu53uFXyXlEyOzkec20kKfurycVz/AOzCu7xZrYWVYn/sttrsM4PmR17d/wAJ5+zz/wA+fhv/AMJx/wD4xR/wnn7PP/Pn4b/8Jx//AIxWVel7am6d7XNKU/ZzU+xuqbKBC17qN8gJ+/HLhQf6fjUb30Nj++huLq8i4IEqBgf+BCsb/hPP2ef+fPw3/wCE4/8A8Yo/4Tz9nn/nz8N/+E4//wAYryXk+luf8P8Agnof2lrfl/H/AIB0TS6VqUPm3enzoAf9bE5BB+oqW0XS2Q/YdVuJAvG2SUEg+lcx/wAJ5+zz/wA+fhv/AMJx/wD4xR/wnn7PP/Pn4b/8Jx//AIxTWUO1nP8AD/gk/wBoLpH8f+AaGrOZZRBBcXazsCVXaGDU21hniiK3TR5OPvhkJ/pVH/hPP2ef+fPw3/4Tj/8Axij/AITz9nn/AJ8/Df8A4Tj/APxis3kl3fn/AA/4Jp/arSsofj/wCxb6RtvftEV7cxRE/MnzbT+OKm1do7cpJbaiPNTpHM+5GPuKo/8ACefs8/8APn4b/wDCcf8A+MUf8J5+zz/z5+G//Ccf/wCMU/7F0tz/AIf8EFmjvdx/H/gFubV9aMYRbTTzHjkhw+ffFZEynDPcTT2hY5KxWwVT79etXP8AhPP2ef8Anz8N/wDhOP8A/GKP+E8/Z5/58/Df/hOP/wDGKTyS/wBv8P8AglLNUvsfj/wCLTtS1GNwIYYJrfvLFBh8/St2C713aZI7oyQ44iNvhs+vFY//AAnn7PP/AD5+G/8AwnH/APjFH/Cefs8/8+fhv/wnH/8AjFNZK1tU/D/gieaRe9P8f+AOu73WdRBWGG3t2zjN0SG/AVlTeHyzM9zcfvG6yI/I/KtP/hPP2ef+fPw3/wCE4/8A8Yo/4Tz9nn/nz8N/+E4//wAYoeSu9/afh/wQWa205NPX/gGRH4CF7suIJrm6IOR55IUY9K3bfwzdQQCN7GCYnriPj881D/wnn7PP/Pn4b/8ACcf/AOMUf8J5+zz/AM+fhv8A8Jx//jFN5Nfep+H/AARf2q1tH8Rf7Mu7SQqLK1iPTCRM2DU114d1HVERZNTto48fPGIto/SoP+E8/Z5/58/Df/hOP/8AGKP+E8/Z5/58/Df/AITj/wDxihZJFO7n+H/BB5tK2kS1ZeEvKukRLieKKPlnjiIU/ia1dQsbCzgJt75hMFIDFcHP1xWB/wAJ5+zz/wA+fhv/AMJx/wD4xR/wnn7PP/Pn4b/8Jx//AIxT/sWNrc34f8Eh5lJu7X4mjo8GpzSFkv52TqWkk4PtjFbc+gatfRhf7SuolPeE7CfxNcn/AMJ5+zz/AM+fhv8A8Jx//jFH/Cefs8/8+fhv/wAJx/8A4xThkyjvP8P+CE8ylJ6RsdPD4AhjHmNIz3AGPOkcyMPxNU73SrqNjaQ3t5ckgArAFXA/3qxP+E8/Z5/58/Df/hOP/wDGKP8AhPP2ef8Anz8N/wDhOP8A/GKcsng9pW+X/BJjmU1ujpobJtMtUE1hiMcfPKXkP1NNk2xQyPEsdqj9Ut4sO593PP5Vzf8Awnn7PP8Az5+G/wDwnH/+MUf8J5+zz/z5+G//AAnH/wDjFT/Y3RT/AA/4I1mGt3H8Td0izvJCD9giSI5/ety2PXnJ/E0ur6vp1sWtSJrm6AwY4hjn0zWD/wAJ5+zz/wA+fhv/AMJx/wD4xR/wnn7PP/Pn4b/8Jx//AIxQsnsrKf4f8Ef9pXldx/H/AIB1ujKYrVQ8dvpUTDPlqd0je5Jqae8sNxigu1dscsD8qD1J9a4z/hPP2ef+fPw3/wCE4/8A8Yo/4Tz9nn/nz8N/+E4//wAYq/7Kdrc/4f8ABI+vK9+X8f8AgG3La6TOWaJpL+c8s/mHb+fQCpNP0GBlaSOO2hhj+ZpQoCp6ncetYH/Cefs8/wDPn4b/APCcf/4xR/wnn7PP/Pp4b/8ACcf/AOMVH9jK9+f8P+Caf2nK1kvx/wCAc/43+JvgTw7NLFbyNr+oxDiODDQ7vRpDxx3wDXhnjL4s+J/E/mwvdCw09uFtLP5FA9C33j7819J/8J5+zz/z6eG//Ccf/wCMUf8ACefs8/8APn4b/wDCcf8A+MV6FDA0KLvGOpx1MVVqbs+LG60lfan/AAnn7PP/AD5+G/8AwnH/APjFH/Cefs8/8+fhv/wnH/8AjFdZznlX7FP/ACVPVf8AsCy/+j4K+1K8w+F/iX4V6zr9xb/DyDSI9WW1aSU2ektaP5IdAcuY1yNxTjPoccV6fQB4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUAKvWvtD4KeDvCWofCzwzd6n4Z0a8vJoXaWee0V3c+a45J68AV8XjrX2z8ELgJ8KfCq56QP/AOjnrjx1V06aa7nRhqfPKx8nfFC2trP4jeJrWxgit7WHUZ0ihiUKkahyAoA6AVy1dX8VTu+JXihvXUpz/wCPmuUrqi7xTMGrOwUUUVQgooooAKKKKACiiigAooooAKKKKACiiigAooq3p1jPf3aW9su6RvXoB6mhtJXY0m3ZFdY3ZGdVYquNxA4Gemabiu/sdAFvYFZg+zkuh4MhBAII7kDnHb61W8UeB5rDzZ9LmjvIVUStDFkyRxkZDEdwO/pXPHFU3LludEsJUjHmOIopcd6K6DmEooooAKKKKACiiigAooooAKKKKACiiigBaKSigD6A/Yp/5Knqv/YFl/8AR8FfalfFf7FP/JU9V/7Asv8A6Pgr7UoA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgBRX2J8HJ9nwx8MrnpC//AKNevjxPvV9XfCa42fDnw6uekTf+jXryM4ny0ovz/Rno5bHmqP0/yPnb4mHd8QvEh9dQmP8A4+a5iuj+IjbvHfiA+t9Mf/HzXOV6dL+HH0RwT+JhRRRWhIUUUooASipI4nkDbEZgo3MQM4HqaaeBQOw2ilpKBBRRRQAUUUoFACUtXLDTrvUH2WUEkzAZO1eB9T0rqtG8HFsPqUobKlkgt23uw9eOnI6Gs6lWFP4ma06M6nwo5jStNk1CbapCRLgySt0Uf1PtXouiWWmWFrbw2bym9JYrM0e3LZ4P1GOO3PrVrTvDqiET3RjssH/R4o0+dsDOSO3+NaF99tgn06W4tPs0i/cWVclx1IB7YHOfWvMxGK9q+VbHqUML7JXe4WUcthZzT2W24uTLl2kBdvMP3tq9BgHr61uWInF88H2frCZnJOSxAwAx+pyee+KykVYme0j3+fwD853l+uFxxgDn1zgGtQ289q7RzTC6aILIQrGJLcZwFbH3ySe/vxXnVHfc74qxyfiDwBHq9ibvSQsGsLH51xbEbIpF55U9FcngL0OO1eT3MMlvO8M8bxyodrI64Kn0Ir6Mu9TvvPnDPFvRQi7zshIPJcHuf4QBWX4z8Kaf4hWERtFbaiv7pGjj+aRiMlpD2jX1PI/SuzC5hKm+Stt37f8AAOHE4FVPepb9jwGitXxDoeoaBqD2ep27RSjlTj5XX+8p7isuvbjJSXNF3R4zTi7MSiiimIKKKKACiiigAooooAKKKKACiiigD6A/Yp/5Knqv/YFl/wDR8FfalfFf7FP/ACVPVf8AsCy/+j4K+1KAPAP21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+KqAHJ96vpj4ZXGzwHoK56RN/6MavmdOtfQXw9n2+C9FXPSNv/AEY1eTnEeajH1/RnqZV/Efp+qPIfF8aXXjzWI5J4oFkv5QZZc7UG88nAJx9BXOzKEkZVZXAJG5eh9x7Vr+M2z4s1g+t3If8Ax41iV6VJWpxXkjz6rvN+oUUUVoZhSryaK0NA0yXWdbsdNt8CW6mWIEnhcnkn2A5pNpK7Gk27I6fwpaS2Wlm8dJEF22xWUj5lBxtx7nnPtW1L4esLq3ebVFzdZPmyRL5fyjuuBjP1HNep3/hltIsFbSGsb62Ki0t7e5g/ecdAD/EvU8+tcjPa3NpIkMVrJHPI4aZFYhkceuei44ArwXjXVlzRdrnvQw0YQUWr2ODufBllNbG60vUj9nC7v38fJHtistvB98yrJFcWbRt0YyFc/gRXqNpo810THFD5BVyGMC/IX9TjOOO/GfSpLLT00qW5VRdyWULFJoyerf7x7e1arHzjpe5m8DTlra3oePR+G9RkmEccUbEyeWDvGCfx7e9XpfBep20oW6a3iQnAk3FlJ9AQOfwr1ZTpdlcKkUKPdTxllMnzMy9QSV4IxwOKbdQyXoW2N3GiEmWJRG7Spjtnpmm8xqN7WRKy+mlq2zzSHwRPIZMX1nJ5QBkEcgz+GetaWj+FhBPI8mk/a4YcZknmCqT2G3uT2Arf/s2wHmsJ7kX8afIrIAnB+bDev9avaNHNeXuYheXYkGxo93I9B+WeaKmLqWev6FQwlNNaalRdPQWglZha2zIFgfHyq/VlSMc4HTJ6+taekWEMoM8lxJFPcgskNsoMjj3+uOfyq9f/ALqWYTSTKAwtYjD8htVPJG3u+O57VJbIJ5oUAeXyYghueUUofujP8J/3etcMqjcTsUEmUxaTQaigvkWOR2LxRoy7ExyS/XBH5VY8RQw39+tybmaFgubaTdgbQOTn37CpbiS5s7U2ek2UsF4wKRyEBwVzztz1GfXnvUVlpMd0o/tPU/3G4+b5cJzgdOR1YnoB271mntNuxTX2SrbvZqUkQeZJOpg88H5QfU57554I966K3s7T+w7ePTrU3d0x8yXbJxIV/jYnonHX0z61FY2F7f28UlppizqFIj81hg88DyxwD3J/WtO00+7tIZnvJLZVSYJM8Qw0zHooX0GcAdO9ZVJq25UVbcqeWt3N9pvreTykO2KeJADLJjn/AHUXsB9TV/w/pt5dardSJGBp9vsE0gOVznOzPfsSB7VrRxWmiloJ7V7jy/kSNJC53nnB9zTtF1S4vrNYLW1k+zwlnnll/cxA5/1agD5ifasubmTshyKPjXSNE17SzbXsUk+mWyk+Yifv2mZvvo2OufwPSvnXx14E1PwnMJJonm02Ukw3IHQZwBIB9xvY9e2a+sL+d9umfaZ47SOTJ3GPavAyTGh7AZAZupOa8k8SeNLe4sb3TNOsCtjLKY2N0RIJFHGSvc9Tz0PNd+BxFWlPljrHscWJw8K0bvR/1ufPdNra13ToILknThM0BG7bKuGX/EVjYr6WMlJXR4U4ODsxKKKKZIUUUUAFFFFABRRRQAUUUUAfQH7FP/JU9V/7Asv/AKPgr7Ur4r/Yp/5Knqv/AGBZf/R8FfalAHgH7a3/ACSzSv8AsNRf+iJ6+Kq+1f21v+SWaV/2Gov/AERPXxVQA5Ote3eB7jb4T0lc9EP/AKG1eIr1r1jwlPt8Oaauein/ANCNefmUeamvX9D0Mtdqj9P1R554sO7xNqh9bmT/ANCrIrW16OS48R36wo8kjTvhVGSeT2rJruh8KOGfxMKKKKokcvWvW/gj4UTUYdU1u9mjt4IR9ltpHB5lblsY9BxkdNwryWNSzBVGWPAHqa9l8O3N3oPh2GztpAIh87ecQFDn73B7ZrizCclS5I7s7cBBSqcz2R6Tc6Ff6Vp1vHe2sl1B5u97xJB5oGc/eH9RU+rvo1/dPaNf3i3M8I8uOSJd4x/dkPB9Nua5zQvHGo26brV4rlWYedg/NgdlBrXuvF/hrVpo5tR01rW+GD5sLEF3B4DIeDXzrpyvdo9znJLLRxDp7J4cvdQVnbJs2iwy/wB4gckficVlan4fvbSURxM55EouJiXG7+LavVj7HpXepdW062cljcyW2ovwI9y7gfTd6H3qudN1ZrieZdWmnuD/AAXDAqB/dDr+VZKo1r1K39Dyfybiz1OJWt7ONpcvH5iksw6dume46CpCLnSbhDdxQzrLulMUQyqY/ibHJ+ma9JGuSPJAdYi8q1VzHuS3X5TnAwx7UzVFto4LmOO2vJoVYfuliUKA394gdD3xWrxDfQUYHG29laywXRKX/wBkibz3uJPu27DsBjOSaj8Nut1qEqu76fPEx3STZlZiegRe34812bf2X9h2S2zPAfla2h39O4AzyfrXQ6Pe+H9KgEVvpcyXOd8eyHzJmGP4ewb9RSjU57xbCd46pXOPfwwslhdzN5k5J3OLmIRxsepYg/MzH0ArE0qKWO8vnksr1gGGJ5Y9pPGAFLfKoHQcE16HeNp+t4gaLV9PKM2+R2Yyk+gPI/HtRJY3UMyRqbu4lhXzWMsin5R3B9fc/hUc7imtwT76HEaN4d1DUdQW4uTJbBVKonmF5zG3GwL2z/ePQZNdDZaBoWhSXE9zdSST27fMHJ8qDPTywfvMcYyeOtbNpZausPm2V+sUMgLqqxAtt/u726/73auZ1EaNY35l1LXLK5G3JWdGdBu4PC8NjtRzSloGl9zclv5JBGtkpe2mQzSSRruQn+FOMHH1xmktptR1a7tpIofs0cW7ZI8Kuzt03L/CGyO/Sua1zxxpGn2sOmWYe+hWRQYIV8tZYxyB0zj/ACKw9W8W6/qZVLfZbiSciO0jYxiJT0G32HrVQoTa5thOa6HoOrtZeH7Vbi/u4BdRRljER88iHkhTnO492rlfFPxLtlvbH+x4pY7houVWPKBOyhe3+c15tfXFramafUriWS4ZhGsKPubbnk5Pb2HWs5tct5riWOzhKWUZ3STuSS2OxJ6/QcV2UsFfW10YTrJaPc2NZ8T32rao8d9ey3t1FloxnCRseO3HHQAVzZuZJ/8AQ4oWeSNifNXlQScYP94k/hWfqOrMheayeMqxOVUc5PfI9OlUpdWvktUgLGFPvKeB8uPb2zXpU8PZaI4p4hXs2SX32mO5e4vZiWbKIIhkN6isq5tfNlQQL+8YZbJAGT2FaJ14zljcoMInlxKgwFHrT9OeIXMRso8zcKDIctk9wO2B3rrTlBao5mo1HoznZI2jcq4KsDgqRgg0ytzxHNFOyfJ/pCkhnHfnp7/WsQgg9K2jLmVzmnHldhtFLSVRAUUUUAFFFFABRRRQB9AfsU/8lT1X/sCy/wDo+CvtSviv9in/AJKnqv8A2BZf/R8FfalAHgH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAKOtej+G5tuh2Sk9FP8A6Ea84Fdtocu3SbUZ6Kf5muXFx5oHZgnabOa1eV01u8dGKt5zEFTg9azqt6qc6ndH1kb+dU66Y7I5ZbsKKKUUyTS0CJX1BZHi81IhvMecFselb8+rxQRv5U00trI+DDKCQB369CKxbKKJIE+ZVkk583dgL/sn3q3FqMzLHbyKgw/yvIcjPvXNUjzO+52UnyxtsdvoGr6c2nxxeUhcn92JAASfb0pl5qO+dmaxeMxHgPJ3HeuFnmjkvWHkpDj/AFgU8N9Mfzq3Y+I54LT7OHJUkqGYgsv1/wAa5XhNW4nVHF/Zkelfa7W5tI5Zb2Z5yMoUK4B9OSM07Tdc1TSXiWaK8vQRiMJLjIByMqOK86/4SC4S1SKa2hxjHmMCQ3+0OxrT0/X47VlbfLalVx87bg3+7XPLBtJ3VzeOKjLqeswfEq9vJytxa2kUEY2i3lCs27vkDv0q1/wnVlqUAgNrPby8qIRKw3MerORjaPYV43baq8hu7o3CSSSZOSnzlR04FbUesbtADw2P79xtjaR8lj+dc9TBR7GkK6Z66df8OaI8Xl2syTOmxnlkLAn3A5NU5PGkl0ETTTqc0kD7i7kBBnqUOOuOg/OvMNLurq0SOG8it4Wz1jffn6+/vU8mqm0eTdfvARyAXGAKyeF17miqrc9OufFkBgF0miTRRr/x8zXbfvXHrn+gHNZeq/EJ9SkS2sLVUiZQDahC245+8Nv3iPfgV5ydRjubpfI+3z3T/MrSZKuPUDpit3TfJNtPcapfG0gjO2WG2/1sp9N3X8uKbw0YatAp32JPFfiDW/tipcak8iSKBIipgYXoMA8kflTtN8J6jPZR32oyNY2nmB914vl5Hc7TyT9BVP8A4WHpelw+VoehLHeEny5pcSygdjk52/lXM6zrGuamkkl/eNCJTnczlmx+PSt40ajSVuX1/wAjKVWCba1OpvPEHhrQL+V7KKfU7wEM+5dsaehrl9Y8QN9ukubuQRArlIoFwEz0H+99a5p5J7SNfLk84A78FcgHsfc/WsszmaMiYlsAgFugJ6n6+9d1HBwXvXu+5x1cXLbY07nULYSRTwKXkc5kLDcx9AOwFV5LsTs0c8zrEoyY1wAT6D09yaoRyxhlCx4wMHccgn1qBup/pXZGmkcUqrZZS42RunAjJyEH8Xpk+gqOWV5d0spLP0BPT6CoeDnjmgn9K0sZczHYweevWnJLIjl0cqxPVeDTATj2NCMUOR1oBGzZ38Rh2sitcAbIi4+WMd3PqaoXVs6OWmJK/wB7p+H1qpnn3rXtGN/H5LlQyDCk9EHc+7Goty6o15ufR79DFZSOtNq8wWN2BVpIUOM4wGPvVWRMHPrzj0rRO5k42I6KWkpkhRRRQAUUUUAfQH7FP/JU9V/7Asv/AKPgr7Ur4r/Yp/5Knqv/AGBZf/R8FfalAHgH7a3/ACSzSv8AsNRf+iJ6+Kq+1f21v+SWaV/2Gov/AERPXxVQAorp9Lm26fAM9B/U1zArWtJtttGvoKyqx5kbUJcsijfndezkd3NVyCKtx3P2fUhOYYZwj7vLlXcjexHcVWlfzJHfaq7iTtUYA9hWi2MpbsZVvTbb7XdJEWCryzMegAqqK3dDMdtbSTvvy52nA+XZ3yfc0py5VdF0480rMl2QeXGmN7O21lEo2sR0PsasSTtBaSw4Wd3bIzHuI9jirCzQXKK8US+UG+beh6e5H86jutk86Q+YkYI4MUmQB7j1rk5ruzO3lstGc9cK7vkqVl6lVXAFPlVXdGRyJSOhGKvziFWEcd2RFzgyrkA98GqisNnkpMgzkZYdfxPSuhO5zONtx08yxxoElmkx95GGFH0xULHzlyI2jXrn5m/WrNsI1hkVpXWRBjAYOG/4DjpUsSIFjEM7yBzja6H5W/A0rpDs5FZIJIJAfNkjbHys52cVOVH2f91eooj+YDec57kAfzNaMHhfX7uMS/YW8ncP3krDYB7knNbyeArrSdQhbWzaskgDYgYMVHfisZ4inHeSubU6E5fDHQ4y2Dz7AI2uGbpEAWI963ItP0zTwJdckmjbIJgxuc+xHYV3t54f0e30vyNF1m/uLreGaKK1WPB7DcTwK808Q6Vf2F27XxL3Dc53h22+pweKyp144h2TsaTpOirtXNG58VM48jRLZbeMD74j+c46c1kJeSicy3UhaRwS0LsQPc596jtYTcIoify1/iLtgv7ACq97aiOQs7gHqcKT+Fbxpwi+VIxlUqNczL6azAsJEUAt5nO3MQwFHrnqahudSjcDc0t1InQyfd+uKzyw8hljBC5+YFc/r2qLeFkDRDHpnnmtFTjuZSrS2JriSWQ7mdyOuMYFQO5YBQflHOKeS5ZhK+fXnJNRgnflQOKtGbdxp9PSgHqetANKeAMr+NMgQ8dBSkDHUHjtSDmgdemaADPSkopcUAJU1q5SdDnAzyfaohj6UqgdT+HvRvoNOzubmtSRywRLAAsajIUDt6msaUgt8o57+5rX0wLLYsgQSzOdqJnrju3oo9KypERJGQvkg43Dp7mohpobVbu0u5FIozlce9REY61cAj27tuPTPQD39aZNAUVd/DMNyjvj1NaJmLiVaKUjFFMkSiiigD6A/Yp/5Knqv/YFl/8AR8FfalfFf7FP/JU9V/7Asv8A6Pgr7UoA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgAqRZCAAKjooBOwpOTmkopcUAKgywHSupsZ3kttlsDsVdu1CCVI747g1zUIw4JG4dxWnb6pNHIPLG7b90gDeB9e9ZVE5LQ3oyUdWOFzcfaFRj9nYnBC/KD7+1XYjHIRDMAoUkgkg4PopHX6GoDdRz3QmuLovuXAIXGPZqhj8syytcoNg6BHwwP94DvUONzVSt1JJROjqAyyx5+TPG0emKkt9QEEvkXNspB6gKACKrhxIjFgHLHBYk5+uemfrSS2xRdzSM0bHgs27P4UWT0kK7v7pI0IcNcW4hhQttPlynd9Mdfyrq9E0FFVZJFN0Twv7tvl+rDgfjVHw/o87LFLsiYMcIzsFz7e1e46JoIksLaCJ5YbkoXeGMr5a/7xz/AI152Mxfs7RTO7C4dP35GDZafp/9nL9kt5ZL8KA3nyecg+ijg1qxeHLaC0iYanj5svFJApwT2Gfuj2q7ozaVpOs/Z59MUTAZaSzlYNu9CwxWwr6A5d0i+yFztkW4UyPJz6+vvXjSnLdM9Jehg6dpdmt7OzC5h+X70aH98p6jjjFcvq6aFPG9vYRtBCrFCSOS3fPc/nXoF7Hbzywwx27f2epwEMrbB9QOfwFYeq+Eo5bG7uEjVHjJK+TKzYXsDu4z9KKVVc15NjlG6tY8ZvNFns552uCGtU5ikWPapHtzXNai4aVGVAIgeCGzu98V7oNG8MatpBF7rE8Tbdv2RFNwwYf7VeQa3p+m2WoTx2q3MkUQynn9PqRXu4TEqo2nueViqLivd2OYeQsoAGFznGaaRu2hRz3xV5Ld9QuEW1h2BiBgnAyfevV/Dvw78H6dYreeL9ekuJyu4WVkQoA/2nP9K7KuIhRXvb9jhhQnV+FaHjZj2oM5DE+1Ct5f8KMffmu48T33hL7S9voOmywQq3MpYtx7n/CsO6sLW8VTptwrlRlg3yKo/wA9zThW5ldxa9QlRadk02YcjF25I/AYppPHGcepqa4tpLdsSKdp6NggEVA36Ctt9jBprRhnPX9KKU5wAPyFGMHnn6UCEHJ9qPp6Uppox3oAcKTPHFBPpTjnjmgDU0GbZM0O3G8fMe59vpUGqwtBesZV27uQp4/SpfDjFdRUqF3AHBf7q/7R9h6d6XXG86/kMIZx08xuWc+vt9Ky2qHRvSKKxs43de/60+6wbhizbmPU9yadE+y3VCQMtnj+ZpI0JLMOw5Zu3pVkdLDRD5iIAPvZIx+tVZIih9R6jpV9tsTbBuLtwx9vSpFt3k3Ig3Ljc+OgPpQpWBwuZJpKu3dm0JG35sjcQOSo9TVMirTvqjJpp2Z7/wDsU/8AJU9V/wCwLL/6Pgr7Ur4r/Yp/5Knqv/YFl/8AR8FfalMR4B+2t/ySzSv+w1F/6Inr4qr7V/bW/wCSWaV/2Gov/RE9fFVABRRRQBNarC0yi5d0h/iKKGYcdgSKjAptSRH94M9B7ZoAtSQz2ar5sJTdyr/4EVDnq247jVkSrMoimmEajlSE4/HFQAhCd4Ei/dHOPyNSvMtpdBqySIuQSAwwcjg0pmZiDxx0wOlCSGM44ZR/CeRRJIJGJCKhPZOlAXt1NAXRlhMckdmFYfeC4YH14q5Y29wbEvFexr5fziNwQD9D0rJUSTBJPLUqnBIUfrWvbwzzAGCVniA+aLIDL9AetZT0WhvTfM7s6jwFaC7DTi4n+1k7guSDIfQY4Ne36Lrt7pWnTR3FjFJOVyFC+WQO29sYBryP4YxXiOJIESWNWJJwEYexzXtdr4ikudNuLWXT5zGVKN5MYbb77u9fPY+TdVntYaNqSM6wubHVJibqNrcoOZDMGVifQD71aWqHRrSKOOwnuZZmwWSdfLAPvwDVfQ4NM1WEyXMP2e4Vdnzo4UkdCAvSsS9k+yasLbdagucJMUds/Ut8w/GuFLTQ6N3uXbGF7m7kjvdRhjYnMULcIPoSc1oX7rKi2DX95euw2tDDCPKP48Gsu2tkTVFNzGsobhZ7UgJu9CzcV0pvmt4Wtoru0WYj5YuFcj6gYH1pdRs8n8U6XL4elnXT576wjm5kEaAA+w9K8j114pZ99uJnctkvI3UV9A+NUkt7NvtNihtnX7z3O5ie+D1NeN6vodtat9ouY2a1b7oQcp9cV7OX1rr3tzgxtNte6YOn3DWUbSqqyyAfIpYbVPcjHWqf2hLm4ZtRlmP+ygOW9q2rH7LIZrextj5p+7sXe/4noKxrvT5rOYh3COT93P8AM16sXFt30Z501JRVtUVrxVBHk27QxdgxJJ+pqO3lkgcyRYyvqOK3vDnhXV/E1w32VdsCcvPOxWNR65Nad94W0TTWMN34gS4nVdxW3T5foCev9KJV6cXyN3f3kRoVJe8lZfcc4k1zqriKVwzdQDwPqfWob/T5rZiWKug43J93PpnvVua1sFcLYzmeTPClcD8T6V10uk/btNWNIzLP5eWfafLjX3bp+AqZ1lTatsaQoOomnqzzmgDPtWz/AMI3qUskos7aaeKL78u3CL+J4rKmi8mRkdgWU4O05FdCnGWzOWUJR+JERyOMUlOo/GmSHbHrQRzjrTzFhQT949FobDYI+hzQOxY0yMz3kUUane7AACr+riO3uTDC5YnhnUfLjuF9fc1J4dsXub1nDLHGi5eRztAXv9BTdREc1/M9sWaFRjzGGNw9h2HoKxcrz9DojG1P1ZlHbgjb7nHarcaEW8ZXqfmBPAU+w7/Wn2tiZ5vLCFVIzhj+prXhQO/k2sXMYwXIyR7AetE6iWiCFNvUowabJJAZJcRr1y3XH07VejhnmSFYIVEAOApPBP8AeY9/pTIrG4mmKRoZgW/eZfjjsT/Ouv06zlWFBCFlOdsOF+ViOrAdwO3r16VzVa3Lq2dVKlfoYEGnSTO6wxsw3bpGI5k9gPSsDxjp8OnahEkW1XkjEksaHKoxJ4H4Yr2DwhoEt0THBJ5jOGIkY5Lt/E5PQKvTP5Vwvxs0ZNE1vTIIgdklkJNzHLPl2yx+uPyrPC4nnrciY8XRUKPM9zuv2Kf+Sp6r/wBgWX/0fBX2pXxX+xT/AMlT1X/sCy/+j4K+1K9U8k8A/bW/5JZpX/Yai/8ARE9fFVfav7a3/JLNK/7DUX/oieviqgAooooAKlhKrJ867h9cU6ytpLy6it4ApllbaoZwgz7kkAfjSGMxztGwAZSVPORx7igaNGO2jMbSxyJIuOVk+Vl+lEEMojM0SCWM/K2Rn8x2NUgvGVfJ6YB/zmn2881sTJDIY26cHGazaZqpLqi21qPPCQOY5GGds64/I1WVkR3WdHVh08sjANXF1G4mVVudrDORIflI/Gm3F1btOpa2Ein7xckc+uRUpy2ZbUd4sqQlfN3MxDZ+6ARmpLkp5i4jeJ+xxjPvxV57OG4j3Wrxuq8mMyEOB7Z61TljV3TyFeNh0WR8lvpTUk2JxcUbXhHVbnSrgEFPKkORubIz9K9W0+/u5bdJpbJbhGOCvzJkH0C9fxrx7SNC1LXb1oNPsnknGM9uP8+le5eCvhT43itx55QwuM+XNJz9BmvLx0Kbd01zHoYOrKKtLbuXoIdQht1aCO6sIZDhRJLgAey5JP4Vq2E8sW6O31JMICJZHtvlX2LElqqN4L8UaZdSXDR3CRp8qo4Dpn178Vu2Njr0doslx4ftJVHzNNb265+oz3+teNODWh6aqJrR/iV2ntr+2jit4XumjOSWcxxuP7wHcUWFta3MU7zvYxyI+GUKd7AdhzwPpWnJd6L5VvPPqt7ZXKkKyy7AYx3PHGPauK+IXijQrRmj0q4ury4bC+Y+0KffCj+ZqYUpSdkJ1EtGZvxE8T2Mls9lb2lszYwWjXLKPUntXlMN45Cw3C72fiNpjxt+g6ir+s3Iky8oiZWydg/j/Ada525R0QTyIykjk9MD0HoK93C4eMIcp59eq3K6OhgkhtNTtTP+9twMvHF+7Qn04/rXZ24sNRkF4NAKGM4iCqHZvqO38684bxT9lto7bTY44F/jkZdzZ9eetdx4G15Yf3kL7gvVpjgE9yBWeKpTUee2pWHqQk+W4njj7aLSNHge0hJ4RH/UqDgfjXl906JMw85ZCvTH3fxPf+Vdz8RPEKakDbwyNNlsEoQEU/hjP61wV3YrDFu8+Nm7qOf1rpwMXGmufRnPjJXlaOth9rcq1zCvzFFOdq4y59816lol214kMbXC/ZoWyyHJUt6D+8fc8CvKLa1TzEe7LJE3TaP5ntXpHgHTp7+VkRx9jQDLOOI1+nT86Mco8nN2HgpS5rHReKvtOsW4guJWGmxL8tvajYhJ6ZP8Rry3W/DVxaOZBAIIuoVn+6PUn1r2W7hFqIo7WKe4lc4hTJyx7sT3+gqhL4fSR5hdKBdKB5mDnaT/AAjsP5152GxXsVpsduIwyq77nhOzbwFDN0x70zb85DHGOxrsPFeiNpt4zKY1P3jGvLKD6selcy1rudmAwvqc4r3KdWM48yPFqUXCXKyvEhklA3YzyWz2qeK1aVsLhU6hj0A9TWlBZQOQrl1wuc7cAmul0TwddXjCSNysajJZzhVHuewqKmIhBXk7GlPDSnsir4X0gvZT3LEiJTuXzRxn129z6Z4FVruwm84uMhAd7f3ifU+ld6ujXCW0VnZrPOFUEySR+Ujse4zzipf+EZkgtvJuFSYsQ05XhQPQnrj2Fea8YlJybPSWGvFRS2OSs4oldH+V5JRn5RuLD0AqwLaRZEjlEdurkuwQ5fb2Bx3NekW3hyyceQNtvLIB50nl8xp2UD19B0Heu6sPCWk2NvHLaWO4kYVj80kh+p6+7dB2rmljU7uKNVR5bKR5Fouirez/AGKCFpEUf6lBtBPcMewHc9zXR2OgyWthcy3bKjzOIt0QwWQceVHn7qk9W9M16Fomks0lzHAqJJI2yR4B8qD/AJ5oT1P95ug7U++0ixSeAzSeZbQMI1AJJuJegjjHZR3auSdapPbY0ThHQyNAsQ8YsraFks1UNczhcLJg8Iv+zngL35Jrxr9p6USeNNMVQAI9ORcZ/wBt6+h/tSxOLdGE7I20rHgebMf4F9FUdT2Ar5t/aPjWPxnZfNvlayVpHH3Wbe/3R2UdB64zXXlf+8L0ZyY93pN+h1H7FP8AyVPVf+wLL/6Pgr7Ur4r/AGKf+Sp6r/2BZf8A0fBX2pX0p4Z4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUAFFFFABUkS7mPBOATUdWLRC8wUZ5BzjrigaV3Y6Txt4YuPCOtDTL2aF5jBHco8JyrRyKGXIPzI3OCrDPfoQa5+OQg52ox75HWrN5IZp3laWSWUnLSSsd5+uetKz3LW43gSBujdxWV9DW3QrTPGxUohUfxKCcVOo3R4KyKmNyIRuFV1idnVcYBPfoKugXEOFLMVzxJGd2KbfYIq+5BIiFVdQCx4woKla7Lwfo9zqF4kPmK0ZILSMA5UVyzSssxRrgXAbnJypBr0X4aXE1tqCZ3xu5z5luTz6ZGOfrXJi5uFJtHXhYxlUPXbDR4NF0ozxw6dLIFz+5PlSt9PeuK1nx1fgG2jn1SBQ3AkuTujPt7V6Tr39o3OhglppFx/zz3L+PGa8C1TTry11JxcxedHI27y2BUZ9ga8LCRjUbcmerVbSskenaH8VNXDwae8ylkwrvIS7SL6j3+tdxqXiLVNd0trfT550LLtYrgMfoq5P5187LBfCbNqpwp3BQ43L9W7fSu+8GeIZLORFe31aa4B+c27HaPrjrWuIpOKvBk03GT95amX4s8Na1pp+0Xdtc+W3LSbSSB/uHv8ASuWt/s5X7NJPsY8qZEyc/Qc19MxeIbeG1R7gTSKRnypwq7vbcTxXJat4i8J31z513axRwplSsbqx3fgBk0qeJsrJX9P+GBwbeq/r7z541Lw7e/aGeCOadwN2UTac9ic9BXPXDS+a8V5I5lTouMkn3Ne+3tr4WuRNf6fd30TkjMMT5Lf8BHFWdC0azu5C9/5cMbf6tbiJCcepOK7I5jyL3onPPBKfwux85CRowCIiGPAYn9as6XeS20qso3DP3m5x9B619Fal8PNKnje6iudPuSOu4ZX6fLwK5OTwRo0g824jiaVThILVyo/E9a1jmdKas0zFYCpF3jI5a2lXUICn+h2fHLMgaU/4Vgaj4ZuY386PzGgB4klXAPsB1Jrs73wzpFjOgklktp25WO3PzfiTn9aswwfYpUun1PYF+VVkJdvzxipjiVDWmbSw/tFaoc/4X+G3ivxZKI9Psbox/wAUki+XEg9ST39hXrt/pekfDXRYrK9Emoa2yZOJcxw+pAHGfc5qhpXjvU4UmSHVkSDATAbJ+gHc1h6hqthc3Ya+afULtmy0OCU+hC8k/WuWtWqV7RmrLyNKVGNJtxZLL4o/tS9jYyzoI12x29uxDyk/33/hH61rW2kahBE95PElon3442bGSerN/QVP4dvI9Vuo0s9IklWL/WFYxEiY7DP8zXXamkupQwm6aC2sw2VtLU+ZJcMOgZh1H04964qk1F8qVjqim9b3PMLrQZdVZY4182eXLMxXagHqe5pY/hxb6bbyXuuXADyHbDbRkcDoM+hPoMmvTbfSLq3c3F9BbWe7hfOO5/YKg/makZIJ1LxQyzTKdou2AJ3HjCZ+VT7jJoWKqRXKnYTpwk77nN6Z4GshbJAkMEbHBmlcZ8sen1rtYtG023htLLSLBJAvzyXVyPkXH91P4j+lULG6stFhNvAou7pfvJCN6x+248Z9WJqCXVtW1RNsESxRSnGAfmdR3HfHb0rPnbXvO4OLvpoie4jjM893KwjtEJAu7gZM0ndgO+OgA4Famm2mlxPbJ9nlmZf3i+YfmeTsSvc/oKgt7SYzmfV54wVULCD92Eew7mt2whihQyWa7VZdisf9Y4789RnuRShG7JqSsrHK3lq99ez3lyIhaxvgQrnbkdnbufYfpV+4kkFsjX16S8uNttAQhf0TPYeuOAK0J9lzDNDMoWzT5HMYGWYniNB6+poFpDFEsdpZxxyEHaCc7QO5Y9B2zRyvdBzklqyW1ikDyLJcbf3ggXEceekaDucf4mqcEptbdwI0S7cnBZt2wdyx9h/COnel01DDcFS73MudoMabY0J64/8Ar5NWZ7dfLudRlQfZLddqljxK46Ko7jPU07OS06EtpPXqYgiGiWM+p3HV1K26PxlTyWb3PX8hXzr8ebia68R6bPcgLK9irFe4+dsZr3bxKb24tBda2Q9xJhIbSHomfX1b9BXgfxxieDxNZRSyKzpZoCqj5Y/mb5Qe/ua78rt9YVuzMMff2Db7o7n9in/kqeq/9gWX/wBHwV9qV8V/sU/8lT1X/sCy/wDo+CvtSvpTwTwD9tb/AJJZpX/Yai/9ET18VV9q/trf8ks0r/sNRf8AoieviqgAooooAUAk8Ak+1aGjWrXl8I4yQwUtleox6VUtp5baVZYJHjkXoynBFeifADSLLXPiJHZakkjwNaTtmPG5SEyGGeuPSoqS5YNounbnVzkNQtZre55Lu79CyY3fjVQeasp+VlI6rzX1F4o+CFxeW5l0K8julHzCNnMbKfb0PtXkep+CdZh1GSCawuHeHjzCg3KfTI4YVw08ZFr39Gd8sNf4Hc8/iknmZY1OW7Agcir9lavJI6+bb28w6rK23P58Vp3OmTWjvDdWzKoPz/uiCD9TyKrjRrt3V0KvEpyA7Bjj+la+1jJaMlUpRequV5tOkkwTDCMHDFGGD7g9609E1EaXqEbECWHIU4LblPvz0+lJBpM1zIY1c2kn9xh19/8A9VXYPDN1LKyXpUr/AAuW3bvyGaxnUg1yzZtCnJPmij3nwJq1vqEKoZY4oyMDMkuf5kVD4p8F6ne6gZtHgmu+pCxoUUj/AIH1P0NeXaT4X8QTlBpN6pjU4G2XH4c4IPtXoXhWDx3oj7tQ1O5trUfwy4lJ/wCAlv5V40qcKcuZS/zO/mlLSxX0f4TX1xcPNqGnsZC25xdTiEr7DGciuzs9GTw1A+wRRygfLHJO0gH0xxS3v2/UlSdr64afHAkiWMMP++s1NpthAjNLPDJNdZywlIfPtz2+lYVKrqaalxTjueaeNdav9Ske3g0uCWR8os1srEqfqRXGW3w88XX7B/7DvrlO0ZTCH34xX0Rq3iu/0yERxR2NhH2+zp8y/UEVzkfxK1q4kdVuI2iX+JmwT9cdK66OIVJWivwMZ0p1NbfieOXPwr8ZmVFXw9ewAnPlQn5fxJNTjwF4qtrsW/2JkcrgxGYv+Ldfyr2V/Hevana/Z7aWGBn+USoeF/8Ar1Wg07WLJvPgmaa4P3pWugCT9AeadTHyei/IIYa3xafM8vm8I+JdMtxcXZ1IhBwiKRGo9AK51dN8Qag0kkEepmNeGURlef6V9HWtnqtyyG91di7H7qICR7c8/pWnZtJY6h5Vzd+eD92NpFjIPuAM/nUQxclq0vUc6cbWufOGi/C/xnq8wa202Zh2M0mzaPcn+ldJcfBXW4pIxrWvadFMRlbWGUyMPc54A96911ee83nyryMQY5ghbOPq3SuT07w5ZXWpNdRrK7EnzGDFwR/tOeAPYVc8dU+FbmUKMX7zehx3hf4Q6XLqMY1TUWuY04EVo5DN6g4r0LWNI8OaBaJpenG306aVfuQJ8wHqzcsx/GtW50fhbhZGggjGPNJEKAenXLViXtreXF8n2aBhGePtAUAhe5LHp9BXPVq1XHlnqzWCi5Xi9EYi6XocEdtZWdxqM8m7JOzCP6gg449zmt+w1SHRo5DAILebp5rqJZSPYdFHpmti5trSxsI2tQzSNw1w8YO31Cg9TVvRNIsbIB1gmed/nO4ZYn1LHgfhmojTnKWjsOVWHLqrnF3cF5e6kt7fRXEqbSVSYgSN9I//AIritBV01tqTNOJUTPlGTiIH1PYn1x0rU1syTXbiKFt8QxHFF8qgnux6n8TWTYXU8c7W7WavLn97IhByfVj0rKSUZNbmqblG9h+qxaWulxbjCsIIEcEIKpuPTPdj/Pvip7O5i0yzlS0SNpj/AK5wBx/s57n2HAqve2Laq5VisUMbb3EfJ47vIeB9BVFBaSxNBbAzRD7qW/TPux4pSk73XUIpONmzZsdOtzHJqeoPuuMYALeYc+ijoPw6VWs5Pne182cOfvoP9Zj/AGm/hHOPWk0u4ntl+z2Fk6z/AN+Vvuj1yeg/U1atbCPT7eW41D95JM/ygnAkb2Hp9aq17NCel02V7ydVSC10x0eQPtIRs7fUA/zPYcVtTaVLemBvtohijYGZgMCUgcIB3FcskUlrLJcwN5iSvtBVMJuPRUUct/L1rXW4ezvILGBmu9YlG5gx3C3j7kgcA/kKdNr7SJqJpLlZpXlrHYI9zcTtOcbIrYMI40B6lj/kmsTWGn1SGNr7UWtbeJlMUFqm0RqPbqSegFTXAl1LURbQSksgzmPlgO7A9EH+2fovPNZl0LSOZbexczyq+3zS2F3eg9APzPtTnJ2vHYVOGvvbkF0LjUNWCpCEa3XMcTHK24/vSn+Jz2UdK8I/aIsDp/ivTY3bfI9isjsTySXfqO3TpX0LFaSPDKYJykSPlpE4Dv6Z749B/Ovnj9oaKSHxZYRyvuYWK8E5YfO33vf2rsyr/eF6MwzD+C7PqjrP2Kf+Sp6r/wBgWX/0fBX2pXxX+xT/AMlT1X/sCy/+j4K+1K+nPBPAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgAooooAK9T/ZxuIrX4nW7zo7Rm0uFYqM7Mofm+gry2vWv2YmlX4qQ+Qu6X7Dc4GAc/uz2PB+lZV/4UvQ0pfGj6cFj9mY3sUs8jDlRExjVx+HGfrVy786W0+0WTGKRl+5M5K59MEcVPFceXlHW3s5G6jyvlP+8mf5VXvdLuUeaS3iSwHBMsTt5Ug9dvIFfMeztG0V+h7XPeXvM5+AW96ZItS8Nh79sjzZcGIj1BHFVrTwzpFvPJE9igf/AJ5zRIAv+4wOcfXNbWjG5t7yaKcR3UX3lk84qT/ukdvwpniJtKe3WS509ZT93dLmQr9GAyKxSvC9zbmalZdTlml0zSrrZcWVrNGoOHS1DH6Fl4NXLPVLR3xZ6BYxySHIm8p4ePcg9a2LG6stVtPIga3dV42AFenucVdWyS3t9ptVjlcYWMIW3f8AfJINSoy6Mtzit1qc7NoV3qLs/m21s/dXQuQPXNSt4fv4LNYjrFxsHQ7EmUfQDkVsiOzt9G2TIJJl/wCWU/7pgT6bjxTbDUILO1DahY3lrGf4XmOR/wB8gj9aagtEyXVk9V0K9gPscG2eWJwP+WskO0/iSKsfbLdQ3lXERYjkrukP6cVW1GUmYLpcbGCbJPBdj+P+NMtXeG1aFkmS8xnyZpWVAPX5QBU3toPlurswptOWe7nW81NLaFzlQ44YehyeKTSNK04tIbRrJolP+v8ALZQT7EnBrRtrCNn3RTxJP9547ciZmP8AwLIqHVJpo4HbVbbeobEaOmRjtkcc+wqNVE2vd2uSx6TbmZriCYXBUcrGgEefdun4CremM1k/m3VpbxStwHyF49gMk1Dppt57YyXBdFA/dxQ2rkj/AIDjGav6AIVuvs8elXSyygt5rAeYR/tHBC/QVUVdp7Gc5WTTLtrLpoPzRAnP3YC3zH+v41PctaWds1xJYWFpED8v7xTIx+p4B/OoZdLs4ppCqQx3DZHmRt5vlL3z2zVe1i8MBpDaK9zdIcFjCxIPtkZ/KuhOS0djn916q42+1S1vLcIs0rs4wqxpuz9CRj8hinWs1/HDE11NaW0cZ+SJsMD6fL0FUL64mSR/7TubWKAn93anav4sOSfx/Kp4JnkliuJIBcwrwux1yvvggAD9ax5nzXNlD3bI0LnUb678tVjW/UHl1AVI/f0NUra2vrhp5UuJ4VU4a4kg8wf7sag449TWxpc1tNM1xLOnlp0VpBtBHYev14qe81H+0QNohSzQ5aZ3OD/ujp+JzW/KpLmlIw53F8sYmRe39pYRn7Kry3yY3z3XLfTPIX6AVNbzXEbNM6Xb3Moz5KttAHq7n7o9hzThNb3V6rWodorfuqBUVvbPVverz20tvbNcWE0ZXqd7bsn/AGpG/pRFSbv0XYG4pcttX3Ob1dtRu5Tbq0VlahS8swbGB7dz9ao6fplta2TyyXM8pP3A+UT67f6nk9q2W331vO995cJHVl5Lfie1Z+m6ZJOokhkeK2Rshifmcj1Y9B7Dn6VztNvTU6E0o66F+30e4vhANVlJtMZjslXy1f3ZRzj/AHjzVr7dYxs0Nh5EECnYZ9v3j3CAcbR60kmm6kGLvPH5TDIjZTmT6852/Wqhnnj1CBU2T3DDCCNRtjA6sOwA7n8q0b5Vaxlbnd73NhALW0ZrG04PJlm4Lt6nufpWRrKRTKHmPmORh7q44VV7rHGO3v8Azp93rM8shitFWZYuHmkb92D7nuf9kVX0K2u5NSe5uQb24kPyPMQqRj0C9h7fnTnJS92IRi4+9IBJEJYJZkZZVQ/Z43+VYF7tj1PrTNIaDTLO9vbtJI7S5kBJiQme6PQZzztHana6yHU08hxcTKf30vAQHsn+1/ujp1Naen2j3NvLcXTMVHLys4z9A3RB9Mk1MYvmsug5NKF31M24uruewuYLGyjsYJueH+dkxy7H6dKppHb2lkJZLITJEAEwQqA9lXP3mPr+XrWlbWzvdyLfTW9tZZDup4wvYHPJJ96m1fWNJtZ42KmedflgjIzj3x9KXK5e9J2KTt7sVcz3ae6lgmuHNnYw8COPgyv2Rfp3avnT9pJXHjDTi0flxNYKY1AwNu9+nf15PJr6Us5ftjSSyuiPGheeZyNsEfXGegOOfYda+Vvjv4i0jxL40FxoM0lxbwQLA87AhZGBJJQHnaMgc9cE9K9HKoOVbnWyT1OPHySp8j3O5/Yp/wCSp6r/ANgWX/0fBX2pXxX+xT/yVPVf+wLL/wCj4K+1K+iPGPAP21v+SWaV/wBhqL/0RPXxVX2r+2t/ySzSv+w1F/6InrEvYNE0Hwp8JoLTwl4Vmm1/T4/td3deHjqE25beJ94jiKu7Esc9T39aAPkWivqnxfb6Hrn7NHiHX/8AhFPDOl63bXKWzSabYRwvGVuolPGC8TFTyhOQDz1r5WoAns5YobmKSeBbiJWy0TMVDj0yOR+Fesfsx3McHxchmMTiMWlydkYLbRsP5gV5BXqX7OVzLafE2CW3fY4tLj5vL3j7h6j0rKvLlpyfkXTXNNI+xL2LS7+2M93C8kY6mNiSvuVHIqhZyTWMTJby3L2J5RndZlA+nXFUII31GNryxt4ftuMNsjKMPUrk8j2qG3sDJI1ncXkdtct8wUNtwfUBuD9OK+YlUcmpJfPa57cadlyyei6djUghiQFwkd2pO4IjeSU9gKikv4lvl23N1Zw4x80wkXPoV6/jUb2O1FtZZxd3EeCCsJA+uQf5GqOoLqlvdJF526DbzEYBMxP+y3X8KmUnFWHGCk9xlxPdXt+Cs1nJCjfNLbxAsPr04q/b2T3B8xL21tyDwREwz+IbH6VQt0gjvVhm822aQZzKzop+hHQ/WiTSbF9SdokViwy6xTv859SOhNZxb+J6msrbLQrRyyTaoY5ZLKeEHB3QlmY/R66SPRrhl+S4lgtCOY0Cxg/hWJDBLEJbYyCNT/q5jalnT69jT4tGuLC3ecXEmoNgsNy7V/75bgU6em6v+Ap67O3yuaCOiTSWbzSQrGowImw4H0Oc1japFawWgeKc3G5sKJLljIzenH8qsRk6jbJJbB1wdsphT5kPcDBxUsui6fApkgvIfO6kXS/OT+OMmk7yWiCNoNXZiqktgVWyjtReyDcQysu0e5AzUF3fGKeMaxJaNk8OifKn4tzSedPbvNPeRW0j7sKysSh9Aq85NPs7iSWZVvba0QHkpPEBgfyFYX6HTbqWtPu4FmkaSUyRDlcOMj8ATUeoT394GCTyw2jEFEkkEZP/AAFfmI9quGLRlLtbiMTMMEQRhR/30cAVXt7aWFjJa2MsZboyXKc+5IBP61dmtCLp62HNPf2Mcf2l5PIx91F2rn2XrVkC9ubbMN1Llj9y3jUbB7saZHBJDHLIkcYuGGWc3hyfYnHAoZ4Y/Lt4/nuJecxybEHvx1/E0tU9RXvsXYbcQIsX2JoEUZNywVRn1z1/GqT2ll5ouYlguiMndhmZj7c4/GmyreRHy724W4tmGBBCm8/Vm71Be26R2pmEFwsKDhJAI4vqfWqk/IUY+ZpWtjE8Uss/2awD/MRvBb8v8ePas+XzZpkhsUaWFzhAW3tJ6sWPA/lTtKtr3VYQ8f2OzgB5k3+bI2PRQAo/E10G24toDDaQxRLjEl7dsWJ99o/qauMOZJ7Eynyu25z8tldRMDdMohT+GBiyr7Y/jb9K7VLWzl09JGIeVVwpb52U+w6A/hXFalqdmqS20N697cOpX5hsXnvhece1XfCFu3lLaQve3JhX95NLiJF9vYfrVUZKMnFK9yK0XKHM3axNd2cNmGkvpGdz921Q/Kg9ZGPU+tWbbXROoi0uJriVRgvHH8kfsrEYz7jpVmaCKB2dLWO7A5Bdj5QPuTyx+grP1PUnuLWSKW7CwRn9+8SGOGMf3Bjlj7Cqa9ntoQvf3V/67Akd1dytJNHJcRJ80jGTbAp9yeX/AM8VA6yGW4knmgZSB+6BIG0d3I5x6LTL6aK8WK3vrkxWsYDJAD+8Ydj5a8KPrWJeag/2gWNjYSwQ5+UAbpZD/ePYD3asZNG0Itmtb3S6nu+0QTLYRZCIieVGR3IHXHuafczW8kSu7Jbw8RpFGxAAPQHHJJ9BzUTvI8K21zC0luR+8Ct+7+hbq5/SqJtCrSSMG06zyFEgGGcngKg6kn2qeZlqK6mrIUjkgFrYxyTFtpeYZdV/2UHC/Q8+tS3d/cfaYxeHKr/qLSAbgn+2x6Z9zwO1OhntdNt1iiRvN25IPLAerHoPpSafYXes3AlaIJaq24B2wD7n1/lWivfljuzN23lsVL22i8sTTRRrltyR8vub+856uc9qqXcem+G9Jn1XxBeLp9rndJcXB3ysTztRRyXPZR06npVb4ifEnw34BVhK39q68BiKyiO3yz6yH+Bf/Hj2HevlDxx4y1jxpq5v9buPMIyIoEyIoFP8KL29+5716GFy11XzT+E462O5Fyx3Os+KvxUuvFjHTNFhk0vw0hytru/eXDf35mHUn+70Huea8wJoJzSV9BCEaa5YqyPJlJyd2fQH7FP/ACVPVf8AsCy/+j4K+1K+K/2Kf+Sp6r/2BZf/AEfBX2pVEngH7a3/ACSzSv8AsNRf+iJ65/T/AB58MNS8K/D3+1PGeo6TrfhqwiSNrKydjHKYERw2+3kVsbSOOPrxXv8A418HaF430qLTfE9j9usophcJH50kWJArKDlGB6MwxnHNcV/wz58MP+hZ/wDJ+6/+OUAePfETxp8NIfgt4n8OeD/EFzqOrardJeyvc20wlupjcRPI7MY1QHah4GBxwMnn5hr7/wD+GfPhh/0LP/k/df8Axyj/AIZ8+GH/AELP/k/df/HKAPgCvV/2aPIPxTtlu7j7PC1pcKz5A6oeMmvqj/hnz4Yf9Cz/AOT91/8AHKt6b8Dvh9pd0LnTNFubO4AKiW31S7jfB4IysoODUVI88HHuVCXLJMnOiQ2duGhWO5AOVaRzG3th1/qKpXUcZuFfW9Df7Iq/613EhB9mXqK3B8M/DgHB1wfTX7//AOPUrfDXw68ZjdtdaM8FTr9+Qfw86vMeW6Wi0vkdixmt2cq0Wkzq6aJvMbcPHuzs/A/MKhS0u57KW3itYZ5Y/undiQY6YIwa6mL4U+FIf9VBq6f7uuXw/wDa1A+FPhRZfNWDVxJnO8a5fZz9fOrF5VNu/Ml6XNlj4rZP5nH2GtuR/Z2t2UsskQBLykrj8+CaQ3E4uXeyIMI+75TqCPriu0ufhd4Xuhi6TWZh6Sa7ft/Oao4fhP4Sg/1Fvq0ef7mt3w/lNSllNR/aRSzCC+z/AJHEpq+tw3wXUZLY2bjCK8il2PoO9Vob+xhnuJb+2n3sePLUsAP8+td9L8JvCMy7ZbbVZF9G1u+P/talHwo8JhNgt9WCdNv9uX2P/R1J5TVvfnGswp2+E5zR75YVElpC0Vu3IzCrKffgAiodWe2k/wBJntJTjrIkmFHueM110Xwx8NRR+XENbRP7q69fgfl51DfC/wAMMgRl1oqDkA69f4B/7/VTyqo48vMQsfBS5uU4FYESIT6XeSI7fNiNMk/99f4Vo3Bn2Q3NzJHmP5trquW/Oupk+FPhSVw8kGru46M2uXxP/o6o/wDhUXg7fu+x6nu9f7avc/8Ao6p/sia2kW8yi94nJapJqesQxi0jxGBgwFAi/wDAn6/lUllZXVpaKupRo0gGPklIjH0WuuHwr8KqMLFrAHtrt9/8epj/AAm8IyffttVb663fH/2tR/ZE9+ZXJ/tGOyjocTqH2eYeXdXgC9RbRwmQY9wv9TVeN7K3mjVIrRc8K80BT8AM816BF8KPCcR/dQaun+7rl8P/AGtTx8L/AAwJBIE1oSDjd/b1/n8/Opf2RP8AmRSzKCVrM891S6jF1DEy3EgcZ3AmONQPoBzV62/dpvaB/LbkNLKGbHrlzwPoK7Zvhl4bZst/bhPqdev/AP49VY/CLwd5jObPU97feb+2r3J+p86hZRU/mQf2lBq3KzjrW3glmaaCTyJQeSZvMH5D5aknjutQRomnu3bGEZ0VEP055rsf+FUeE8qfI1f5fu/8Ty+4+n76pV+GHhlZfMUa2JMY3DXr/P5+dTWTz25hPMo9jhfJjtkis3treacL8zx5Du3tgfy/OpopIU3WV4y20EYz5Yb5F/AcsfrXZr8MPDKuzqutB24YjXr8E/X99UK/CbwikplW21VZc53jW74HP186j+yJraSD+0YvdGVeSWsOlZ865ZWXapI2Z46KO31Nc8NRito4bcxoVJzG8jFlB/2RwMD15ruZfhX4VlYNLFrDsvQtrt8cf+Rqib4ReDnm81rTU2lxjedavScfXzqqeVVJPSSRMMfCKtJNnnkCSDUpWshLeXLcu2B8o9WPQD0FaEw/sq1e6mhe4kPPlxksXPue/wDKu5j+FvheNSscesqpOSF12+AJ/wC/1Sv8NPDrhQ511gvTOv35x/5GqI5NJfa1NHmaenLoea6dd6pfTtdTRJHt4QyJiK3Hoi/xt7nioY7q7m10zXYafYSsIDZCDHJx6nv04r0xvhb4XYANHrJA6A67f/8Ax6mw/CvwrCCIYdYjGMfJrl8P/a1Dyio/toFmVNfYODlks7WO41LxBew2lhb/ADESMAkfpn1J7Dk15D8Sfj5Pc276R4CE1jZEYl1CXieb12j+Afr9K+i774I+AdQjjjv9Iu7mOMkos2q3jhSepAMvGapf8M+fDD/oWf8Ayfuv/jlduEy6NHWerOTE4x1tI6I+BZpXmkZ5XZ5HJZmY5JJ7k96jNff3/DPnww/6Fn/yfuv/AI5R/wAM+fDD/oWf/J+6/wDjlekcR8AUV9//APDPnww/6Fn/AMn7r/45R/wz58MP+hZ/8n7r/wCOUAeAfsU/8lT1X/sCy/8Ao+CvtSuK8FfC7wd4I1WXUvDGj/Yb2WE27yfappcxllYjDuR1VTnGeK7WgD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    First-trimester umbilical cord cyst.",
"    <br>",
"     (Panel A) Two cysts within the amniotic cavity are identified in relation to the umbilical cord.",
"     <br>",
"      (Panel B) Note the extraamniotic yolk sac.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32102=[""].join("\n");
var outline_f31_22_32102=null;
var title_f31_22_32103="The pleura in lung transplantation";
var content_f31_22_32103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The pleura in lung transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32103/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32103/contributors\">",
"     Marc A Judson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32103/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32103/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32103/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32103/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32103/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/22/32103/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural disease has important implications both before and after lung transplantation. Preexisting pleural disease must be evaluated in every candidate prior to lung transplantation, and de novo disease may complicate transplantation, sometimes as a manifestation of acute rejection.",
"   </p>",
"   <p>",
"    The preoperative evaluation and postoperative management of pleural disease in patients undergoing lung transplantation will be reviewed here. Issues regarding the selection of candidates for lung transplantation and the physiologic changes that occur following lung transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17194?source=see_link\">",
"     \"Physiologic changes following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETRANSPLANT CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preexisting pleural disease was initially considered to be a contraindication to lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/1\">",
"     1",
"    </a>",
"    ]. This belief was based upon an early report in which four of 12 postoperative deaths after heart-lung transplant (HLT) were attributed to pleural hemorrhage caused by lysis of pleural adhesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/2\">",
"     2",
"    </a>",
"    ]. Anticoagulation, which was required for cardiopulmonary bypass, may have aggravated the degree of pleural hemorrhage in this setting.",
"   </p>",
"   <p>",
"    Lung transplantation has now been successfully performed in patients with previous pleural procedures including pleurectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/3\">",
"     3",
"    </a>",
"    ]. The outcome of lung transplantation does not appear to be adversely affected by a previous pleural procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients with cystic fibrosis require removal of both native lungs prior to bilateral lung transplantation (BLT) or HLT because of the underlying chronic suppurative lung disease, which would place a transplanted lung at risk of infection from a remaining native lung, especially with life-long immunosuppression following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/5\">",
"     5",
"    </a>",
"    ]. At the time of BLT or HLT, pleural fibrosis or adhesions increase the risk of pleural hemorrhage due to lysis of adhesions and the technical difficulty of removal of the native lungs. Patients with cystic fibrosis are more likely to have preexisting pleural disease due to the high incidence of pretransplant pleural complications (eg, pneumothorax) in this population. Although pleural disease is not a contraindication to lung transplantation, efforts should be made to minimize the extent and degree of pleural fibrosis during the pretransplant course of disease.",
"   </p>",
"   <p>",
"    It is estimated that approximately 3.5 percent of cystic fibrosis patients develop at least one pneumothorax by adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/6\">",
"     6",
"    </a>",
"    ], a percentage that is likely to increase with improved survival. Pneumothorax may be treated by observation, tube thoracostomy with or without pleurodesis, open or thoracoscopic resection of apical blebs with or without talc poudrage, pleural abrasion, or parietal pleurectomy. The degree and extent of pleurodesis depend upon the selected procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H5#H5\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'Cystic fibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We use the following approach to minimize the development of pleural fibrosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumothorax in a patient with cystic fibrosis should be treated initially with chest tube drainage and observation for up to five days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the air-leak persists at five days, a procedure that minimizes the extent of pleurodesis should be attempted, such as thoracotomy, thoracoscopic stapling, or blebectomy with apical talc",
"      <span class=\"nowrap\">",
"       poudrage/abrasion.",
"      </span>",
"      This approach will usually be successful, since 85 percent of pneumothoraces in cystic fibrosis result from rupture of apical blebs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Only if the limited procedure fails should diffuse chemical pleurodesis or extensive parietal pleurectomy be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that lung transplantation is",
"    <strong>",
"     not",
"    </strong>",
"    absolutely contraindicated, even if unrestricted chemical pleurodesis or pleurectomy has been performed. Several reported patients have undergone successful transplantation in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiopulmonary bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary bypass is rarely required in patients who undergo a single lung transplant (SLT) unless they have severe pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/12\">",
"     12",
"    </a>",
"    ]. It is also used infrequently for bilateral lung transplantation (BLT), as the sequential single lung technique is generally employed, in which a SLT is performed, followed by a contralateral SLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, extensive pleural adhesions can prolong the duration of dissection and anesthesia, and may result in severe, difficult to control air-leaks during the procedure, potentially necessitating cardiopulmonary bypass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EARLY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax and pleural effusion are common early postoperative problems, occurring within the first two weeks after lung transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pneumothoraces resolve spontaneously within days after transplantation; however, approximately 10 percent of lung transplant recipients have an air-leak lasting more than two weeks after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/15\">",
"     15",
"    </a>",
"    ]. Virtually all of these air-leaks resolve with tube thoracostomy alone and require no further intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The significance of a pneumothorax varies with the clinical setting. As an example, pneumothoraces may occasionally be seen in the early posttransplant period because of undersized donor lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/16\">",
"     16",
"    </a>",
"    ]. These pneumothoraces are usually small, clinically insignificant, and resolve within days to a few weeks. On the other hand, a pneumothorax resulting from dehiscence of the bronchial anastomosis is a more serious complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26121?source=see_link&amp;anchor=H15#H15\">",
"     \"Airway complications after lung transplantation\", section on 'Bronchial necrosis and dehiscence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pleural effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions are extremely common in the early postoperative period. As an example, in one series of 100 patients, all had ipsilateral pleural effusions after lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/18\">",
"     18",
"    </a>",
"    ]. At least three mechanisms may contribute to the accumulation of pleural fluid during this period:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased alveolar capillary permeability because of allograft ischemia, denervation, and subsequent reperfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Disruption of lymphatic flow due to severance of allograft lung lymphatics",
"     </li>",
"     <li>",
"      Acute lung rejection, an event that occurs at least once in almost all lung transplant recipients and is most common in the second to sixth week after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postoperative pleural effusions are usually small to moderate in size (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53151 \" href=\"mobipreview.htm?2/46/2789\">",
"     image 1",
"    </a>",
"    ), but rarely can be massive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/21\">",
"     21",
"    </a>",
"    ]. Most resolve spontaneously within 14 days following transplantation, although a small percentage may increase in size over the first three postoperative weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/19\">",
"     19",
"    </a>",
"    ]. Most cells in the effusion are of recipient origin, with donor cells accounting for less than 1 percent of the total pleural cell count by the eighth postoperative day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of pleural effusions without clinical evidence of infection or rejection have been studied following SLT in nine patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/23\">",
"     23",
"    </a>",
"    ]. The pleural fluid was initially bloody, exudative, and neutrophil-predominant (",
"    <a class=\"graphic graphic_figure graphicRef65922 \" href=\"mobipreview.htm?1/19/1342\">",
"     figure 1",
"    </a>",
"    ). Over the next seven days, the percentage of neutrophils and the LDH concentration decreased, while the percentage of macrophages and lymphocytes rose. The pleural output gradually diminished in all but one patient, who developed the primary lung graft dysfunction, a form of noncardiogenic pulmonary edema that occurs within four days of lung transplantation (",
"    <a class=\"graphic graphic_figure graphicRef67671 \" href=\"mobipreview.htm?7/48/7951\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/19\">",
"     19",
"    </a>",
"    ]. Resolution of pulmonary edema generally paralleled the decrease in daily pleural fluid output. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/13/36057?source=see_link\">",
"     \"Primary lung graft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions are associated with acute lung rejection, an event that occurs once in almost all lung transplant recipients and is most common in the second to sixth week after transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. The evaluation and treatment of acute lung transplant rejection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3994?source=see_link\">",
"     \"Evaluation and treatment of acute lung transplant rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural fluid analysis of posttransplant effusions has revealed that the fluid is exudative and often contains more than 90 percent lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/24\">",
"     24",
"    </a>",
"    ]. Even though pleural effusions may occur with acute lung rejection, the sensitivity, specificity, positive and negative predictive value of a pleural effusion detected on chest CT for the diagnosis of acute lung rejection is poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the combined CT findings of volume loss, pleural effusion, and septal thickening are very specific for the diagnosis of acute lung rejection, this is a relatively uncommon occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not believe that new or increased pleural fluid on the chest radiograph is diagnostic of acute lung rejection. Nevertheless, these radiographic findings should heighten the suspicion of rejection if they are observed in the first few weeks to months after transplantation. Furthermore, we suggest that a patient with acute lung rejection does not require investigation of a small to moderate sized pleural effusion unless the pleural fluid fails to improve within one to two days after treatment of the rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural space infection complicates about 7 percent of lung transplantations, and approximately one-quarter of pleural effusions that develop within 90 days of lung transplantation are infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/26\">",
"     26",
"    </a>",
"    ]. In a study of 455 lung transplants, fungal, bacterial, and mycobacterial pathogens accounted for 61, 25, and 8 percent of pleural infections, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/26\">",
"     26",
"    </a>",
"    ]. Candida albicans was the predominant organism. Patients with pleural space infection had a significantly diminished one year survival compared to those without infection (67 percent versus 87 percent, respectively).",
"   </p>",
"   <p>",
"    In a study of 392 patients who underwent SLT, BLT, or HLT, empyema developed in 4 percent and was not related to the underlying indication for transplantation or the type of transplant performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/27\">",
"     27",
"    </a>",
"    ]. Mortality was 29 percent among patients who developed empyema.",
"   </p>",
"   <p>",
"    Opportunistic tuberculous empyema has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/26,28\">",
"     26,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chylothorax is the accumulation of chyle, lymphatic fluid, in the pleural space and may occur as an early or late complication of single and bilateral lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/29\">",
"     29",
"    </a>",
"    ]. The fluid is characterized by lymphocytosis, a triglyceride level greater than 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and the presence of chylomicrons. Chylothorax occurs after lung transplant due to disruption of the thoracic duct or its tributaries with chyle leakage into the pleural space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/29\">",
"     29",
"    </a>",
"    ]. In patients who undergo lung transplant for lymphangioleiomyomatosis, chylothorax may also be caused by leakage of chylous ascites across the diaphragm or more diffuse leakiness of the thoracic lymphatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several treatment modalities are utilized for chylothorax, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    infusion, pleurodesis, thoracic duct ligation, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    , and pleuroperitoneal and pleurovenous shunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. For patients with chylothorax following lung transplantation for lymphangioleiomyomatosis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    therapy may ameliorate the effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Living lobar transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural space problems appear to be relatively common in recipients who undergo living lobar transplantation. In one review of 84 living lobar transplantations, pleural space problems developed in 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/34\">",
"     34",
"    </a>",
"    ]. The most common pleural space problem was a persistent air leak due to bronchopleural fistula (38 percent of all pleural space problems). The increased frequency of a persistent air leak may be caused by size disparities between the donor and recipient lungs that prevent complete apposition of the donor lungs to the chest wall. Loculated pleural effusion was the next most common pleural space problem (21 percent); empyema was rare, occurring in only 2 of the 84 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LATE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study reviewed the early and late pleural complications in 133 lung transplant recipients and noted the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural complications (infection, pneumothorax, parapneumonic effusion) were less frequent following SLT (5 of 53, 9 percent) than after BLT (22 of 80, 28 percent).",
"     </li>",
"     <li>",
"      All but one of the pleural complications after SLT were caused by pneumothoraces that persisted for more than fourteen days. No patient developed an empyema or parapneumonic effusion following SLT; these were seen only after BLT.",
"     </li>",
"     <li>",
"      Pleural complications were most common in recipients with underlying cystic fibrosis (10 of 27, 37 percent) and chronic obstructive pulmonary disease (12 of 40, 30 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transbronchial biopsies, when performed to assess rejection in lung transplant recipients, infrequently cause a pneumothorax, probably because of postoperative pleural adhesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/20,35-37\">",
"     20,35-37",
"    </a>",
"    ]. However, a pneumothorax may occur from superimposed pathology, such as invasive fungal disease, or from progression of the underlying disease in the native lung after contralateral SLT. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Pleural complications in the native lung'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pulmonary venous anastomosis problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, pleural effusions may result from abnormalities of the pulmonary venous anastomosis, including stenosis, kinking, or thrombosis. These abnormalities may cause unilateral or bilateral pulmonary edema with pleural effusions. Although this complication often occurs in the immediate postoperative period, pleural effusions from pulmonary venous abnormalities have been reported more than one year after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Malignant pleural effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients are at increased risk of developing malignancies due to long-term immunosuppressive medication. Pleural metastases and primary pleural mesothelioma may manifest as a pleural effusion, which is often hemorrhagic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/60/12233?source=see_link&amp;anchor=H2#H2\">",
"     \"Noninfectious complications following lung transplantation\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pleural fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fibrosis has been found at autopsy in heart-lung transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/40\">",
"     40",
"    </a>",
"    ]. An experimental study of heart-lung transplants shed some light on the mechanisms that may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/41\">",
"     41",
"    </a>",
"    ]. Pleural fibrosis developed in animals who received allografts but not in those who received autografts (their own heart-lung bloc). This observation suggests that chronic rejection, not the surgery, was responsible for the pleural fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INTERPLEURAL COMMUNICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During HLT, the anterior pleural reflections are severed so that interpleural communication develops, allowing air or fluid to move between the pleural spaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. Similar interpleural communication has been observed after heart transplantation and with mediastinotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/43\">",
"     43",
"    </a>",
"    ]. This phenomenon persists for more than two years after HLT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] and is most likely permanent. Interpleural communication may also occur after sequential lung transplantation performed through bilateral anterolateral thoracotomies and transverse sternotomy (clam-shell), because anterior pleural reflections are also severed with these approaches.",
"   </p>",
"   <p>",
"    Awareness of the interpleural communication after transplantation is important because pleural disease in these recipients must be managed aggressively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empyemas need to be diagnosed early and drained promptly, so that infected pleural contents do not contaminate the contralateral pleural space",
"     </li>",
"     <li>",
"      A tension pneumothorax in such recipients is likely to be bilateral and therefore life-threatening",
"     </li>",
"     <li>",
"      A single thoracostomy tube is likely to be successful for HLT recipients with bilateral pneumothoraces [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PLEURAL COMPLICATIONS IN THE NATIVE LUNG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural complications may develop in the pleural space surrounding the native lung after contralateral SLT. Pneumothorax is the most common problem, a not unexpected finding in patients with the disorders that lead to lung transplantation (eg, cystic fibrosis, COPD, alpha-1 antitrypsin deficiency).",
"   </p>",
"   <p>",
"    These secondary spontaneous pneumothoraces are rarely treated successfully with tube thoracostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/47\">",
"     47",
"    </a>",
"    ]. In comparison, both thoracoscopic talc poudrage and thoracoscopic parietal pleurectomy have been successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32103/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20674488\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preexisting pleural disease was initially considered to be a contraindication to lung transplantation. Based on subsequent studies, however, the outcome of lung transplantation does not appear to be adversely affected by a previous pleural procedure, although operative time may be longer. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pretransplant considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following lung transplantation, both pneumothorax and pleural effusion are common and typically occur within the first two weeks after lung transplantation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Early complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Small pleural effusions that develop in the early postoperative period after lung transplantation may be observed without diagnostic studies until their resolution which should occur within two weeks. However, large or rapidly increasing pleural effusions and effusions associated with fever, dyspnea, or pleuritic chest pain should be evaluated promptly to determine the cause. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pleural effusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most post-transplant air leaks resolve with tube thoracostomy drainage alone. However, sudden onset of a large pneumothorax on the side of the transplant may reflect a bronchopleural fistula or dehiscence of the bronchial anastomosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pneumothorax'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26121?source=see_link\">",
"       \"Airway complications after lung transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Postoperative pleural effusions are usually small to moderate in size (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53151 \" href=\"mobipreview.htm?2/46/2789\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pleural effusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pleural effusions developing in the second to sixth week after transplant may be due to acute lung rejection. These effusions are typically exudative and lymphocytic (eg, 90 percent lymphocytes). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pleural effusions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3994?source=see_link\">",
"       \"Evaluation and treatment of acute lung transplant rejection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most common pleural space problem among patients undergoing living lobar lung transplantation is a persistent air leak due to a bronchopleural fistula. It is thought that size disparities between the donor and recipient lungs may contribute to the increased frequency of persistent air leaks in living lobar lung transplantation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Living lobar transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late complications, occurring more than two weeks after lung transplantation, include pneumothorax, malignant pleural effusion, hydrostatic pleural effusion due to obstructed flow through the pulmonary venous anastomosis, and pleural fibrosis, which may be a manifestation of chronic rejection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Late complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interpleural communication is typically present after heart-lung transplantation and after sequential bilateral lung transplantation performed through bilateral anterolateral thoracotomies or transverse sternotomy (clam-shell). The significance of this communication is that a single chest tube can drain bilateral pneumothoraces; tension pneumothorax is likely to be bilateral; and that pleural space infection can be transmitted to the contralateral side. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Interpleural communication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who undergo single lung transplantation, secondary spontaneous pneumothoraces can occur in the native lung due to the underlying disease (eg, cystic fibrosis, COPD, alpha-1 antitrypsin deficiency). Given the severity of the underlying disease, intervention to prevent recurrence, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"       talc pleurodesis",
"      </a>",
"      or thoracoscopy with stapling of blebs and obliteration of the pleural space, is usually necessary. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pleural complications in the native lung'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H9#H9\">",
"       \"Secondary spontaneous pneumothorax in adults\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/1\">",
"      Egan TM, Kaiser LR, Cooper JD. Lung transplantation. Curr Probl Surg 1989; 26:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/2\">",
"      Tazelaar HD, Yousem SA. The pathology of combined heart-lung transplantation: an autopsy study. Hum Pathol 1988; 19:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/3\">",
"      Dusmet M, Winton TL, Kesten S, Maurer J. Previous intrapleural procedures do not adversely affect lung transplantation. J Heart Lung Transplant 1996; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/4\">",
"      Detterbeck FC, Egan TM, Mill MR. Lung transplantation after previous thoracic surgical procedures. Ann Thorac Surg 1995; 60:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/5\">",
"      Shennib H, Adoumie R, Noirclerc M. Current status of lung transplantation for cystic fibrosis. Arch Intern Med 1992; 152:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/6\">",
"      Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/7\">",
"      Noppen M, Dhondt E, Mahler T, et al. Successful management of recurrent pneumothorax in cystic fibrosis by localized apical thoracoscopic talc poudrage. Chest 1994; 106:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/8\">",
"      Noyes BE, Orenstein DM. Treatment of pneumothorax in cystic fibrosis in the era of lung transplantation. Chest 1992; 101:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/9\">",
"      Rich RH, Warwick WJ, Leonard AS. Open thoracotomy and pleural abrasion in the treatment of spontaneous pneumothorax in cystic fibrosis. J Pediatr Surg 1978; 13:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/10\">",
"      Curtis HJ, Bourke SJ, Dark JH, Corris PA. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant 2005; 24:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/11\">",
"      Madden BP, Hodson ME, Yacoub MH, et al. Heart-lung transplantation for cystic fibrosis. BMJ 1992; 304:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/12\">",
"      Bando K, Keenan RJ, Paradis IL, et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 1994; 58:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/13\">",
"      Triantafillou AN, Pasque MK, Huddleston CB, et al. Predictors, frequency, and indications for cardiopulmonary bypass during lung transplantation in adults. Ann Thorac Surg 1994; 57:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/14\">",
"      de Hoyos A, Demajo W, Snell G, et al. Preoperative prediction for the use of cardiopulmonary bypass in lung transplantation. J Thorac Cardiovasc Surg 1993; 106:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/15\">",
"      Herridge MS, de Hoyos AL, Chaparro C, et al. Pleural complications in lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/16\">",
"      Griffith BP, Zenati M. The pulmonary donor. Clin Chest Med 1990; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/17\">",
"      Mills NL, Boyd AD, Gheranpong C. The significance of bronchial circulation in lung transplantation. J Thorac Cardiovasc Surg 1970; 60:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/18\">",
"      Ferrer J, Roldan J, Roman A, et al. Acute and chronic pleural complications in lung transplantation. J Heart Lung Transplant 2003; 22:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/19\">",
"      Siegleman SS, Sinha SB, Veith FJ. Pulmonary reimplantation response. Ann Surg 1973; 177:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/20\">",
"      Trulock EP. Management of lung transplant rejection. Chest 1993; 103:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/21\">",
"      Raju S, Heath BJ, Warren ET, Hardy JD. Single- and double-lung transplantation. Problems and possible solutions. Ann Surg 1990; 211:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/22\">",
"      Judson MA, Sahn SA, Hahn AB. Origin of pleural cells after lung transplantation: from donor or recipient? Chest 1997; 112:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/23\">",
"      Judson MA, Handy JR, Sahn SA. Pleural effusions following lung transplantation. Time course, characteristics, and clinical implications. Chest 1996; 109:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/24\">",
"      Judson MA, Handy JR, Sahn SA. Pleural effusion from acute lung rejection. Chest 1997; 111:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/25\">",
"      Gotway MB, Dawn SK, Sellami D, et al. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis. Radiology 2001; 221:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/26\">",
"      Wahidi MM, Willner DA, Snyder LD, et al. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 2009; 135:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/27\">",
"      Nunley DR, Grgurich WF, Keenan RJ, Dauber JH. Empyema complicating successful lung transplantation. Chest 1999; 115:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/28\">",
"      Penketh AR, Higenbottam TW, Hutter J, et al. Clinical experience in the management of pulmonary opportunist infection and rejection in recipients of heart-lung transplants. Thorax 1988; 43:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/29\">",
"      Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996; 335:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/30\">",
"      Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangioleiomyomatosis. Chest 2003; 123:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/31\">",
"      Fremont RD, Milstone AP, Light RW, Ninan M. Chylothoraces after lung transplantation for lymphangioleiomyomatosis: review of the literature and utilization of a pleurovenous shunt. J Heart Lung Transplant 2007; 26:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/32\">",
"      Ohara T, Oto T, Miyoshi K, et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg 2008; 86:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/33\">",
"      Sugimoto R, Nakao A, Yamane M, et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant 2008; 27:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/34\">",
"      Backhus LM, Sievers EM, Schenkel FA, et al. Pleural space problems after living lobar transplantation. J Heart Lung Transplant 2005; 24:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/35\">",
"      Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/36\">",
"      Greene CL, Reemtsen B, Polimenakos A, et al. Role of clinically indicated transbronchial lung biopsies in the management of pediatric post-lung transplant patients. Ann Thorac Surg 2008; 86:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/37\">",
"      McWilliams TJ, Williams TJ, Whitford HM, Snell GI. Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant 2008; 27:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/38\">",
"      Liguori C, Schulman LL, Weslow RG, et al. Late pulmonary venous complications after lung transplantation. J Am Soc Echocardiogr 1997; 10:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/39\">",
"      Chhajed PN, Bubendorf L, Hirsch H, et al. Mesothelioma after lung transplantation. Thorax 2006; 61:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/40\">",
"      Yousem SA, Burke CM, Billingham ME. Pathologic pulmonary alterations in long-term human heart-lung transplantation. Hum Pathol 1985; 16:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/41\">",
"      Haverich A, Dawkins KD, Baldwin JC, et al. Long-term cardiac and pulmonary histology in primates following combined heart and lung transplantation. Transplantation 1985; 39:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/42\">",
"      Engeler, CE, Olson, PN, Engeler, CM, et al. Shifting pneumothorax after heart-lung transplantation. Radiology 1992; 185:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/43\">",
"      Wittich GR, Kusnick CA, Starnes VA, Lucas DE. Communication between the two pleural cavities after major cardiothoracic surgery: relevance to percutaneous intervention. Radiology 1992; 184:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/44\">",
"      Paranjpe DV, Wittich GR, Hamid LW, Bergin CJ. Frequency and management of pneumothoraces in heart-lung transplant recipients. Radiology 1994; 190:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/45\">",
"      Sacks EM, Unger EC. Heart-lung transplantation: postoperative pleural effusion. AJR Am J Roentgenol 1990; 154:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/46\">",
"      Holland SA, Hutton LC, McKenzie FN. Radiologic findings in heart-lung transplantation: a preliminary experience. Can Assoc Radiol J 1989; 40:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/47\">",
"      Spaggiari L, Rusca M, Carbognani P, et al. Contralateral spontaneous pneumothorax after single lung transplantation for fibrosis. Acta Biomed Ateneo Parmense 1993; 64:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/48\">",
"      Venuta F, Rendina EA, de Giacomo T, et al. Thoracoscopic treatment of recurrent contralateral pneumothorax after single lung transplantation. J Heart Lung Transplant 1994; 13:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32103/abstract/49\">",
"      Waller DA, Conacher ID, Dark JH. Videothoracoscopic pleurectomy after contralateral single-lung transplantation. Ann Thorac Surg 1994; 57:1021.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4653 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32103=[""].join("\n");
var outline_f31_22_32103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20674488\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETRANSPLANT CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiopulmonary bypass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EARLY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chylothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Living lobar transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LATE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pulmonary venous anastomosis problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pleural fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INTERPLEURAL COMMUNICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PLEURAL COMPLICATIONS IN THE NATIVE LUNG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20674488\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4653|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/46/2789\" title=\"diagnostic image 1\">",
"      Pleural effusion lung TPL PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4653|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/19/1342\" title=\"figure 1\">",
"      Pleural fluid after lung transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/48/7951\" title=\"figure 2\">",
"      Pleural fluid output after lung transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26121?source=related_link\">",
"      Airway complications after lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3994?source=related_link\">",
"      Evaluation and treatment of acute lung transplant rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=related_link\">",
"      Lung transplantation: Procedure and postoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/60/12233?source=related_link\">",
"      Noninfectious complications following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/50/17194?source=related_link\">",
"      Physiologic changes following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/13/36057?source=related_link\">",
"      Primary lung graft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_22_32104="Scorpion stings in the United States and Mexico";
var content_f31_22_32104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Scorpion stings in the United States and Mexico",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32104/contributors\">",
"     Frank LoVecchio, DO, MPH, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32104/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32104/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32104/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32104/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32104/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/22/32104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scorpion envenomation is a significant problem in the southwestern United States and throughout Mexico. In the United States, Centruroides exilicauda (sculpturatus) stings are associated with major neurologic toxicity, especially in young children. In Mexico, multiple toxic species exist, and annual mortality due to scorpion envenomation is ten times higher than that due to snakebite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/1\">",
"     1",
"    </a>",
"    ]. An estimated 5000 deaths occur annually from scorpion stings worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supportive care is the key component of management. Antivenom therapy with equine derived Fab fragments reduces the duration of symptoms.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/50/22307?source=see_link\">",
"     Centruroides antivenom",
"    </a>",
"    is available in Mexico; in the United States, its use is restricted to that of an approved investigational drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENTOMOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scorpions, which are grouped in the phylum Arthropoda, have a lobster-like body shape with seven sets of paired appendages: the chelicerae, the pedipalps (claws), four sets of legs, and the pectines (a pair of comb-like structures on the ventral surface) (",
"    <a class=\"graphic graphic_figure graphicRef78165 \" href=\"mobipreview.htm?37/1/37906\">",
"     figure 1",
"    </a>",
"    ). The segmented tail curves upward dorsally, ending in a terminal bulbous segment called the telson, which contains paired venom glands and the stinger. In the United States, a subaculear tooth on a small, slender scorpion is specific to Centruroides exilicauda (sculpturatus), also known as the bark scorpion (",
"    <a class=\"graphic graphic_picture graphicRef66559 \" href=\"mobipreview.htm?35/28/36290\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75239 \" href=\"mobipreview.htm?43/0/44032\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55476 \" href=\"mobipreview.htm?20/43/21172\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Envenomation occurs through stinging, not biting. Scorpions clutch prey in their pedipalps (claws) and thrust the tail overhead to sting. Although envenomations are sometimes reported as bites, true scorpion bites have not been documented and would be inconsequential if they did occur. Scorpions can sting multiple times, although the first sting depletes or nearly depletes the telson of venom.",
"   </p>",
"   <p>",
"    A characteristic physical property of scorpions is that they fluoresce when illuminated by ultraviolet light, as from a black light or a medical Wood's lamp (",
"    <a class=\"graphic graphic_picture graphicRef54120 \" href=\"mobipreview.htm?27/38/28257\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/7\">",
"     7",
"    </a>",
"    ]. This property is used in collecting scorpions for breeding or venom harvesting and in providing pest control. The fluorescent pigment in scorpion cuticle is most likely riboflavin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCORPION GEOGRAPHY AND APPEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scorpions are found on all continents except Antarctica. Scorpions characteristically live in desert areas, semiarid grasslands, and the tropics.",
"   </p>",
"   <p>",
"    Estimates vary regarding the number of scorpion species. Researchers report 1400 scorpion species divided into nine families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/8\">",
"     8",
"    </a>",
"    ]. Buthidae is the largest and the most dangerous family and, with few exceptions, contains the only species capable of producing clinically significant envenomations, through their neurotoxic venoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2\">",
"     2",
"    </a>",
"    ]. At least 30 species can inflict potentially fatal stings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ]. All of the genera commonly recognized as dangerous are buthid scorpions: in the United States and Mexico this includes Centruroides and Tityus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Centruroides exilicauda",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. exilicauda, (also called C. sculpturatus or the bark scorpion, due to of its preference for residing in or near trees) measures 4 to 7 cm long in length and varies in color from yellow to brown or tan (",
"    <a class=\"graphic graphic_picture graphicRef66559 \" href=\"mobipreview.htm?35/28/36290\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75239 \" href=\"mobipreview.htm?43/0/44032\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef55476 \" href=\"mobipreview.htm?20/43/21172\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66854 \" href=\"mobipreview.htm?1/46/1767\">",
"     picture 5",
"    </a>",
"    ). The presence of a subaculear tooth, a tubercle at the base of the stinger, is specific to C. exilicauda and is helpful in differentiating this highly neurotoxic scorpion from other species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. C. exilicauda is found primarily in northern Mexico and the southwestern United States (eg, Arizona, New Mexico, western Texas, southeastern California, and near Lake Mead, Nevada).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Centruroides vittatus",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. vittatus, the striped scorpion, has a black intraocular triangle and black stripes on the thorax. C. vittatus is found primarily in the Southwest and Texas but also extends into southern Indiana and Illinois [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Centruroides suffusus",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. suffusus, also known as the Mexican scorpion, is yellow to tan with dark longitudinal strips on the abdomen and measures 5 to 7.5 cm. C. suffusus is found throughout Mexico and is considered the most dangerous among the many species found there.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VENOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scorpion venoms are complex mixtures containing mucopolysaccharides, hyaluronidase, phospholipase, acetylcholinesterase, serotonin, histamine, protease inhibitors, histamine releasers, and neurotoxins.",
"   </p>",
"   <p>",
"    Neurotoxins are the most important venom constituents in human envenomations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/11\">",
"     11",
"    </a>",
"    ]. In neuronal membranes, these toxins cause incomplete inactivation of sodium channels during depolarization that result in a slow inward sodium current. This action causes membrane hyperexcitability, and leads to repetitive uncontrolled firing of axons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2\">",
"     2",
"    </a>",
"    ]. As a consequence, release of neurotransmitters at synapses and the neuromuscular junction is enhanced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/12\">",
"     12",
"    </a>",
"    ] and leads to excessive neuromuscular activity and autonomic dysfunction.",
"   </p>",
"   <p>",
"    Some scorpion neurotoxins also have effects on calcium-activated potassium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/13\">",
"     13",
"    </a>",
"    ], chloride channels, and L-type calcium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The venom of C. exilicauda venom does not cause local tissue destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2,3,8,11\">",
"     2,3,8,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REGIONAL EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. exilicauda (sculpturatus) is the culprit in most reported envenomations. Its sting causes a significant number of systemic reactions, and is known to be potentially fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Centruroides vittatus, the common striped scorpion, is the second-most commonly reported species in envenomations.",
"   </p>",
"   <p>",
"    From 1931 to 1940, more than 40 deaths were attributed to C. exilicauda envenomation, mostly in young children and infants. No deaths have been reported from scorpion envenomation in Arizona since 1968. In 2001 a scorpion-related fatality was reported, although death was ascribed to anaphylaxis rather than to direct venom toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/15\">",
"     15",
"    </a>",
"    ]. Mortality can usually be prevented with appropriate supportive care; prior fatalities were caused by respiratory failure that was complicated by metabolic acidosis, hyperthermia, and rhabdomyolysis from excessive muscular activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mexico",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 134 native species are regarded as dangerous. Among the eight members of the Centruroides genus, C. exilicauda (sculpturatus), C. noxius, and C. suffusus (the Mexican scorpion) are usually cited as the most dangerous. Most fatal cases occur in the summer months from April through July. In the 1980s, hundreds of scorpion fatalities occurred nationwide per year, with respiratory failure as the proximate cause of death; this figure probably underestimates the true total by a factor of two to three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/16\">",
"     16",
"    </a>",
"    ]. In Mexico, scorpion deaths outnumber snakebite deaths ten to one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human scorpion stings are usually accidental as scorpions would rather escape humans than attack. Stings most commonly occur when a human unintentionally steps on a scorpion or reaches under wood or rocks.",
"   </p>",
"   <p>",
"    The majority of scorpion envenomations in the United States and Mexico cause local or no pain with minimal to no inflammation. However, C. exilicauda (sculpturatus) and C. suffusus often produce similar neuromuscular effects that can be life-threatening. C. vittatus stings are less likely to cause systemic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Centruroides exilicauda (sculpturatus)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings after C. exilicauda envenomation are categorized into four clinical grades (",
"    <a class=\"graphic graphic_table graphicRef67046 \" href=\"mobipreview.htm?35/21/36187\">",
"     table 1",
"    </a>",
"    ). Clinical findings after envenomation by C. suffusus follow a similar pattern:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Grade I envenomation",
"      </strong>",
"      &ndash; Grade I envenomations produce local pain and paresthesias at the sting site. Usually, no local inflammation occurs, and the puncture wound is too small to be observed. If no scorpion is seen, the diagnosis may require historical or epidemiologic clues or other physical signs.",
"      <br/>",
"      <br/>",
"      The \"tap test\" has been empirically recommended to confirm a C. exilicauda (sculpturatus) sting, although its reliability has not been rigorously tested. With the patient looking away or otherwise distracted, gently tapping the sting site will greatly exacerbate the pain, a sign that does not occur with other scorpion envenomations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2,5,6\">",
"       2,5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Grade II envenomation",
"      </strong>",
"      &ndash; Grade II envenomations produce local symptoms as well as remote pain and paresthesias. The more distant symptoms often radiate proximally up the affected extremity but may occur in even more remote sites (eg, contralateral limbs) or as generalized paresthesias. Children may present with unexplained agitation or inconsolable crying.",
"     </li>",
"     <li>",
"      <strong>",
"       Grade III envenomation",
"      </strong>",
"      &ndash; Grade III envenomations produce",
"      <strong>",
"       either",
"      </strong>",
"      cranial nerve",
"      <strong>",
"       or",
"      </strong>",
"      somatic skeletal neuromuscular dysfunction.",
"      <br/>",
"      <br/>",
"      Cranial nerve dysfunction can manifest as blurred vision, abnormal eye movements, slurred speech, tongue fasciculations, and hypersalivation. The combination of bulbar neuromuscular dysfunction and increased oral secretions may cause problems with airway maintenance. Abnormal eye movements most often are involuntary, conjugate, slow, and roving. Chaotic multidirectional conjugate saccades resembling opsoclonus and unsustained primary positional nystagmus may also be seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/17\">",
"       17",
"      </a>",
"      ]. Many patients with abnormal eye movements prefer keeping their eyes closed.",
"      <br/>",
"      <br/>",
"      Somatic skeletal neuromuscular dysfunction typically appears as restlessness, fasciculations, shaking and jerking of the extremities, alternating opisthotonos (arching of the back), and emprosthotonos (tetanic forward flexion of the body). These signs can be mistaken for a seizure. However, the abnormal skeletal muscle activity appears more undulating and writhing than the tonic-clonic movements of generalized seizures. Also, unlike patients with seizures, victims of scorpion stings often remain awake and alert.",
"     </li>",
"     <li>",
"      <strong>",
"       Grade IV envenomation",
"      </strong>",
"      &ndash; Grade IV envenomations manifest both cranial nerve dysfunction",
"      <strong>",
"       AND",
"      </strong>",
"      somatic skeletal neuromuscular dysfunction. On close examination, victims with skeletal muscle hyperactivity usually also have cranial nerve dysfunction, meeting criteria for Grade IV. In the most severe cases, stridor and wheezing can occur.",
"      <br/>",
"      <br/>",
"      Hyperthermia up to 40&deg;C (104&deg;F) may occur due to excess motor activity. Respiratory failure, pulmonary edema, metabolic acidosis, sterile cerebrospinal fluid pleocytosis, rhabdomyolysis, coagulopathy, pancreatitis, and multiple organ failure have all been described, especially in children with severe envenomation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/18\">",
"       18",
"      </a>",
"      ]. Pancreatitis, commonly associated with Tityus scorpion envenomation, rarely occurs with Grade IV Centruroides envenomation and is typically transient.",
"      <br/>",
"      <br/>",
"      Scorpion venoms generally do not produce coagulopathy or other significant hematologic effects, although disseminated intravascular coagulation has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Onset and duration of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;After C. exilicauda (sculpturatus) envenomation, symptoms may begin immediately and typically progress to maximum severity within five hours. Infants can reach Grade IV in as quickly as 15 to 30 minutes after being stung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/20\">",
"     20",
"    </a>",
"    ]. The symptoms abate at a rate that varies with the age of the victim and the grade of envenomation. Symptomatic improvement typically occurs within 9 to 30 hours without antivenom therapy in patients with Grade III or IV envenomation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2\">",
"     2",
"    </a>",
"    ]. Pain and paresthesias are exceptions and have been known to persist for up to two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Toxicity in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although adults appear to be envenomed more often, children are more likely to develop severe illness requiring intensive supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. In an observational study of 673 patients with C. exilicauda (sculpturatus) envenomations, over two thirds of stings occurred in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/5\">",
"     5",
"    </a>",
"    ]. However, 26 percent of children less than six years of age had severe envenomations (Grade III or IV) versus 6 percent of adults over age 20.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Centruroides vittatus envenomation",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. vittatus stings commonly produce local symptoms of pain, bleeding, burning sensations, erythema, edema, hives, local paresthesias, and pruritus.",
"   </p>",
"   <p>",
"    Systemic reactions occur in approximately 20 percent of victims, but are typically less severe than those caused by C. exilicauda (sculpturatus) and C. suffusus. The most common systemic features include paresthesias (face, tongue, and perioral region), dysgeusia (unpleasant or altered taste), chills, sweating, dysphagia, fasciculations, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies are not needed in patients with mild (Grade I to II) envenomation.",
"   </p>",
"   <p>",
"    The following studies should be obtained in patients with severe envenomations (Grade III to IV):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])",
"     </li>",
"     <li>",
"      Blood urea nitrogen and serum creatinine",
"     </li>",
"     <li>",
"      Serum lipase",
"     </li>",
"     <li>",
"      Serum creatine kinase",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing may be needed depending upon the clinical scenario. As an example, it is reasonable to obtain a complete blood count and coagulation studies in a young child with an unwitnessed bite. For those patients showing signs of exacerbation of underlying ischemic heart disease, obtain an electrocardiogram, cardiac biomarkers, and chest radiograph.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5833441\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Centruroides scorpion sting is based upon clinical findings including recent visit to or residing in an endemic region for the scorpion, history of a scorpion sting (often not present) and characteristic signs of envenomation including local pain exacerbated by tapping near the sting site, hypersalivation, abnormal eye movements (ie, chaotic multidirectional conjugate saccades resembling opsoclonus and unsustained primary positional nystagmus), alternating opisthotonus, fasciculations, and clonus. Mental status is typically preserved. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Support laboratory findings include evidence of rhabdomyolysis and pancreatitis in patients with moderate to severe envenomation (Grade III or IV) (",
"    <a class=\"graphic graphic_table graphicRef67046 \" href=\"mobipreview.htm?35/21/36187\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young children from endemic areas presenting with unusual neurologic symptoms (such as agitation, choreiform movement, or abnormal eye movements) may be assumed to have been envenomed without history of a sting or scorpion. However, the clinician should always consider other possible diagnoses when evaluating a patient suspected of scorpion envenomation.",
"   </p>",
"   <p>",
"    In older patients, a history of scorpion sting is typically present. However, scorpion stings may be confused with a wide array of other diagnoses. Although geographically confined in the United States, scorpions have been known to \"hitchhike\" on passenger baggage or freight and cause stings in regions far removed from the Southwest. The abnormal eye movements following severe C. exilicauda envenomation are rarely seen in other diseases.",
"   </p>",
"   <p>",
"    Conditions with symptoms that may overlap with those of scorpion envenomation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Spider bite",
"      </strong>",
"      &ndash; Bites or stings from other arthropods may present with symptoms similar to scorpion envenomation. Specifically, black widow envenomation may produce hypertension, tachycardia, sweating, and other signs of adrenergic excess. However, it does not produce the abnormal eye movements, fasciculations, or paresthesias, or induce a positive tap test as found with C. exilicauda (sculpturatus) scorpion stings. In addition, black widow spider bites frequently produce a characteristic halo lesion at the site, whereas C. exilicauda stings produce no such lesion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25081?source=see_link\">",
"       \"Bites of widow spiders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Botulism",
"      </strong>",
"      &ndash; Botulism is a rare but potentially life-threatening neuroparalytic syndrome resulting from the action of a neurotoxin elaborated by the microorganism Clostridium botulinum. Botulism is classically described as the acute onset of bilateral cranial neuropathies associated with symmetric descending weakness. The Centers for Disease Control has also suggested that the following be considered as key features of the botulism syndrome:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Absence of fever",
"     </li>",
"     <li>",
"      Symmetric neurologic deficits",
"     </li>",
"     <li>",
"      The patient remains responsive",
"     </li>",
"     <li>",
"      Normal or slow heart rate and normal blood pressure",
"     </li>",
"     <li>",
"      No sensory deficits with the exception of blurred vision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in contrast to a scorpion sting, botulism does not cause hypersalivation, fasciculation, or painful skeletal muscle contractions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link&amp;anchor=H10#H10\">",
"     \"Botulism\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Esophageal or airway foreign body",
"      </strong>",
"      &ndash; Excessive oral secretions and respiratory distress from a scorpion sting may mimic the presentation of an upper airway or esophageal foreign body. However, paresthesias, skeletal muscle abnormalities, and cranial nerve abnormalities are not seen in patients with foreign bodies.",
"     </li>",
"     <li>",
"      <strong>",
"       Status asthmaticus",
"      </strong>",
"      &ndash; Occasional wheezing may occur following a C. exilicauda (sculpturatus) or a C. vittatus sting and be mistaken for an asthma exacerbation until systemic symptoms (eg, paresthesias, neurologic abnormalities) become evident.",
"     </li>",
"     <li>",
"      <strong>",
"       Toxic exposure",
"      </strong>",
"      &ndash; Several poisons have physical findings similar to those of scorpion envenomation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Organophosphate compound and nicotine ingestion can cause excessive oral secretions and muscle fasciculations. However, organophosphate and nicotine overdose frequently cause paralysis, which is not seen with scorpion envenomation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link\">",
"       \"Organophosphate and carbamate poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sympathomimetic agents (eg, methamphetamines, cocaine), hallucinogenics (eg, phencyclidine [PCP]), and anticholinergic agents (eg, antihistamines, Jimson weed) often cause motor excitability and hyperthermia that is similar to the skeletal muscle dysfunction seen after a severe scorpion sting.",
"      <br/>",
"      <br/>",
"      A case series of 18 inadvertent methamphetamine poisonings among children in central Arizona included three victims initially misdiagnosed with a scorpion sting and inappropriately treated with antivenom; one patient had an anaphylactic reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/21\">",
"       21",
"      </a>",
"      ]. However, poisoning with these agents does not typically cause cranial nerve findings and is usually associated with delirium. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1784?source=see_link&amp;anchor=H5#H5\">",
"       \"Designer drugs of abuse\", section on 'Methamphetamine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"       \"Anticholinergic poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/570?source=see_link\">",
"       \"Phencyclidine (PCP) intoxication in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6425?source=see_link\">",
"       \"Phencyclidine (PCP) intoxication in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Strychnine intoxication, tetanus, or dystonic reactions from medicines that antagonize dopamine receptors (eg, antipsychotic agents) may all present with painful muscle contraction (eg, opisthotonus), tonic-clonic movements, and a preserved mental status, similar to the clinical picture of severe scorpion envenomation. A history of an infected wound (tetanus), exposure to a precipitating agent (dystonic reaction), or strychnine ingestion can facilitate making these alternative diagnoses. In addition, patients with tetanus and strychnine exposure do not typically have abnormal eye movements, and patients with dystonia usually respond rapidly to administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"       benztropine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40022?source=see_link\">",
"       \"Strychnine poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12105?source=see_link\">",
"       \"Treatment of dystonia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Seizure",
"      </strong>",
"      &ndash; Patients with seizures may have muscle movements similar to victims of scorpion envenomation, but usually do not have an intact mental status or the characteristic roving eye movements that are seen in victims after a scorpion sting.",
"     </li>",
"     <li>",
"      <strong>",
"       Meningitis",
"      </strong>",
"      &ndash; Fever, neck stiffness, hypertonia, and cerebrospinal fluid pleocytosis are seen in children with meningitis and, rarely, in those with severe scorpion envenomation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/18\">",
"       18",
"      </a>",
"      ]. As with many other diagnoses, roving eye movements are characteristically not seen with meningitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=see_link\">",
"       \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Neuroblastoma",
"      </strong>",
"      &ndash; Abnormal eye movements (Opsoclonus-myoclonus-ataxia [OMA]) is a well-known paraneoplastic syndrome that occurs in 1 to 3 percent of cases of neuroblastoma. Conversely, as many as 50 percent of children with opsoclonus-myoclonus have an underlying neuroblastoma. The characteristic symptoms of OMA are rapid, dancing eye movements, rhythmic jerking,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ataxia. Unlike children with severe scorpion envenomation, those with neuroblastoma do not typically demonstrate hypersalivation, acute onset of cranial nerve deficits, or skeletal muscle effects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\", section on 'Opsoclonus myoclonus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Consultation with medical toxicologists experienced in treating C. exilicauda and scorpion envenomations in the United States can be obtained by calling the Banner Poison Control Center in Phoenix at 1-602-495-4884 or the Arizona Poison and Drug Information Center in Tucson at 1-520-626-6016.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUPPORTIVE TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Asymptomatic or mild envenomation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most scorpion stings result in mild envenomations (Grade I or II) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/5\">",
"     5",
"    </a>",
"    ]. Pain management with oral medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum single dose 800 mg), cleansing of the sting site, and tetanus prophylaxis typically suffice. These patients should be observed for four hours to ensure no further progression of symptoms, although experience with C. exilicauda envenomation in Arizona indicates that progression of envenomation grade in children occurs rapidly (mean time: 14 minutes, range 0 to 140 minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to discharge, patients should tolerate oral intake, have no progression of symptoms, and their pain should be adequately controlled with oral medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Severe envenomation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims with significant systemic symptoms (eg, restlessness, muscle fasciculations, hypersalivation, cranial nerve dysfunction, roving eye movements) are at heightened risk for respiratory compromise, myocardial infarction (in adults with ischemic heart disease), hyperthermia, rhabdomyolysis, and multiple organ failure. They warrant close monitoring for these complications.",
"   </p>",
"   <p>",
"    Key supportive interventions for these patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent suctioning of oral secretions.",
"     </li>",
"     <li>",
"      Endotracheal intubation in patients with significant difficulties maintaining their airway or with pulmonary edema accompanied by hypoxemia.",
"     </li>",
"     <li>",
"      Close monitoring for and treatment of myocardial ischemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acute decompensated heart failure in patients at risk.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      for pain. Fentanyl is preferred if antivenom administration is planned because, unlike",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , fentanyl does not cause histamine release.",
"     </li>",
"     <li>",
"      Intravenous benzodiazepines (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      or continuous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      infusion), titrated to effect, for sedation and to treat muscle spasticity if antivenom is",
"      <strong>",
"       not",
"      </strong>",
"      used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benzodiazepines should be used carefully or avoided if antivenom administration is planned. Antivenom reverses the excitatory effects of the scorpion venom and children who have received high doses of long-acting benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ) may become oversedated, occasionally requiring intubation. Thus, a short-acting benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , initial dose: 0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is preferred for management of excess muscle activity and anxiety in pediatric patients. Once antivenom is administered, the clinician should closely monitor respiratory and mental status for signs of oversedation and further dosing with benzodiazepines should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ANTIVENOM TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Centruroides antivenom",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antivenom for Centruroides envenomation in the United States has been controversial because of the low risk of mortality from the scorpion sting (given proper supportive care), the lack of availability of an FDA approved antivenom, and the approximately 3 percent risk of anaphylaxis from administration of the goat-derived antivenom (no longer available).",
"   </p>",
"   <p>",
"    In Mexico, scorpion-specific equine antivenom with activity against several Centruroides species has long been used because of the higher risk of mortality in these patients and the lower risk of medical complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients in the United States or Mexico with Grade III or IV symptoms after Centruroides scorpion envenomation (skeletal muscle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cranial nerve dysfunction) receive intravenous scorpion-specific F(ab')2 equine antivenom.",
"   </p>",
"   <p>",
"    Antivenom (Anascorp&reg;, US; Alacramyn&reg;, Mexico) is widely available in Mexico. Anascorp&reg; is approved for use in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/22\">",
"     22",
"    </a>",
"    ]. Further information about administering or obtaining F(ab')2 equine antivenom may be obtained from the Banner Good Samaritan Poison and Drug Information Center at 1-602-253-3334 or from the nearest regional poison control center at 1-800-222-1222.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large observational study of 38,068 adults and children from Mexico, 20,000 received horse serum antivenom with no immediate hypersensitivity reactions and no deaths [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A blinded trial of scorpion-specific F(ab')2 antivenom (Anascorp&reg;) in 15 children, ages 6 months to 18 years, who were admitted to a pediatric intensive care unit showed total resolution of clinical symptoms within four hours of treatment in all eight antivenom recipients versus one of seven placebo recipients (P = 0.001) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/4\">",
"       4",
"      </a>",
"      ]. Plasma venom concentrations were undetectable in all eight antivenom recipients but in only one placebo recipient one hour after treatment. No immediate hypersensitivity symptoms of serum sickness occurred in patients receiving the antivenom.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for the",
"    <span class=\"nowrap\">",
"     patient/guardian",
"    </span>",
"    to understand that scorpion envenomation is unlikely to be a fatal disease process. Therefore, antivenom is not life saving. However, without antivenom, the patient will likely have a prolonged period of distressing symptoms, and of all available treatments, current evidence indicates antivenom is likely to be effective and may significantly reduce the duration of suffering and hospitalization",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Precautions to prevent allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the administration of scorpion-specific F(ab')2 antivenom, medications and equipment for the treatment of anaphylaxis should be immediately available, including IV fluids, epinephrine, and intubation equipment.",
"   </p>",
"   <p>",
"    Allergic reactions should be managed by immediately stopping intravenous infusion of the antivenom (if applicable) and treating symptoms appropriately (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed serum sickness-like reactions were not seen in the 15 patents receiving scorpion-specific F(ab')2 antivenom reported in one case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/4\">",
"     4",
"    </a>",
"    ]. However, all patients receiving antivenom should be informed of the possibility of serum sickness and the symptoms suggestive of serum sickness and advised to seek medical care if such symptoms occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scorpion-specific F(ab')2 equine antivenom is given intravenously in a dose of three vials dissolved in 20 to 50 mL of normal saline infused over 30 minutes. Subsequent single vial doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/50/22307?source=see_link\">",
"     Centruroides antivenom",
"    </a>",
"    , up to a total of five vials administered at thirty minutes intervals may be given until resolution of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Goat-derived Centruroides antivenom",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scorpion-specific F(ab')2 equine antivenom has been distributed to rural hospitals in Arizona by legislative mandate. Goat-derived antivenom is no longer used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/4\">",
"     4",
"    </a>",
"    ]. It was associated with a 3 percent frequency of immediate hypersensitivity reactions and up to a 60 percent risk of delayed serum sickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reducing small cracks and crevices in homes decreases the risk of human-scorpion interactions. In scorpion-infested areas, clothing, shoes, packages, and camping gear should be shaken out and checked for scorpions. Footwear is recommended. Unnecessary ground cover and debris should be removed to reduce potential nesting places.",
"   </p>",
"   <p>",
"    Certain insecticides, including organophosphates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/9/12436?source=see_link\">",
"     pyrethrins",
"    </a>",
"    , and several chlorinated hydrocarbons, are known to kill scorpions. Spraying insecticides around the home can work indirectly by killing other insects in the area and reducing the scorpions' food supply. A village-wide scorpion eradication program with pyrethroid insecticides in the state of Morelos, Mexico reduced the incidence of scorpion stings by 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32104/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scorpion envenomation is a significant problem in the southwestern United States and throughout Mexico. In the United States, Centruroides exilicauda (sculpturatus) stings are associated with major neurologic toxicity, especially in young children. In Mexico, multiple toxic species exist, and annual mortality due to scorpion envenomation is ten times higher than that due to snakebite. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Regional epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of scorpion envenomations in the United States or Mexico cause only local or no pain with minimal to no inflammation. However, C. exilicauda (sculpturatus) and C. suffusus often produce significant neuromuscular effects that can be life-threatening. C. vittatus stings are less likely to cause systemic effects. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical findings after C. exilicauda envenomation are categorized into four clinical grades of envenomation (",
"      <a class=\"graphic graphic_table graphicRef67046 \" href=\"mobipreview.htm?35/21/36187\">",
"       table 1",
"      </a>",
"      ). Envenomation by C. suffusus is similar. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After C. exilicauda (sculpturatus) envenomation, symptoms may begin immediately and typically progress to maximum severity within five hours. Infants can reach the highest severity of envenomation in as quickly as 15 to 30 minutes after being stung. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Onset and duration of symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although adults appear to be envenomed more often, children are more likely to develop severe illness requiring intensive supportive care. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Toxicity in children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory studies are not needed in patients with mild (Grade I to II) envenomation. Patients with severe effects (Grade III to IV) should undergo assessment as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])",
"     </li>",
"     <li>",
"      Blood urea nitrogen and serum creatinine",
"     </li>",
"     <li>",
"      Lipase or amylase",
"     </li>",
"     <li>",
"      Serum creatine kinase",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional tests, such as a complete blood count and coagulation studies may be needed depending upon the clinical scenario. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Management of mild envenomation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain management with oral medications (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose 800 mg), cleansing of the sting site, and tetanus prophylaxis typically suffice in these patients. These patients should be observed for four hours to ensure no further progression of symptoms. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Asymptomatic or mild envenomation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to discharge the patient should tolerate oral intake, have no progression of symptoms, and their pain should be adequately controlled with oral medications. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Asymptomatic or mild envenomation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Management of severe envenomation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Victims with severe systemic symptoms (eg, restlessness, muscle fasciculations, hypersalivation, cranial nerve dysfunction, roving eye movements) are at heightened risk for respiratory compromise, myocardial infarction (adults with coronary artery disease), hyperthermia, rhabdomyolysis, and multiple organ failure and warrant close monitoring for these complications. Key supportive interventions in these patients encompass:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Frequent suctioning of oral secretions.",
"     </li>",
"     <li>",
"      Endotracheal intubation in patients unable to maintain their airway or who develop pulmonary edema.",
"     </li>",
"     <li>",
"      Intravenous administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mcg/kg.",
"      </span>",
"      Fentanyl is preferred if antivenom administration is planned because, unlike",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , fentanyl does not cause histamine release.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous administration of benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      infusion titrated to effect) for sedation and to treat muscle spasticity. The use of benzodiazepines should be limited or avoided if antivenom administration is planned. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Severe envenomation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients in the United States or Mexico with Grade III or IV symptoms after Centruroides scorpion envenomation (skeletal muscle",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cranial nerve dysfunction) receive intravenous scorpion-specific F(ab')2 equine antivenom (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Centruroides antivenom'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Klauber LM. Rattlesnakes: Their Habits, Life Histories, and Influence on Mankind, University of California Press, Berkeley 1997. Vol 1, p.838.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/2\">",
"      LoVecchio F, McBride C. Scorpion envenomations in young children in central Arizona. J Toxicol Clin Toxicol 2003; 41:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/3\">",
"      Gambhir IS, Singh DS, Pattnaik DN. Stroke in a young woman. Postgrad Med J 1998; 74:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/4\">",
"      Boyer LV, Theodorou AA, Berg RA, et al. Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med 2009; 360:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/5\">",
"      Curry, SC, Vance, MV, Ryan, PJ, et al. Envenomation by the scorpion Centruroides sculpturatus. J Toxicol Clin Toxicol 1983-1984; 21:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/6\">",
"      Russell FE. Venomous arthropods. Vet Hum Toxicol 1991; 33:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/7\">",
"      Krifi MN, el Ayeb M, Ben Lasfar Z, et al. Improvement and standardization of antivenoms sera. Arch Inst Pasteur Tunis 1992; 69:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/8\">",
"      Hutt MJ, Houghton PJ. A survey from the literature of plants used to treat scorpion stings. J Ethnopharmacol 1998; 60:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/9\">",
"      LoVecchio F, Welch S, Klemens J, et al. Incidence of immediate and delayed hypersensitivity to Centruroides antivenom. Ann Emerg Med 1999; 34:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/10\">",
"      Stipetic, ME, Lugo, A, Brown, B, et al. A prospective analysis of 558 common striped scorpion (Centruroides vittatus) envenomations in Texas during 1997 (meeting abstract). J Toxicol Clin Toxicol 1998; 36:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/11\">",
"      Sofer S. Scorpion envenomation. Intensive Care Med 1995; 21:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/12\">",
"      Vatanpour H, Rowan EG, Harvey AL. Effects of scorpion (Buthus tamulus) venom on neuromuscular transmission in vitro. Toxicon 1993; 31:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/13\">",
"      Garcia ML, Hanner M, Kaczorowski GJ. Scorpion toxins: tools for studying K+ channels. Toxicon 1998; 36:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/14\">",
"      Arie-Saadia G, Sofer S, Zlotkin E, Shainberg A. Effect of Leiurus quinquestriatus hebreus venom on calcium and deoxyglucose uptake in cultured cardiac cells. Toxicon 1996; 34:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/15\">",
"      Boyer, L, Heubner, K, McNally, J, Buchanan, P. Death from Centruroides scorpion sting allergy. J Toxicol Clin Toxicol 2001; 39:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/16\">",
"      Dehesa-D&aacute;vila M, Possani LD. Scorpionism and serotherapy in Mexico. Toxicon 1994; 32:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/17\">",
"      Clark RF, Selden BS, Kunkel DB, Frost MD. Abnormal eye movements encountered following severe envenomations by Centruroides sculpturatus. Neurology 1991; 41:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/18\">",
"      Berg RA, Tarantino MD. Envenomation by the scorpion Centruroides exilicauda (C sculpturatus): severe and unusual manifestations. Pediatrics 1991; 87:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/19\">",
"      Annobil, SH. Scorpion stings in children in the Asir Province of Saudi Arabia. J Wilderness Med 1993; 4:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/20\">",
"      Amaral CF, Rezende NA. Both cardiogenic and non-cardiogenic factors are involved in the pathogenesis of pulmonary oedema after scorpion envenoming. Toxicon 1997; 35:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/21\">",
"      Kolecki P. Inadvertent methamphetamine poisoning in pediatric patients. Pediatr Emerg Care 1998; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     Approval letter - Anascorp. US Food and Drug Administration. file://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm266726.htm (Accessed on August 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32104/abstract/23\">",
"      Ramsey JM, Salgado L, Cruz-Celis A, et al. Domestic scorpion control with pyrethroid insecticides in Mexico. Med Vet Entomol 2002; 16:356.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6490 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-CE64EF4B76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32104=[""].join("\n");
var outline_f31_22_32104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENTOMOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCORPION GEOGRAPHY AND APPEARANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Centruroides exilicauda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Centruroides vittatus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Centruroides suffusus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VENOM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REGIONAL EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mexico",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Centruroides exilicauda (sculpturatus)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Onset and duration of symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Toxicity in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Centruroides vittatus envenomation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5833441\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUPPORTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Asymptomatic or mild envenomation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Severe envenomation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ANTIVENOM TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Centruroides antivenom",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Informed consent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Precautions to prevent allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Goat-derived Centruroides antivenom",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Management of mild envenomation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Management of severe envenomation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6490|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/1/37906\" title=\"figure 1\">",
"      Scorpion anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6490|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/28/36290\" title=\"picture 1\">",
"      Centruroides exilicauda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/0/44032\" title=\"picture 2\">",
"      Centruroides exilicauda 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/43/21172\" title=\"picture 3\">",
"      Centruroides exilicauda 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/38/28257\" title=\"picture 4\">",
"      Scorpion fluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/46/1767\" title=\"picture 5\">",
"      Centruroides exilicauda 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6490|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/21/36187\" title=\"table 1\">",
"      Centruroides scorpion envenomation grades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/26/16813\" title=\"table 2\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18221\" title=\"table 3\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25081?source=related_link\">",
"      Bites of widow spiders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/47/1784?source=related_link\">",
"      Designer drugs of abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6425?source=related_link\">",
"      Phencyclidine (PCP) intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/35/570?source=related_link\">",
"      Phencyclidine (PCP) intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40022?source=related_link\">",
"      Strychnine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12105?source=related_link\">",
"      Treatment of dystonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_22_32105="Surgical treatment of Parkinson disease";
var content_f31_22_32105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical treatment of Parkinson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32105/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32105/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32105/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/22/32105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 50 percent of patients on levodopa for five years experience motor fluctuations and dyskinesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/1\">",
"     1",
"    </a>",
"    ]. These symptoms are especially common in patients with young-onset (eg, under the age of 50) Parkinson disease (PD); they are unique to levodopa and are not produced by the other antiparkinson drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical management of patients with advanced PD who are experiencing motor fluctuations will be reviewed here. The medical management of motor fluctuations associated with PD and levodopa therapy and the general approach to therapy of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=see_link\">",
"     \"Motor fluctuations and dyskinesia in Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Motor fluctuations and dyskinesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients typically experience a smooth and even response to the early stages of levodopa treatment. As the disease advances, however, the effect of levodopa begins to wear off approximately four hours after each dose, leaving patients anticipating the need for their next dose. This phenomenon has been explained by the observation that dopamine nerve terminals are able to store and release dopamine early in the course of disease but, with more advanced disease and increasing degeneration of dopamine terminals, the concentration of dopamine in the basal ganglia is much more dependent upon plasma levodopa levels. Plasma levels may fluctuate erratically because of the 90 minute half-life of levodopa and the frequently unpredictable intestinal absorption of this medication.",
"   </p>",
"   <p>",
"    Motor fluctuations are alterations between periods of being \"on,\" during which the patient enjoys a good response to medication, and being \"off\" during which the patient experiences symptoms of the underlying parkinsonism. Dyskinesia consists of abnormal involuntary movements that are usually choreic or dystonic but, when more severe, may be ballistic or myoclonic. Dyskinesia usually appears when the patient is \"on.\" They may occasionally occur in the form of painful dystonias when the patient is \"off,\" especially in the morning on awakening, when dystonic intorsion of a foot or curling of the toes (usually on the side of greater parkinsonian involvement) occurs as a withdrawal reaction because of the long interval without medication overnight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rationale for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two downstream effects of nigral degeneration and dopamine deficiency in PD are excessive subthalamic nucleus (STN) excitation of the internal globus pallidus (GPi) and excessive GP inhibition of the thalamus. These, in turn, cause reduced thalamocortical activity, which is believed to mediate the symptoms of akinesia and rigidity.",
"   </p>",
"   <p>",
"    Pallidotomy reverses the excess pallidal inhibitory effect and improves parkinsonism by targeted ablation of the internal segment of GP (GPi). High frequency deep brain stimulation (DBS) suppresses neuronal activity and also activates efferent fiber pathways leaving the targeted nucleus.",
"   </p>",
"   <p>",
"    Thalamotomy and pallidotomy are immediate in effect but irreversible; DBS makes no major lesion, but it requires intensive adjustments in the postoperative period and lifelong maintenance with risk of hardware complications and infection.",
"   </p>",
"   <p>",
"    Since DBS produces a safe and entirely reversible physiologic effect without destroying brain tissue, DBS is now being used in place of lesions (pallidotomy and thalamotomy) to suppress excessive GPi or STN activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEEP BRAIN STIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep brain stimulation (DBS) is currently the most frequently performed surgical procedure for the treatment of advanced PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/2\">",
"     2",
"    </a>",
"    ]. The use of DBS for patients with shorter duration PD is also being explored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effectiveness in advanced PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prospective randomized controlled trials that compared DBS with best medical therapy have shown that bilateral DBS improves motor function in selected patients with advanced typical PD and motor fluctuations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One large multicenter controlled trial (the VA-NIH) with blinded assessment included 255 adults with advanced PD and motor complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/3\">",
"     3",
"    </a>",
"    ]. The mean age of subjects was 62 years (range 37 to 83). Patients were randomly assigned to either bilateral DBS (n = 121, with 60 to subthalamic nucleus stimulation and 61 to globus pallidus stimulation), or best medical therapy (n = 134). The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the primary outcome measure of \"on-time\" without troubling dyskinesia at six months, patients in the DBS group (pooled subthalamic nucleus and globus pallidus stimulation) improved by a mean of 4.6 hours a day, versus zero hours a day for the best medical therapy group (mean difference, 4.5 hours a day, 95% CI 3.7-5.4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/3\">",
"       3",
"      </a>",
"      ]. In addition, patients in the DBS group had a significantly higher rate of clinically meaningful motor improvement (71 versus 32 percent) and improved quality of life, as assessed by the Parkinson Disease Questionnaire (PDQ39).",
"     </li>",
"     <li>",
"      The rate of serious adverse events was significantly higher in the DBS group than in the best medical treatment group (40 versus 15 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/3\">",
"       3",
"      </a>",
"      ]. However, the excess in the DBS group was largely attributable to events related to the surgical procedure, such as postoperative headache and pain. The most common serious adverse event was infection at the surgical site in the DBS group (10 percent). Two deaths occurred in the DBS group; one was due to a fatal cerebral hemorrhage 24 hours after lead implantation but the other was due to lung cancer in a patient who did not have implantation.",
"      <br/>",
"      <br/>",
"      Many fewer adverse events were recorded during the four to six month epoch, when only falls (generally not serious) and dystonia were significantly more common in the DBS group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/3\">",
"       3",
"      </a>",
"      ]. It is unclear whether the increase in falls was related to the surgery itself or was a consequence of increased mobility and activity following DBS surgery. There were few permanent complications.",
"     </li>",
"     <li>",
"      Compared with presurgical baseline, the DBS group had mildly diminished performance on several measures of cognitive function at follow-up, including working memory, processing speed, verbal fluency, and delayed recall, though the clinical significance of this is not clear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/3\">",
"       3",
"      </a>",
"      ]. In contrast, the best medical treatment group showed slight gains on some of these measures. There were no significant changes from baseline to six-month follow-up for either treatment group in measures of depression or dementia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of the VA-NIH trial phase that directly compared bilateral subthalamic nucleus with bilateral globus pallidus stimulation for advanced PD are discussed below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Subthalamic nucleus versus globus pallidus DBS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The other multicenter trial was unblinded and evaluated 156 patients with advanced PD from Germany and Austria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/4\">",
"     4",
"    </a>",
"    ]. Centers enrolled patients in pairs, with one patient from each pair randomly assigned to subthalamic nucleus DBS and the other to best medical treatment. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DBS stimulation of the subthalamic nucleus was associated with significant improvements at six months compared with medication alone in both quality of life, as assessed by the PDQ39, and in the off-medication motor score of the Unified Parkinson Disease Rating Scale (UPDRS) (",
"      <a class=\"graphic graphic_table graphicRef68974 \" href=\"mobipreview.htm?33/46/34530\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/4\">",
"       4",
"      </a>",
"      ]. The DBS group experienced a 4.4 hour gain in \"on-time\", essentially identical to the 4.6 hour gain reported for the DBS group in the VA-NIH study discussed above.",
"     </li>",
"     <li>",
"      Serious adverse events were significantly more common with DBS than with medical treatment alone (13 versus 4 percent), and included a fatal intracerebral hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/4\">",
"       4",
"      </a>",
"      ]. In contrast with some earlier studies, cognitive and behavioral complications were infrequent and not significantly different between DBS and medical treatment groups. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cognitive and behavioral complications'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, these trials demonstrate that, for patients with advanced PD, DBS of either the subthalamic nucleus or the globus pallidus is more effective for improving motor function and quality of life than best medical therapy, at least in the short-term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, the benefit comes at the cost of an increased risk of complications related to surgery. Limitations of these trials include the lack of a sham surgery control group, and in the case of the German-Austrian trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/4\">",
"     4",
"    </a>",
"    ], the lack of blinded assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Subthalamic nucleus versus globus pallidus DBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep brain stimulation of the subthalamic nucleus (STN) and globus pallidus pars interna (GPi) appears to have similar effectiveness and safety. Supporting evidence comes from the multicenter randomized controlled VA-NIH trial, which directly compared STN DBS (n = 147) versus GPi DBS (n = 152) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 24 months, the mean change in the primary endpoint (motor function on the Unified Parkinson's Disease Rating Scale, part III, while off medication) did not differ significantly between treatment groups",
"     </li>",
"     <li>",
"      By self report from patient diaries, there was no significant difference between groups in the time per day for states of good motor function, troublesome dyskinesia, poor motor function, or sleep. Likewise, there were no significant differences between groups for improvement on quality of life measures",
"     </li>",
"     <li>",
"      The use of antiparkinson medication (levodopa equivalents) decreased more for patients assigned to STN DBS compared with those assigned to GPi DBS",
"     </li>",
"     <li>",
"      The rate of serious adverse events was high for both STN and GPi treatment groups (56 versus 51 percent), but the difference was not statistically significant",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92694887\">",
"    <span class=\"h2\">",
"     Effectiveness in early PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefit of DBS for amelioration of symptoms in early PD is illustrated by the results of the two-year EARLYSTIM trial that evaluated 251 patients (mean age 53 years, mean duration of disease 8 years) with levodopa-responsive PD, mild motor complications, and no dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The subjects were randomly assigned to either bilateral DBS of the subthalamic nucleus (STN) plus medical therapy or to medical therapy alone. Compared with the medical therapy group, patients in the DBS group showed a statistically significant and clinically meaningful improvement in self-assessed quality of life (the primary end point) as measured by the change from baseline in the Parkinson Disease Questionnaire (+7.8 versus -0.2 for medical therapy alone, between group difference 8.0, 95% CI 4.2-11.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, the DBS group had significant improvements in the motor disability and ADL subscales of the UPDRS, levodopa-induced motor complications, and time with good mobility and no dyskinesia. Two patients in the DBS group and one in the medical therapy group committed suicide, and major depression occurred more often with DBS. There were 26 serious adverse events in the DBS group related to surgery or the implanted device, with complete resolution in all but 1 case related to impaired wound healing.",
"   </p>",
"   <p>",
"    Given these findings and those of a previous small trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/8\">",
"     8",
"    </a>",
"    ], DBS of the STN is a viable, earlier treatment option for appropriate patients with PD in whom typical levodopa-related motor complications cannot be managed with best medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. However, more data are needed, particularly about the long-term effects of DBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Factors predictive of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative levodopa responsiveness is a robust predictor of postsurgical improvement after DBS of the STN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In nearly all cases, outcome of surgery will only be as good as the best preoperative levodopa response. Those symptoms that do not respond to preoperative levodopa are unlikely to improve following surgery. However, in cases in which the preoperative levodopa dosage has been limited due to adverse effects, STN DBS may produce a better response than subtherapeutic levodopa dosage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Duration of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence suggests that DBS of the STN and GPi provide a persistent beneficial antiparkinsonian effect for at least three to five years after electrode implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. Most of the data are derived from patients treated with STN stimulation. As an example, in a five-year follow-up, 49 patients treated with bilateral DBS of the STN showed marked improvement compared with baseline in motor function while off medication, and improvement in dyskinesia while on medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/13\">",
"     13",
"    </a>",
"    ]. Motor function while on medication was not improved. Akinesia, speech, postural stability, freezing of gait, and cognitive function worsened over the five years of the study, consistent with the natural history of PD, and with the impression that DBS is not neuroprotective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent benefit was also seen in a study of 69 patients treated with bilateral DBS of the STN (n = 49) or GPi (n = 20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/15\">",
"     15",
"    </a>",
"    ]. Both treatment groups were associated with significant improvement in the cardinal motor features of PD (tremor, rigidity, bradykinesia, and gait) in the off-medication state at three to four years compared with baseline. The benefit was greater for DBS STN than GPi and was especially impressive for prolonging the amount of daily \"on\" time without dyskinesia. Daily levodopa dosage was significantly reduced in the STN group only. Significant worsening occurred in the on-medication motor states of the UPDRS motor score, ADL, and gait in both groups, and in speech and postural stability in the STN group. Adverse events were more common in the STN group, including cognitive decline, speech difficulty, postural",
"    <span class=\"nowrap\">",
"     instability/gait",
"    </span>",
"    disorder, and depression.",
"   </p>",
"   <p>",
"    While these data suggest that there is equivalent efficacy between Gpi and STN targets for stimulation at least until 24 months, extended follow-up will be necessary to determine whether this effect remains stable in the long-term. In this regard, a meta-analysis of data from 11 non-randomized, observational studies evaluated the effects of DBS beyond three years postsurgery on motor symptoms in patients with PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/21\">",
"     21",
"    </a>",
"    ]. With a mean 4.5 years of follow-up, the improvement in cardinal signs (tremor, bradykinesia, and dyskinesia) after DBS was maintained while postural instability and gait dysfunction worsened after DBS despite initial improvement. Although plagued by high drop-out rates, studies reporting follow-up for 5 to 10 years after DBS suggest similar findings, with sustained motor benefits for tremor, rigidity, motor fluctuations, and dyskinesia, along with deterioration in dysarthria, postural instability, freezing of gait, and cognitive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious surgical complications of DBS are infrequent. An evidenced-based practice parameter from the AAN issued in 2006 reviewed adverse events from four studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/23-26\">",
"     23-26",
"    </a>",
"    ] involving 360 total patients (288 with PD) who had DBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/12\">",
"     12",
"    </a>",
"    ]. Adverse surgical events (within one month of the procedure) included death in 0.6 percent and permanent neurologic sequelae in 2.8 percent.",
"   </p>",
"   <p>",
"    Additional surgical complications that did not result in permanent neurologic sequelae included infection in 5.6 percent, hemorrhage in 3.1 percent,",
"    <span class=\"nowrap\">",
"     confusion/disorientation",
"    </span>",
"    in 2.8 percent, seizures in 1.1 percent, pulmonary embolism in 0.6 percent, cerebrospinal fluid leak in 0.6 percent, peripheral nerve injury in 0.6 percent, and venous infarction in 0.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2006 systematic review, 29 studies of STN DBS with 778 patients reported adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/27\">",
"     27",
"    </a>",
"    ]. The most common adverse events attributed to DBS surgery were transient confusion and intracerebral hemorrhage in 15.6 and 3.9 percent. Others were infection, seizures, pulmonary embolism, and miscellaneous in 1.7, 1.5, 0.3, and 3.3 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hardware complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hardware problems following DBS are not uncommon. In the AAN review of DBS complications in 360 patients, lead replacement due to fracture, migration, or malfunction occurred in 5 percent of patients, lead repositioning due to misplacement in 2.8 percent, extension wire replacement due to fracture or erosion in 4.4 percent, implantable pulse generator (IPG) replacement due to malfunction in 4.2 percent, IPG repositioning for cosmetic reasons or for skin growth in 1.7 percent, and allergic reaction to the hardware in 0.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2006 systematic review of 29 STN DBS studies, the most common adverse events attributed to DBS hardware were",
"    <span class=\"nowrap\">",
"     electrode/wire",
"    </span>",
"    replacement, device dysfunction, infection, and migration in 4.4, 3.0, 1.9, and 1.5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DBS technology is rapidly evolving, and it is likely that future hardware complications will be reduced by procedural and equipment modifications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stimulation-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the AAN evidence-based review of DBS complications in 360 patients, stimulation-related complications of DBS included paresthesia, dysarthria, eyelid opening apraxia, hemiballismus, dizziness, dyskinesia, and facial contractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/12\">",
"     12",
"    </a>",
"    ]. These were generally mild and resolved with adjustment of stimulation parameters.",
"   </p>",
"   <p>",
"    In the 2006 systematic review of 29 STN DBS studies, the most common adverse events attributed to DBS stimulation were dysarthria, weight gain, depression, and eyelid opening apraxia in 9.3, 8.4, 6.8, and 3.6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/27\">",
"     27",
"    </a>",
"    ]. Others were dyskinesia, manic episodes, miscellaneous motor, and miscellaneous psychiatric in 2.6, 1.9, 4.0, and 3.5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cognitive and behavioral complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/30\">",
"     30",
"    </a>",
"    ], most studies have reported only mild or no significant deleterious effects of STN DBS in terms of long-term neuropsychological function and mood, with the exception of declines in tests of verbal fluency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. However, neuropsychological and psychiatric complications in the immediate postoperative period were not uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies suggest that STN stimulation may be associated with adverse cognitive, behavioral, or psychiatric problems, despite clear improvements in motor disability, activities of daily living, and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. In one of these reports, deficits in frontal executive function were seen primarily in patients age 70 or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occasional psychiatric reactions seen in patients after STN stimulation have included transient psychosis, hypomania, pathologic gambling, and sexual disinhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. These reactions are similar to those seen in the dopamine dysregulation syndrome associated with dopamine agonist medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link&amp;anchor=H20#H20\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'Dopaminergic dysregulation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cognitive and mood disturbance may be more common with STN than GPi stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/15,42\">",
"     15,42",
"    </a>",
"    ]. A small trial found evidence of persistent cognitive changes in 2 of 10 patients assigned to STN DBS at 12 months and none of 10 patients assigned to GPi DBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/42\">",
"     42",
"    </a>",
"    ]. Perioperative complications were common in patients assigned to STN stimulation and included persistent cognitive changes in two, transient mild delirium in three, transient anxiety in two, and hallucinations in one that responded to a reduction of the levodopa dose. No perioperative complications in mood or cognition were seen in the patients assigned to GPi stimulation.",
"   </p>",
"   <p>",
"    The cause of the cognitive and behavioral problems in STN stimulation is unclear, but given the small size of the STN nucleus, one plausible mechanism is spread of electrical current from the sensorimotor region of the STN into the nearby limbic region of the STN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Risk of suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is concern that DBS, particularly of the STN, may increase the risk for suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. The largest report was an international survey of 55 centers with data for 5311 patients who had DBS targeting the STN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/47\">",
"     47",
"    </a>",
"    ]. The suicide rate in the first postoperative year after DBS was 0.26 percent per year, 13 times higher than expected when compared with the suicide rate of general population controls matched for age, gender, and country of origin. The general population comparator was considered reasonable because of evidence that patients with PD may have a reduced baseline suicide rate compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Independent risk factors associated with suicide were postoperative depression, single marital status, and a previous history of impulse control disorders or compulsive medication use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/47\">",
"     47",
"    </a>",
"    ]. These accounted for 51 percent of the variance for attempted suicide risk. Suicides were also associated with younger age, younger Parkinson disease onset, and a previous suicide attempt.",
"   </p>",
"   <p>",
"    Although an increased risk of suicide associated with DBS treatment is not firmly established, it seems prudent to screen candidates for DBS surgery and exclude those at high risk for suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/7,46\">",
"     7,46",
"    </a>",
"    ]. In addition, postsurgical follow-up should include continued attention to symptoms of depression and risk factors for suicide. The US Preventive Services Task Force clinical practice guideline for screening for suicide risk can be accessed at",
"    <a class=\"external\" href=\"file://www.uspreventiveservicestaskforce.org/3rduspstf/suicide/suiciderr.htm\">",
"     www.uspreventiveservicestaskforce.org/3rduspstf/suicide/suiciderr.htm",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral DBS of the STN may exacerbate or unmask the symptoms of restless legs syndrome (RLS). In a series of 195 patients with advanced PD who underwent bilateral DBS of the STN, postoperative symptoms of new (n = 9) or exacerbated (n = 2) RLS developed in 11 patients (5.6 percent) despite functional improvement in parkinsonism in all 11 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/49\">",
"     49",
"    </a>",
"    ]. The postoperative RLS may have been caused by the reduced need for levodopa (mean reduction in levodopa equivalent dose of 79 percent) after DBS. The symptoms of RLS improved with therapy in all 11 patients, but levodopa treatment of RLS resulted in worsened or induced dyskinesia in three patients.",
"   </p>",
"   <p>",
"    The use of DBS requires chronically implanted electrodes and an implanted pulse generator (IPG). At least one study has reported the safe use of DBS in a small number of patients with cardiac pacemakers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/50\">",
"     50",
"    </a>",
"    ], although concomitant use of the two systems is felt by some to be contraindicated because of possible electrical interference between the DBS pulse generator and the cardiac pacemaker. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link\">",
"     \"Pacing system malfunction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from randomized controlled trials supports the conclusion that DBS of either the STN or the GPi alleviates the motor fluctuations and dyskinesia associated with advanced PD. Both STN and GPi stimulation are equally effective for motor symptoms including tremor and bradykinesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/5\">",
"     5",
"    </a>",
"    ]. Antiparkinson medication reduction is greater after STN stimulation, while GPi stimulation may be superior for control of dyskinesia with fewer complications related to cognitive, mood, and behavioral problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/5,43\">",
"     5,43",
"    </a>",
"    ]. The long-term durability of both procedures needs to be further investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other surgical procedures have been studied in advanced PD, including thalamotomy, pallidotomy, subthalamotomy, adrenal implant, fetal implant, and direct infusion of growth factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Thalamotomy and pallidotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thalamotomy and pallidotomy have largely been eclipsed by deep brain stimulation, and are seldom performed except in regions where DBS is unavailable or not affordable.",
"   </p>",
"   <p>",
"    Unilateral pallidotomy may be less effective than bilateral DBS of the subthalamic nucleus (STN) in reducing parkinsonian symptoms, although few controlled trials have directly compared pallidotomy with DBS. One of the largest included 34 patients with advanced PD and motor fluctuations who were randomly assigned to bilateral DBS (n = 20) or unilateral pallidotomy (n = 14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/51\">",
"     51",
"    </a>",
"    ]. At six months, patients randomized to the DBS group had significantly greater reduction in \"off\" and \"on\" phase motor scores and duration of dyskinesia compared with the unilateral pallidotomy group. Major limitations of this trial were its short duration and the inability to mask treatment assignment; outcomes assessors correctly identified which treatment patients had received in 77 percent of cases.",
"   </p>",
"   <p>",
"    Unilateral pallidotomy is effective and relatively safe compared with medical therapy in patients with severe dyskinesia and \"on\" and \"off\" fluctuations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. A randomized trial found that those treated with unilateral pallidotomy (n = 18) had improvements in tremor, rigidity, bradykinesia, gait, and balance compared with those treated medically (n = 18), and subsequent follow-up found that the benefits of unilateral pallidotomy were sustained after two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/54\">",
"     54",
"    </a>",
"    ]. The greatest improvement occurred on the side contralateral to the lesion, but significant ipsilateral improvement was also observed for bradykinesia, rigidity, and drug-induced dyskinesia.",
"   </p>",
"   <p>",
"    A systematic review of unilateral pallidotomy found that the risk of permanent adverse effects was 14 percent; symptomatic infarction or hemorrhage occurred in 4 percent, and the associated mortality was 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/55\">",
"     55",
"    </a>",
"    ]. Bilateral pallidotomy carries a high risk of permanent pseudobulbar speech and swallowing impairment in patients already compromised in these functions. Bilateral pallidal DBS can be performed more safely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unilateral thalamotomy and DBS of the ventral intermediate nucleus of the thalamus can safely and effectively control tremor in selected cases of PD. However, they do not help bradykinesia, and since this typically becomes the most important symptom over time, GPi and STN should be considered the targets of choice in patients with PD even if tremor is the main symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Subthalamotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the limited availability of DBS in some regions, subthalamotomy has been explored in several centers as a surgical option in PD.",
"   </p>",
"   <p>",
"    Evidence from several uncontrolled and largely unblinded studies suggests that unilateral subthalamotomy is effective for the treatment of advanced PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/56\">",
"     56",
"    </a>",
"    ]. Unilateral subthalamotomy appears to be as effective as bilateral subthalamotomy and has been associated with fewer adverse effects, but produces shorter lasting ipsilateral improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/57\">",
"     57",
"    </a>",
"    ]. A prospective study comparing bilateral subthalamotomy, bilateral subthalamic nucleus (STN) DBS, and unilateral subthalamotomy with contralateral STN DBS using unblinded ratings showed no significant differences among treatment groups in efficacy or adverse effects when assessed 12 months after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main concern regarding subthalamotomy has been adverse neurologic effects. In a case series of 89 patients who underwent unilateral subthalamotomy, 52 (58 percent) experienced early contralateral dyskinesia that resolved over four to 12 weeks in 38 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/57\">",
"     57",
"    </a>",
"    ]. However, dyskinesia remained unchanged for 14 patients (16 percent) and was severe in eight of these, causing a combination of hemiballism and hemichorea that failed to improve even after stopping dopaminergic medications or treatment with dopamine antagonists. All eight patients required pallidotomy within four weeks to two years after subthalamotomy to eliminate dyskinesia.",
"   </p>",
"   <p>",
"    When STN DBS was first introduced, it was believed that PD would protect against dyskinesia following STN surgery because of changes in striatopallidal circuits caused by nigrostriatal dopamine deficiency. Whereas persistent dyskinesia is rare after STN DBS, it is clearly common after subthalamotomy. There has been considerable debate concerning the role of lesion size and location on the risk of postoperative hemichorea-ballism.",
"   </p>",
"   <p>",
"    In some cases, large lesions extending into fiber pathways dorsal to the STN appear to have protected against postoperative dyskinesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/59\">",
"     59",
"    </a>",
"    ], while in other cases large lesions have produced persistent dyskinesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/60\">",
"     60",
"    </a>",
"    ]. Accessibility, reduced cost, and lack of hardware problems may make subthalamotomy advantageous over DBS in some parts of the world, but subthalamotomy remains an experimental treatment for advanced PD and should be carried out only at experienced centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Neural transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale of neural transplantation is to place dopamine producing cells in or near the sites in the brain where dopamine production is lacking. However, two randomized controlled trials found no clear benefit for embryonic neural transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors of this second trial concluded that embryonic transplantation cannot be recommended for treatment of PD at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/62\">",
"     62",
"    </a>",
"    ]. However, further research and additional clinical trials using a variety of cell implants could change the prospects for benefit from this line of treatment.",
"   </p>",
"   <p>",
"    Though therapeutic benefit has not been established with neural transplantation, important information regarding the etiology and pathogenesis of midbrain dopamine neuron degeneration has been generated from these trials.",
"   </p>",
"   <p>",
"    Histopathologic evaluation of postmortem brains from patients with PD who had fetal mesencephalic dopaminergic cell implants has yielded conflicting results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmortem analyses performed 11 to 16 years after transplantation in three patients with PD found Lewy body pathology in the transplanted neurons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. One interpretation of this finding is that unknown factors responsible for progressive neurodegeneration in PD may account for propagation of the disease from host to graft cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/63,65\">",
"       63,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another postmortem study 9 to 14 years after transplantation in five subjects with PD revealed surviving grafts that included dopaminergic and serotonergic neurons without pathology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further histopathologic study of longstanding neural cell transplants may help bridge the discrepancy between these findings.",
"   </p>",
"   <p>",
"    Adrenal medullary transplant is a difficult double operation with high morbidity and no proven benefit; it is not acceptable therapy, and is not undergoing further study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     GDNF infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct brain infusion of glial cell line derived neurotrophic factor (GDNF) appeared promising in a phase II open label trial of safety and tolerability involving five patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/67\">",
"     67",
"    </a>",
"    ]. Symptoms were significantly improved in all patients, and PET scanning showed increased dopamine storage in the putamen.",
"   </p>",
"   <p>",
"    However, a larger randomized controlled trial comparing intraputamenal infusion of GDNF and placebo in 34 patients followed for six months found no significant benefit in primary or secondary clinical end points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/68\">",
"     68",
"    </a>",
"    ]. The lack of clinical benefit together with safety concerns led the manufacturer to withdraw GDNF from further clinical trials. The safety concerns included the appearance of antibodies to GDNF in four patients, and findings of cerebellar Purkinje and granule cell loss in two monkeys receiving GDNF infusions. Further research regarding these issues is needed to determine if GDNF clinical trials should resume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early human studies of gene therapy for PD are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. One potential approach is to augment the reduced dopamine production that occurs with PD. Another approach is to target overactivity of the subthalamic nucleus that results from loss of dopaminergic input. This can be achieved by inducing the production of the inhibitory neurotransmitter, gamma-amino butyric acid (GABA), thereby converting the output of the STN from excitatory to inhibitory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, an open-label safety and tolerability trial used an adeno-associated viral vector (AAV) to deliver glutamic acid decarboxylase (GAD), the enzyme that catalyzes the synthesis of GABA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/70\">",
"     70",
"    </a>",
"    ], unilaterally into the subthalamic nucleus in 12 patients on the side opposite the more prominent clinical signs of PD. The procedure appeared safe and well tolerated. Preliminary data at one year suggested potential clinical benefit for some aspects of PD. However, two subsequent double-blind randomized controlled trials found different results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first such trial, which evaluated gene therapy for 56 patients with advanced PD, delivery of the gene for neurturin (a natural analogue of glial derived neurotrophic factor) via an AAV into the putamen bilaterally was",
"      <strong>",
"       not",
"      </strong>",
"      beneficial for motor improvement at 12 months compared with sham surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/74\">",
"       74",
"      </a>",
"      ]. However, there was a suggestion of benefit for active treatment in a subgroup of patients who were followed for 18 months. Given the small number of patients included in this secondary analysis and the fact that no adjustments were made for multiple comparisons, this outcome should be interpreted with caution but does suggest further study is needed.",
"     </li>",
"     <li>",
"      A second trial enrolled 45 patients with advanced PD and evaluated data from 37 patients, including 16 assigned to AAV-GAD delivered to the subthalamic nucleus and 21 assigned to sham surgery; eight patients were excluded from analysis because of infusion failure or catheter tip misplacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/75\">",
"       75",
"      </a>",
"      ]. Compared with the sham surgery group at six month, the AAV-GAD group showed statistically significant benefit for improvement in Unified Parkinson Disease Rating Scale (UPDRS) motor scores.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further trials are needed to determine if this will be a useful approach. Another trial evaluating AAV-neurturin is underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174074232\">",
"    <span class=\"h2\">",
"     Duodenal levodopa infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral levodopa infusion is under investigation in patients with advanced PD as a strategy to reduce fluctuations in dopaminergic drug concentrations and thereby minimize motor fluctuations. This strategy appeared promising in earlier studies, but utility was limited by poor solubility of aqueous levodopa and the need for large infusion volumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. A gel formulation of",
"    <span class=\"nowrap\">",
"     levodopa/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"      carbidopa",
"     </a>",
"    </span>",
"    was developed to overcome this problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 24 patients who had PD with motor fluctuations and dyskinesia, intraduodenal infusion of the",
"    <span class=\"nowrap\">",
"     levodopa/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"      carbidopa",
"     </a>",
"    </span>",
"    gel was associated with decreased \"off\" state, increased \"on\" state, and no increase in dyskinesia compared with individualized conventional treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/82\">",
"     82",
"    </a>",
"    ]. The study was not double-blinded or placebo-controlled, and the results require confirmation in a larger controlled trial. Long-term use of this treatment requires placement of a permanent infusion system and a percutaneous intestinal tube inserted via gastrostomy. Potential complications of this intervention include acute and subacute gastrointestinal adverse events related to the percutaneous endoscopic gastrostomy tube or the jejunal extension tube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32105/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13954?source=see_link\">",
"       \"Patient information: Parkinson disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good evidence from randomized controlled trials to endorse deep brain stimulation (DBS) of either the subthalamic nucleus (STN) or the internal globus pallidus (GPi) as an effective therapeutic option for well-selected patients with medically intractable symptoms of PD.",
"   </p>",
"   <p>",
"    DBS is non-destructive, can be performed bilaterally with low neurologic morbidity, and can be modified over time to deal with changing or progressing patient symptoms. Disadvantages of DBS are greater cost, which may be a significant factor in some world regions, the introduction of hardware with risk of infection, hemorrhage, or mechanical breakdown, and the need for periodic reprogramming. Furthermore, DBS does not clearly help axial symptoms, such as postural instability or difficulty with speech and swallowing, and there is no evidence that it slows progression of the underlying neurodegenerative process.",
"   </p>",
"   <p>",
"    Tissue transplantation and intracerebral infusion treatments for motor fluctuations cannot be recommended at present pending future research concerning these approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87734238\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Galit Kleiner-Fisman, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/1\">",
"      Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/2\">",
"      Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 2012; 11:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/3\">",
"      Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/4\">",
"      Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/5\">",
"      Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/6\">",
"      Deuschl G, Sch&uuml;pbach M, Knudsen K, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013; 19:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/7\">",
"      Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/8\">",
"      Sch&uuml;pbach WM, Malt&ecirc;te D, Houeto JL, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007; 68:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/9\">",
"      Tanner CM. A second honeymoon for Parkinson's disease? N Engl J Med 2013; 368:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/10\">",
"      Welter ML, Houeto JL, Tezenas du Montcel S, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002; 125:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/11\">",
"      Kleiner-Fisman G, Fisman DN, Sime E, et al. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 2003; 99:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/12\">",
"      Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/13\">",
"      Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/14\">",
"      Rodriguez-Oroz MC, Zamarbide I, Guridi J, et al. Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation. J Neurol Neurosurg Psychiatry 2004; 75:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/15\">",
"      Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005; 128:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/16\">",
"      Sch&uuml;pbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005; 76:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/17\">",
"      Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010; 25:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/18\">",
"      Weaver FM, Follett KA, Stern M, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 2012; 79:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/19\">",
"      Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2005; 76:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/20\">",
"      Warnke PC. STN stimulation and neuroprotection in Parkinson's disease--when beautiful theories meet ugly facts. J Neurol Neurosurg Psychiatry 2005; 76:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/21\">",
"      St George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology 2010; 75:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/22\">",
"      Rodriguez-Oroz MC, Moro E, Krack P. Long-term outcomes of surgical therapies for Parkinson's disease. Mov Disord 2012; 27:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/23\">",
"      Oh MY, Abosch A, Kim SH, et al. Long-term hardware-related complications of deep brain stimulation. Neurosurgery 2002; 50:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/24\">",
"      Beric A, Kelly PJ, Rezai A, et al. Complications of deep brain stimulation surgery. Stereotact Funct Neurosurg 2001; 77:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/25\">",
"      Umemura A, Jaggi JL, Hurtig HI, et al. Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg 2003; 98:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/26\">",
"      Lyons KE, Wilkinson SB, Overman J, Pahwa R. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 2004; 63:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/27\">",
"      Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006; 21 Suppl 14:S290.",
"     </a>",
"    </li>",
"    <li>",
"     Tarsy, D, Norregaard, TV. Thalamic stimulation therapy in Parkinson's disease. In: Therapy of Parkinson's Disease, 3rd ed, Pahwa, R, Lyons, KE, Koller, WC (Eds), Marcel Dekker, New York 2004. p.293.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/29\">",
"      Obwegeser AA, Uitti RJ, Witte RJ, et al. Quantitative and qualitative outcome measures after thalamic deep brain stimulation to treat disabling tremors. Neurosurgery 2001; 48:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/30\">",
"      Voon V, Kubu C, Krack P, et al. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21 Suppl 14:S305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/31\">",
"      Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999; 46:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/32\">",
"      Woods SP, Fields JA, Tr&ouml;ster AI. Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a critical review. Neuropsychol Rev 2002; 12:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/33\">",
"      Daniele A, Albanese A, Contarino MF, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/34\">",
"      Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/35\">",
"      Parsons TD, Rogers SA, Braaten AJ, et al. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006; 5:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/36\">",
"      Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/37\">",
"      Morrison CE, Borod JC, Perrine K, et al. Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol 2004; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/38\">",
"      Smeding HM, Speelman JD, Koning-Haanstra M, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006; 66:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/39\">",
"      Sch&uuml;pbach M, Gargiulo M, Welter ML, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology 2006; 66:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/40\">",
"      Saint-Cyr JA, Tr&eacute;panier LL, Kumar R, et al. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 2000; 123 ( Pt 10):2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/41\">",
"      Saint-Cyr JA, Albanese A. STN DBS in PD: selection criteria for surgery should include cognitive and psychiatric factors. Neurology 2006; 66:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/42\">",
"      Anderson VC, Burchiel KJ, Hogarth P, et al. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 2005; 62:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/43\">",
"      Okun MS, Foote KD. Subthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return? Arch Neurol 2005; 62:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/44\">",
"      Doshi PK, Chhaya N, Bhatt MH. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 2002; 17:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/45\">",
"      Soulas T, Gurruchaga JM, Palfi S, et al. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2008; 79:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/46\">",
"      Burkhard PR, Vingerhoets FJ, Berney A, et al. Suicide after successful deep brain stimulation for movement disorders. Neurology 2004; 63:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/47\">",
"      Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008; 131:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/48\">",
"      Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson's disease suicidal? J Geriatr Psychiatry Neurol 2001; 14:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/49\">",
"      Kedia S, Moro E, Tagliati M, et al. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 2004; 63:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/50\">",
"      Capelle HH, Simpson RK Jr, Kronenbuerger M, et al. Long-term deep brain stimulation in elderly patients with cardiac pacemakers. J Neurosurg 2005; 102:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/51\">",
"      Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004; 62:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/52\">",
"      Hallett M, Litvan I. Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. Neurology 1999; 53:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/53\">",
"      Lai EC, Jankovic J, Krauss JK, et al. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology 2000; 55:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/54\">",
"      Vitek JL, Bakay RA, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 2003; 53:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/55\">",
"      de Bie RM, de Haan RJ, Schuurman PR, et al. Morbidity and mortality following pallidotomy in Parkinson's disease: a systematic review. Neurology 2002; 58:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/56\">",
"      Tarsy D. Does subthalamotomy have a place in the treatment of Parkinson's disease? J Neurol Neurosurg Psychiatry 2009; 80:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/57\">",
"      Alvarez L, Macias R, Pav&oacute;n N, et al. Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. J Neurol Neurosurg Psychiatry 2009; 80:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/58\">",
"      Merello M, Tenca E, P&eacute;rez Lloret S, et al. Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study. Br J Neurosurg 2008; 22:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/59\">",
"      Lozano AM. The subthalamic nucleus: myth and opportunities. Mov Disord 2001; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/60\">",
"      Su PC, Tseng HM, Liu HM, et al. Subthalamotomy for advanced Parkinson disease. J Neurosurg 2002; 97:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/61\">",
"      Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/62\">",
"      Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/63\">",
"      Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/64\">",
"      Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/65\">",
"      Braak H, Del Tredici K. Assessing fetal nerve cell grafts in Parkinson's disease. Nat Med 2008; 14:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/66\">",
"      Mendez I, Vi&ntilde;uela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008; 14:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/67\">",
"      Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/68\">",
"      Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/69\">",
"      Stoessl AJ. Gene therapy for Parkinson's disease: early data. Lancet 2007; 369:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/70\">",
"      Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/71\">",
"      Svendsen C. The first steps towards gene therapy for Parkinson's disease. Lancet Neurol 2007; 6:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/72\">",
"      Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008; 7:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/73\">",
"      Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009; 73:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/74\">",
"      Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/75\">",
"      LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10:309.",
"     </a>",
"    </li>",
"    <li>",
"     Safety and efficacy of CERE-120 in subjects with Parkinson's disease. file://clinicaltrials.gov/ct2/show/NCT00985517 (Accessed on February 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/77\">",
"      Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986; 20:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/78\">",
"      Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993; 43:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/79\">",
"      Syed N, Murphy J, Zimmerman T Jr, et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998; 13:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/80\">",
"      Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 1993; 45:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/81\">",
"      Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease--long-term experience. Acta Neurol Scand 2001; 104:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/82\">",
"      Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32105/abstract/83\">",
"      Klostermann F, Jugel C, B&ouml;melburg M, et al. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion. Mov Disord 2012; 27:1704.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4897 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32105=[""].join("\n");
var outline_f31_22_32105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Motor fluctuations and dyskinesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rationale for surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEEP BRAIN STIMULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effectiveness in advanced PD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Subthalamic nucleus versus globus pallidus DBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92694887\">",
"      Effectiveness in early PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Factors predictive of benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Duration of benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgical complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hardware complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stimulation-related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cognitive and behavioral complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Risk of suicide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Thalamotomy and pallidotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Subthalamotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Neural transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      GDNF infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174074232\">",
"      Duodenal levodopa infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87734238\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4897|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/46/34530\" title=\"table 1\">",
"      Unified Parkinson Disease Rating Scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=related_link\">",
"      Motor fluctuations and dyskinesia in Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=related_link\">",
"      Pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_22_32106="Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy";
var content_f31_22_32106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32106/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32106/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32106/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/22/32106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/22/32106/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/22/32106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmogenic right ventricular cardiomyopathy (ARVC), formerly called \"arrhythmogenic right ventricular dysplasia\" (ARVD), is an underrecognized clinical entity characterized by ventricular arrhythmias and a specific ventricular pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. ARVC is characterized macroscopically by a scarred appearance with fibrous or fibro-fatty replacement of myocardium in the inflow tract, outflow tract,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    apex of the RV. The RV myocardial scarring initially produces typical regional wall motion abnormalities but later may involve the free wall and become global, producing RV dilation. The tissue replacement can also involve areas of the left ventricle (LV) with relative sparing of the septum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and differential diagnosis of ARVC will be reviewed here. The genetics, pathogenesis, treatment, and prognosis of ARVC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492591\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of ARVC in the general adult population is estimated to be approximately 1 in 2000 to 1 in 5000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/5\">",
"     5",
"    </a>",
"    ]. ARVC is an important cause of sudden cardiac death (SCD) in young adults, accounting for approximately 11 percent of cases overall and 22 percent in athletes in a study from northern Italy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In contrast, ARVC has been rarely diagnosed in the United States. This may reflect a difference in genetic prevalence, but is more likely due to under-recognition of disease. In a series of 100 ARVC patients from a single referral center in the United States, clinical profiles and event rates were similar to those reported in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492598\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARVC can present in a variety of ways, including palpitations, syncope, chest pain, dyspnea, and, rarely, sudden cardiac death. Many patients, however, remain clinically silent and asymptomatic for decades, making the disease difficult to recognize, especially in sporadic cases with no recognized familial involvement.",
"   </p>",
"   <p>",
"    Studies have suggested that 30 percent of cases of ARVC are familial, although this is likely an underestimate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. ARVC is caused by mutations in a variety of genes, most of which encode desmosomal proteins. Two patterns of inheritance have been described in ARVC: an autosomal dominant form, which is most common, and an autosomal recessive form (eg, Naxos disease, Carvajal syndrome) in which ARVC is part of a cardiocutaneous syndrome including hyperkeratosis of the palms and soles and woolly hair. Clinical features associated with mutations in each of the associated genes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link&amp;anchor=H6#H6\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical perspectives of ARVC primarily arise from experience with patients who present with arrhythmia of right ventricular (RV) origin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sudden death. Presentation is most common between the ages of 10 and 50 years, with a mean age at diagnosis of approximately 30 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/8,9,12\">",
"     8,9,12",
"    </a>",
"    ]. The disease is virtually never diagnosed in infants or toddlers and uncommonly before the age of 10.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492605\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the principle symptoms associated with ARVC are dizziness, palpitations, and syncope, as many as 40 percent of persons diagnosed with ARVC remain asymptomatic. In one of the largest reported series of 130 patients at a tertiary referral center, the frequency of specific symptoms was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpitations &ndash; 67 percent",
"     </li>",
"     <li>",
"      Syncope &ndash; 32 percent",
"     </li>",
"     <li>",
"      Atypical chest pain &ndash; 27 percent",
"     </li>",
"     <li>",
"      Dyspnea &ndash; 11 percent",
"     </li>",
"     <li>",
"      RV failure &ndash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 40 percent of patients are asymptomatic when ARVC is identified as part of screening of affected family members. ARVC is often suspected due to the presence of only nonspecific electrocardiographic (ECG) or echocardiographic abnormalities or ventricular arrhythmias on Holter or exercise testing in the context of a positive family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ]. In a review of 37 families, 151 of 365 family members were classified as affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9\">",
"     9",
"    </a>",
"    ]. An additional 17 subjects were classified as healthy carriers (lacking clinical evidence of ARVC but transmitted ARVC to their progeny) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492612\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are diagnosed with ARVC typically present with palpitations or syncope as the manifestation of ventricular arrhythmias. Ventricular arrhythmias can range from frequent ventricular premature beats to sustained ventricular tachycardia (VT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/8\">",
"     8",
"    </a>",
"    ]. The frequency of such arrhythmias in ARVC varies with the severity of the disease. In a series of 151 patients, ventricular arrhythmias were present in all patients with severe disease, 82 percent with moderate disease, and 23 percent with mild disease as defined by echocardiographic markers of disease severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of ventricular premature beats in patients with Naxos disease is as high as 92 percent, and patients with Naxos disease have a higher incidence of sustained ventricular arrhythmias and sudden cardiac death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Autosomal recessive disease and Naxos disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common ventricular arrhythmia is sustained or nonsustained monomorphic VT that originates in the RV and therefore has a left bundle branch block (LBBB) pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As an example, among a cohort of 100 patients with ARVC, 51 of the 69 patients diagnosed antemortem had documented VT with LBBB morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/8\">",
"     8",
"    </a>",
"    ]. VT may originate from the RV inflow tract, RV apex, or RV outflow tract. When VT arises from the RV outflow tract it may be difficult to distinguish ARVC from idiopathic RV outflow tract tachycardia (",
"    <a class=\"graphic graphic_waveform graphicRef56591 \" href=\"mobipreview.htm?36/55/37754\">",
"     waveform 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link&amp;anchor=H9#H9\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Repetitive monomorphic VT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most of these arrhythmias appear to arise from the RV, histopathologic abnormalities (fibrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adipose tissue) in the LV and in the His bundle and its branches were commonly observed in an autopsy series of patients with ARVC and SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/16\">",
"     16",
"    </a>",
"    ]. This observation suggests a possible role for conduction abnormalities, though clinically significant conduction disease is an uncommon feature in ARVC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492619\">",
"    <span class=\"h3\">",
"     Sudden cardiac death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death (SCD) occurs in patients with ARVC and can be the first presentation of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/6-9,17,18\">",
"     6-9,17,18",
"    </a>",
"    ]. In a review from France of forensic autopsies on 1930 cases of unexplained SCD (mean age 34 years, males and females equally represented), 200 (10.4 percent) were associated with ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/16\">",
"     16",
"    </a>",
"    ]. Three-quarters of episodes occurred during routine daily activities, 10 percent during the perioperative period, and only 3.5 percent while participating in sports. (See",
"    <a class=\"local\" href=\"#H1492626\">",
"     'Risk of ventricular arrhythmias during exercise'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492626\">",
"    <span class=\"h3\">",
"     Risk of ventricular arrhythmias during exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both VT and SCD in patients with ARVC can be exercise-induced, and in selected populations ARVC is a frequent cause of SCD in athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/7,9,16\">",
"     7,9,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Arrhythmogenic right ventricular cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from northern Italy evaluating the causes of SCD among 269 subjects under 35 years of age, ARVC accounted for 22 percent of deaths among the 49 athletes and 8 percent among the 220 non-athletes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In young athletes in the United States, ARVC appears to be a less common cause of SCD, accounting for only 4 percent of deaths in one series of 286 cases of SCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of SCD during exercise may be due in part to increased stress on the right ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/19\">",
"     19",
"    </a>",
"    ]. Data from an animal model of ARVC suggest that exercise may increase RV dilation and thus worsen the manifestations of ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/20\">",
"     20",
"    </a>",
"    ]. The association with exercise and RV stress and the frequent induction of arrhythmia by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion suggests a role for catecholamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The sensitivity to catecholamines, which may be acquired, could result from abnormalities in cardiac sympathetic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the increase in SCD risk, patients with ARVC should not participate in competitive sports or intense endurance training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9,25\">",
"     9,25",
"    </a>",
"    ]. In addition, any activity, competitive or not, that causes palpitation, presyncope, or syncope should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Arrhythmogenic right ventricular cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492633\">",
"    <span class=\"h2\">",
"     Supraventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular arrhythmias are present in approximately 25 percent of patients with ARVC referred for treatment of ventricular arrhythmias; less often, they may be the only arrhythmia present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/26\">",
"     26",
"    </a>",
"    ]. In decreasing order of frequency, supraventricular arrhythmias in these patients include atrial fibrillation, atrial tachycardia, and atrial flutter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492640\">",
"    <span class=\"h2\">",
"     Noncardiac manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients with familial ARVC have autosomal recessive disease, which is associated with palmoplantar keratosis and wooly hair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Autosomal recessive disease and Naxos disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492647\">",
"    <span class=\"h2\">",
"     Left ventricular involvement",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492714\">",
"    <span class=\"h3\">",
"     Disease patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The broader use of cardiovascular magnetic resonance (CMR), in combination with longer-term follow-up of probands and family members, is allowing for increasingly comprehensive characterization of disease patterns in ARVC. Among the most notable findings is the recognition that left ventricular (LV) involvement is more common than previously appreciated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link&amp;anchor=H9#H9\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Desmoplakin gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a cohort of 200 probands and relatives, all of whom satisfied criteria for familial ARVC (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    ), CMR was performed as part of a comprehensive clinical evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/27\">",
"     27",
"    </a>",
"    ]. LV involvement was suggested by ECG, rhythm monitoring,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CMR findings in &gt;80 percent of patients. Three patterns of disease expression were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic &ndash; This pattern is defined by isolated RV disease or LV involvement in association with significant RV impairment (78 patients [39 percent], of whom 46 [59 percent] had some LV involvement)",
"     </li>",
"     <li>",
"      Left dominant &ndash; Characterized by early and prominent LV manifestations and relatively mild right-sided disease (10 patients [5 percent])",
"     </li>",
"     <li>",
"      Biventricular &ndash; Parallel involvement of both ventricles (112 patients [56 percent])",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492721\">",
"    <span class=\"h3\">",
"     Left-dominant arrhythmogenic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic process in classic ARVC predominantly involves the RV and sometimes extends to the LV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. In contrast, patients with left-dominant arrhythmogenic cardiomyopathy (LDAC, also known as left-sided ARVC or arrhythmogenic left ventricular cardiomyopathy) have pathological changes that predominantly involve the LV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with LDAC present with palpitations and chest pain in a similar fashion to those with classic ARVC. However, syncope appears to be a less frequent clinical manifestation in LDAC. The clinical characteristics of left-dominant arrhythmogenic cardiomyopathy were described in a 42 patient cohort of individuals with unexplained (infero) lateral T-wave inversion, arrhythmia of LV origin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proven LDAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients presented with arrhythmia or chest pain but not heart failure at ages ranging from adolescence to over 80 years.",
"     </li>",
"     <li>",
"      By cardiovascular magnetic resonance (CMR), 12 of 41 patients (29 percent) had an LVEF &lt;50 percent. CMR findings included late gadolinium enhancement (LGE) of the LV in a",
"      <span class=\"nowrap\">",
"       subepicardial/midwall",
"      </span>",
"      distribution.",
"     </li>",
"     <li>",
"      Fifty percent had previously been misdiagnosed with viral myocarditis, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy, or idiopathic ventricular tachycardia.",
"     </li>",
"     <li>",
"      Arrhythmic events included presentation with ventricular fibrillation in one patient and sudden cardiac death on follow-up of two patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible left-sided ARVC should be considered in patients who present with sustained ventricular tachyarrhythmia or sudden cardiac death as the initial manifestation of apparent DCM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As our initial approach, we recommend a 12-lead electrocardiogram (ECG) and transthoracic echocardiography in all patients with a suspected diagnosis of ARVC. Selected additional testing should be performed based on the clinical scenario or when the results of initial testing are non-diagnostic and may include one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Signal-averaged ECG (SAECG)",
"     </li>",
"     <li>",
"      24-hour ECG monitoring",
"     </li>",
"     <li>",
"      Exercise ECG testing",
"     </li>",
"     <li>",
"      Cardiac magnetic resonance (CMR) imaging",
"     </li>",
"     <li>",
"      Right ventriculography",
"     </li>",
"     <li>",
"      Endomyocardial biopsy",
"     </li>",
"     <li>",
"      Electrophysiologic testing",
"     </li>",
"     <li>",
"      Genetic testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients who present with arrhythmia and a suspected diagnosis of ARVC can be diagnosed using a combination of noninvasive electrocardiographic and imaging evaluations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226212\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     12-lead ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients in whom ARVC is being considered should have a resting 12-lead electrocardiogram (ECG) performed. The sensitivity of ECG alone for the presence of ARVC is suboptimal, with as many as 40 to 50 percent of patients having a normal ECG at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9,34\">",
"     9,34",
"    </a>",
"    ]. However, by six years of follow-up, virtually all patients with ARVC have one or more ECG findings during normal sinus rhythm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/34\">",
"     34",
"    </a>",
"    ]. ECG abnormalities observed in ARVC include the following, some of which are included in the 2010 revised Task Force Criteria (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QRS prolongation, particularly in lead V1 versus V6 &ndash; This prolongation is consistent with delayed right ventricular activation. A QRS duration greater than 110 msec (in the absence of right bundle-branch block) in lead V1 has been observed with varying frequency (ranging from 24 to 70 percent) in ARVC patient populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/36\">",
"       36",
"      </a>",
"      ]. This finding was identified as highly specific for ARVC in small studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Incomplete or complete right bundle branch block &ndash; Epicardial mapping in ARVC patients suggests that these patterns are usually due to parietal block (conduction delay in the terminal Purkinje system) rather than disease of the bundle branch [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13271?source=see_link&amp;anchor=H4#H4\">",
"       \"General principles of asynchronous activation and preexcitation\", section on 'Intraventricular and intramural conduction delay'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolonged S wave upstroke (interval from the nadir of the S wave to the isoelectric baseline &ge;55 msec) &ndash; This finding was identified in 91 to 95 percent of ARVC patients who did not have RBBB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/8,40\">",
"       8,40",
"      </a>",
"      ]. Terminal activation duration of QRS &ge;55 msec from the nadir of the S wave to the end of the QRS (including R') in V1, V2, or V3, in the absence of complete right bundle-branch block is a minor criterion in the 2010 revised Task Force Criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epsilon wave &ndash; Thirty percent of patients with ARVC have an epsilon wave (a reproducible distinct wave between the end of the QRS complex and the onset of the T wave) in the right precordial leads, particularly V1 (",
"      <a class=\"graphic graphic_waveform graphicRef60781 \" href=\"mobipreview.htm?41/5/42078\">",
"       waveform 2",
"      </a>",
"      ). This finding represents low amplitude potentials caused by delayed activation of some portion of the RV. This abnormality is a major criterion in the 2010 revised Task Force Criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inversion of T waves in the right precordial leads (V1, V2, and V3) &ndash; T wave inversion occurs in one-half of cases presenting with VT (",
"      <a class=\"graphic graphic_figure graphicRef70822 \" href=\"mobipreview.htm?41/42/42670\">",
"       figure 1",
"      </a>",
"      ). The extent of T-wave inversion has been correlated with the degree of RV enlargement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/41\">",
"       41",
"      </a>",
"      ]. Inverted T waves are included in the following 2010 revised Task Force Criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"       35",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inverted T waves in right precordial leads (V1, V2, V3) or beyond in individuals &gt;14 years of age (in the absence of complete right bundle branch block with QRS &ge;120msec) is a major criterion.",
"     </li>",
"     <li>",
"      Inverted T waves in leads V1 and V2 in individuals &gt;14 years of age (in the absence of complete right bundle-branch block QRS &ge;120 msec) or in V4, V5, or V6 is a minor criterion.",
"     </li>",
"     <li>",
"      Inverted T waves in leads V1, V2, V3, and V4 in individuals &gt;14 years of age in the presence of complete right bundle branch block is a minor criterion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     ECG evolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the majority of patients develop characteristic ECG abnormalities within six years of presentation. The evolution of the ECG over time has been evaluated in several cohorts of ARVC patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The pace and nature of ECG progression was evaluated in a series of 35 patients who met diagnostic criteria for ARVC; 25 had a documented history of ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/42\">",
"     42",
"    </a>",
"    ]. At a mean follow-up of 59 months, 32 patients (89 percent) demonstrated one or more of the following features of ECG progression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolongation of S-wave upstroke by &ge;10 msec &ndash; 69 percent",
"     </li>",
"     <li>",
"      QRS prolongation by &ge;10 msec &ndash; 66 percent",
"     </li>",
"     <li>",
"      New T-wave inversion in &ge;1 precordial lead &ndash; 37 percent",
"     </li>",
"     <li>",
"      New bundle branch block &ndash; 11 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with the progressive nature of ARVC. The incidence of ECG evolution is probably in part due to the high-risk cohort, as evidenced by the high rate of ventricular arrhythmias and the fact that all patients met diagnostic criteria for ARVC at the time of the baseline ECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Signal-averaged ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;When feasible (ie, the technology is available to perform the test), we suggest performing a signal-averaged ECG as abnormalities in the signal-averaged electrocardiogram are frequently detected in patients with ARVC and are a minor criterion for making the diagnosis. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4391?source=see_link\">",
"     \"Clinical applications of the signal-averaged electrocardiogram: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A minor criterion in the 2010 revised Task Force guidelines is the presence of one or more of the following three signal-averaged ECG (SAECG) abnormalities in the absence of a QRS duration &ge;110 msec on the standard ECG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"     35",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Filtered QRS duration &ge;114 msec.",
"     </li>",
"     <li>",
"      Duration of terminal QRS &lt;40 microV (low amplitude signal duration) &ge;38 msec",
"     </li>",
"     <li>",
"      Root-mean-square voltage of terminal 40 msec &le;20 microV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This minor criterion has been found to have a sensitivity of 69 to 74 percent and specificity of 92 to 95 percent when applied to known ARVC probands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35,49\">",
"     35,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SAECG may contribute to the detection of ARVC in family members. Late potentials were found in 16 percent of 101 asymptomatic family members compared with 3 percent of control subjects. ECG abnormalities were found in 34 percent of the 101 family members, with the combination of late potentials",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ECG abnormalities being present in 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/13\">",
"     13",
"    </a>",
"    ]. These findings suggest that there is a significant incidence of a familial form of the disease that may be undetected in many family members. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10872?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226346\">",
"    <span class=\"h2\">",
"     Cardiac imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients who present with arrhythmia in whom ARVC is being considered can be diagnosed using the combination of noninvasive electrocardiographic and imaging evaluations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/33\">",
"     33",
"    </a>",
"    ]. Echocardiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other noninvasive imaging modalities are frequently performed to look for structural or functional abnormalities (particularly in the RV) in patients without known heart disease who present with VT of LBBB morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients in whom the diagnosis of ARVC is being considered should have a transthoracic echocardiogram performed. Echocardiography is readily available and provides adequate visualization of the right ventricle in most patients. However, if echocardiographic imaging is deemed to be non-diagnostic, additional imaging with cardiovascular magnetic resonance should be performed.",
"   </p>",
"   <p>",
"    The echocardiographic characteristics of ARVC have been reported in a number of cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9,50\">",
"     9,50",
"    </a>",
"    ]. In a report from the Multidisciplinary Study of Right Ventricular Dysplasia which compared 29 probands with newly diagnosed ARVC by the 1994 task force criteria and 29 carefully matched controls, the following echocardiographic findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Right ventricular dimensions were increased (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61638 \" href=\"mobipreview.htm?6/11/6322\">",
"       image 1",
"      </a>",
"      ), particularly the right ventricular outflow tract (RVOT, 37.9 versus 26.2 mm in controls).",
"     </li>",
"     <li>",
"      Right ventricular fractional area change, a marker of right ventricular systolic function, was reduced (27.2 versus 41.0 percent).",
"     </li>",
"     <li>",
"      Right ventricular morphologic abnormalities were present in many probands but no controls (trabecular derangement in 54 percent, hyperreflective moderator band in 34 percent, and sacculations in 17 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One limitation of these observations is that the patients met the 1994 Task Force Criteria (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    ), so applicability to patients with mild disease is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2010 revised Task Force Criteria, echocardiographic criteria include quantitative measures of RVOT enlargement and reduction in RV fractional area changed. Major echocardiographic criteria were selected to yield 95 percent specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"     35",
"    </a>",
"    ]. Minor echocardiographic criteria were selected to yield sensitivity equal to specificity (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52639 \" href=\"mobipreview.htm?27/26/28077\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14880803\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not routinely perform cardiovascular magnetic resonance (CMR) imaging in all patients with suspected ARVC, particularly in those patients whose other test results and clinical features have led to a definite diagnosis of ARVC based on the 2010 revised task force criteria. However, in patients with suspected ARVC and non-diagnostic results of other imaging modalities, CMR should be performed, ideally in a center with expertise in the evaluation of CMR for abnormalities suggestive of ARVC.",
"   </p>",
"   <p>",
"    CMR imaging is an important investigation in the diagnostic assessment of ARVC. CMR examination enables identification of global and regional ventricular dilation, global and regional ventricular dysfunction, intramyocardial fat, late gadolinium enhancement (LGE), and focal wall thinning (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79386 \" href=\"mobipreview.htm?5/19/5428\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/28,29,52-55\">",
"     28,29,52-55",
"    </a>",
"    ]. Abnormalities on CMR are rare in the absence of ECG, echocardiographic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrhythmia manifestations of ARVC, though the possible role of late enhancement as an isolated, early marker of disease expression requires additional evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 revised Task Force Criteria include CMR parameters for regional RV dysfunction, RV volume, and RV global dysfunction (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52639 \" href=\"mobipreview.htm?27/26/28077\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CMR major criterion requires regional RV wall motion abnormality (akinesis or dyskinesis or dyssynchronous RV contraction) and either increased RV end-diastolic volume (&ge;110",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      in men; &ge;100",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      in women) or depressed RV ejection fraction (RVEF &le;40 percent). The sensitivity and specificity of this criterion were 76 and 90 percent in men and 68 percent and 98 percent in women.",
"     </li>",
"     <li>",
"      The CMR minor criterion requires regional RV wall motion abnormality (as above) and milder degrees of RV end-diastolic volume dilation (&ge;100",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      in men; &ge;90",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      in women) or RVEF &le;45 percent. The sensitivity and specificity of this criterion were 79 and 85 percent in men and 89 and 97 percent in women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic accuracy of CMR was assessed in a series of 232 patients undergoing evaluation for suspected ARVC using the 1994 Task Force Criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/29\">",
"     29",
"    </a>",
"    ]. In this series, 64 patients fulfilled 1994 Task Force Criteria for the diagnosis of ARVC, 63 fulfilled diagnostic criteria modified for familial ARVC, and another 7 were obligate gene carriers. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      183 of the CMR studies were interpreted as diagnostic or strongly suspicious for ARVC.",
"     </li>",
"     <li>",
"      All 134 patients who fulfilled 1994 Task Force Criteria modified for familial ARVC, or were obligate gene carriers had abnormal CMR results (diagnostic or strongly suspicious). Thus the sensitivity and specificity of CMR for clinical ARVC were 100 and 50 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, data support the view that ECG abnormalities and arrhythmia are usually the earliest manifestations of ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/43,57\">",
"     43,57",
"    </a>",
"    ]. The CMR results quoted above, however, suggest that CMR may also be sensitive in identifying early changes leading to the diagnosis of ARVC, although the number of gene positive-phenotype negative individuals was small. However, they also reveal a high rate of CMR false positive diagnosis of ARVC.",
"   </p>",
"   <p>",
"    Although clinical studies and the Task force criteria have focused predominantly on RV abnormalities, LV involvement is more common than previously appreciated. CMR identification of LV abnormalities has provided evidence for the frequency and extent of LV disease. (See",
"    <a class=\"local\" href=\"#H1492647\">",
"     'Left ventricular involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5514062\">",
"    <span class=\"h4\">",
"     Concerns with CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some CMR parameters were highly specific for gene-carrier status (eg, specificity of 100 percent for each of these three parameters: RV dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systolic impairment, RV late enhancement, and severe RV segmental",
"    <span class=\"nowrap\">",
"     dilation/regional",
"    </span>",
"    wall motion abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aneurysms), others demonstrated low specificity (eg, specificity of 56 percent for abnormal trabeculations and 44 percent for mild RV localized dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional wall motion abnormalities).",
"   </p>",
"   <p>",
"    An additional concern with CMR is interobserver variability in identifying features of ARVC. Substantial interobserver variability has been identified between experts, although this variability appears to be at least partially related to lack of experience with CMR in the diagnosis of ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/54,55,58\">",
"     54,55,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     CMR use in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR may be less useful for the diagnosis of ARVC in children. This was illustrated in a series of 81 children, average age 11 years, who were referred to a single center for CMR for the purpose of diagnosing ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/59\">",
"     59",
"    </a>",
"    ]. Only one child fulfilled diagnostic criteria for ARVC, and only two additional patients had any findings consistent with ARVC. Because the number of patients who actually had ARVC in this series was not reported, the diagnostic performance of CMR could not be quantified. However, among these 81 patients, 16 had a history of ventricular tachycardia, another 15 had a history of syncope or cardiac death, and 26 had a family history of ARVC. The very low incidence of CMR abnormalities in this at-risk cohort may reflect age-related penetrance and incomplete phenotypic expression in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226485\">",
"    <span class=\"h3\">",
"     Right ventriculography",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not routinely perform right ventriculography in all patients with suspected ARVC, particularly in those patients whose other test results and clinical features have led to a definite diagnosis of ARVC based on the 2010 revised task force criteria. However, in patients with suspected ARVC and non-diagnostic results of other imaging modalities, or in patients in whom right ventricular endomyocardial biopsy is planned, right ventriculography may be performed.",
"   </p>",
"   <p>",
"    In expert hands, RV selective cineangiography may provide an important contribution to the evaluation of the RV structure and function in patients suspected of having ARVC. Angiographic findings include transversely arranged hypertrophic trabeculae separated by deep fissures, and coarse trabeculae in the apical region distal to the moderator band. RV trabeculae may be considered hypertrophic when there is a thickness greater than or equal to 4 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/61\">",
"     61",
"    </a>",
"    ]. The RV volume is almost always increased, but it is often difficult to quantitatively assess RV enlargement because of the complex geometric shape of this chamber.",
"   </p>",
"   <p>",
"    It is important to obtain the RV angiogram in at least two orthogonal views during sinus rhythm, and to avoid premature ventricular complexes. Biplane angiography should be performed in the 30&ordm; right anterior oblique and 60&ordm; left anterior oblique views in order to assess the typical areas of involvement, including the infundibulum, anterior RV free wall, apex, and the inferior wall, particularly in the subtricuspid area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 revised Task Force Criteria (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    ) include as a major criterion the presence of regional RV akinesis, dyskinesis, or aneurysm by RV angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7299579\">",
"    <span class=\"h3\">",
"     Radionuclide ventriculography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, radionuclide ventriculography has been used to detect global",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional RV dysfunction in ARVC (",
"    <a class=\"graphic graphic_table graphicRef66378 \" href=\"mobipreview.htm?26/1/26651\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. However, in current clinical practice, echocardiography and CMR provide better visualization and have replaced radionuclide ventriculography in the diagnosis of ARVC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7299586\">",
"    <span class=\"h3\">",
"     Multidetector computed tomography (MDCT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDCT can identify morphologic features of ARVC such as increases in RV chamber size and RV trabeculation, intramyocardial fat, and scalloping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/66\">",
"     66",
"    </a>",
"    ]. If further evidence of utility becomes available, MDCT may serve as an alternative to CMR for patients in whom CMR is contraindicated due to the presence of a pacemaker or implantable cardioverter-defibrillator. However, until such time, we do not recommend the routine use of MDCT in the evaluation of ARVC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Electrophysiologic testing and electroanatomic mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiological (EP) testing in ARVC is rarely indicated as part of diagnostic or prognostic evaluation. In patients with refractory ventricular arrhythmias, however, EP testing along with ablation of the arrhythmia may be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/56/6025?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Radiofrequency ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electroanatomic mapping, which uses low-intensity magnetic field energy to determine the location of sensor-tipped catheter electrodes in the ventricles, has been applied for mapping of arrhythmias. Low voltage local RV electrograms indicate the presence of abnormal right ventricular substrate in ARVC and preliminary mapping and biopsy correlation studies suggest that the presence, location, and extent of affected regions can be identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=see_link&amp;anchor=H19#H19\">",
"     \"Electrophysiologic cardiac mapping: Techniques\", section on 'Electroanatomical mapping'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic accuracy of right ventricular endocardial electroanatomic mapping and contrast enhanced CMR were compared in a single center study of 23 consecutive patients who met the 2010 diagnostic criteria for ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/68\">",
"     68",
"    </a>",
"    ]. Electroanatomic mapping identified a total of 45 scars in 21 of 23 patients, compared with a total of 23 scars in 9 of 23 patients identified by delayed enhancement CMR (DE-CMR), suggesting that electroanatomic mapping is more sensitive for the detection of RV scarring. However, 9 of the 12 patients with RV scars detected by mapping but not seen with DE-CMR were found to have abnormal late enhancement involving the",
"    <strong>",
"     left",
"    </strong>",
"    ventricle, highlighting the additional diagnostic power of DE-CMR for the detection of non-RV involvement in ARVC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 revised Task Force criteria (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    ) include as a major criterion the identification of a pathogenic mutation categorized as associated or probably associated with ARVC in the patient under evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"     35",
"    </a>",
"    ]. A probable-disease causing desmosomal mutation is identified in approximately 50 percent of ARVC patients who fulfilled diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/69\">",
"     69",
"    </a>",
"    ]. We do not recommend genetic testing in all patients with suspected ARVC but rather proceed with genetic testing in selected patients as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comprehensive or targeted (DSC2, DSG2, DSP, JUP, PKP2, and TMEM43)",
"      <em>",
"       <span class=\"nowrap\">",
"       </span>",
"      </em>",
"      ACM/ARVC",
"      genetic testing",
"      <strong>",
"       is not required",
"      </strong>",
"      for patients satisfying the task force criteria for a definite diagnosis of ARVC but",
"      <strong>",
"       can be useful",
"      </strong>",
"      for patients satisfying task force diagnostic criteria for a borderline diagnosis of ARVC. (See",
"      <a class=\"local\" href=\"#H14880803\">",
"       'Diagnostic criteria'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We",
"      <strong>",
"       recommend",
"      </strong>",
"      genetic testing of an index patient who has satisfied the task force criteria for either a definite or borderline diagnosis of ARVC prior to genetic screening of family members. This will allow more targeted genetic screening in first-degree relatives.",
"     </li>",
"     <li>",
"      We",
"      <strong>",
"       suggest",
"      </strong>",
"      genetic testing for patients with possible ARVC (one major or two minor criteria) according to the 2010 task force criteria.",
"     </li>",
"     <li>",
"      We",
"      <strong>",
"       do not recommend",
"      </strong>",
"      genetic testing for patients with only a single minor criterion according to the 2010 task force criteria.",
"     </li>",
"     <li>",
"      We",
"      <strong>",
"       recommend",
"      </strong>",
"      mutation-specific genetic testing for family members and appropriate relatives following the identification of the ARVC-causative mutation in an index case.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The genetics and pathogenesis of ARVC are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=see_link\">",
"     \"Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomyocardial biopsy is not recommended in the initial diagnostic evaluation for ARVC because it is invasive and lacks sensitivity and specificity. Specialist referral centers, however, have established criteria for histological diagnosis, and a novel immunohistochemical approach to diagnosis has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/70\">",
"     70",
"    </a>",
"    ]. The histopathologic detection of fibrous or fibro-fatty tissue in the myocardium is not specific to ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/71\">",
"     71",
"    </a>",
"    ]. A major cause of limited sensitivity of biopsy is sampling error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Because of concerns that RV free wall biopsy may increase the risk of myocardial perforation, the RV side of the interventricular septum is the usual site of EMB. However, septal biopsy is generally not helpful in patients with ARVC as the septum is the myocardial segment which is usually thickest and least affected in ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/11\">",
"     11",
"    </a>",
"    ]. Since tissue changes in ARVC are often patchy, imaging or electroanatomic voltage mapping guidance has been suggested to improve the diagnostic yield of biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of simulated endomyocardial biopsies obtained from 60 explanted hearts from subjects with ARVC (20), dilated cardiomyopathy (10), control (10), adipositas cordis (10), and control subjects &gt;80 years old (10) indicated that myocardial atrophy is the most important parameter for diagnosis of ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/11\">",
"     11",
"    </a>",
"    ]. Morphometric cut-offs of myocardium &lt;59 percent, fibrosis &gt;31 percent, and fat &gt;22 percent provided 95 percent specificity with sensitivities of 80, 50, and 50 percent, respectively. The antero-apical area was most diagnostic, with 90 percent sensitivity and 95 percent specificity using a myocardium cut-off of &lt;64 percent, although fat content in this region was not helpful. No diagnostic cut-off could be identified for any parameter for the septum or left ventricular sampling sites",
"   </p>",
"   <p>",
"    The 2010 revised Task Force Criteria (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    ) include the following criteria for EMB samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Residual myocytes &lt;60 percent by morphometric analysis (or &lt;50 percent if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on EMB.",
"     </li>",
"     <li>",
"      Residual myocytes 60 to 75 percent by morphometric analysis (or 50 to 65 percent if estimated), with fibrous replacement of the RV free wall myocardium in &ge;1 sample, with or without fatty replacement of tissue on EMB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The observation of altered plakoglobin signal on immunohistochemical analysis of EMB specimens in several cases of ARVC raised the question of whether this was a non-specific change related to underlying heart disease, or whether it was a specific disease feature of desmosomal disease or ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/57\">",
"     57",
"    </a>",
"    ]. Normal localization of plakoglobin at the intercalated disk has been seen in explanted hearts of patients with end stage hypertrophic, dilated, and ischemic cardiomyopathy. In a small study of EMB specimens from patients with (n = 11) and without (n = 10) ARVC, the identification of a reduction in plakoglobin signal on immunohistochemical analysis of EMB specimens had a high sensitivity (91 percent) and specificity (82 percent) for the diagnosis of ARVC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/73\">",
"     73",
"    </a>",
"    ]. In a study from Denmark of 34 patients with a clinical diagnosis of ARVC, the sensitivity of altered plakoglobin signal for the diagnosis of ARVC was 85 percent, with a specificity of only 57 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/74\">",
"     74",
"    </a>",
"    ]. Further data are needed to establish the utility of immunohistochemical analysis of EMB specimens in ARVC. One potential advantage of this method is that the plakoglobin signal level was reduced diffusely in ARVC samples, including those obtained from the interventricular septum and left ventricle, and thus sampling error does not appear to be an issue.",
"   </p>",
"   <p>",
"    The safety of EMB targeting non-septal locations in patients with ARVC has been a concern, given the thinner RV free wall and apical myocardium. However, in a cohort of 482 patients with unclear cardiomyopathy that underwent 3777 EMB samples taken from six different RV locations (septum, inferior, supra-apical, free wall, outflow tract, and anterior), there was no significant difference in the rate of cardiac perforation resulting in pericardial effusions between patients with ARVC (6 of 161 patients, 3.7 percent) and those with a diagnosis other than ARVC (17 of 321 patients, 5.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/70\">",
"     70",
"    </a>",
"    ]. This suggests that in experienced hands, it is safe to perform EMB targeted to areas of the RV likely to yield a higher rate of diagnostic biopsies for ARVC.",
"   </p>",
"   <p>",
"    General considerations and recommendations for EMB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14880771\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ARVC can be challenging, requiring a high degree of clinical suspicion and frequently multiple diagnostic tests or procedures to arrive at the correct diagnosis. Because many of the clinical findings and test results have reduced sensitivity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specificity for ARVC, diagnostic criteria have been published by professional societies in an effort to standardize the process of arriving at the correct diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35,63\">",
"     35,63",
"    </a>",
"    ]. The gold standard for diagnosis ARVC remains endomyocardial biopsy, but even this has a relatively low sensitivity for making the diagnosis.",
"   </p>",
"   <p>",
"    The diagnosis of ARVC should be considered in a variety of clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who present with symptomatic or asymptomatic VT of LBBB configuration in the absence of apparent heart disease",
"     </li>",
"     <li>",
"      Patients with multiple QRS morphologies when VT is induced during electrophysiology testing",
"     </li>",
"     <li>",
"      Survivors of SCD, particularly SCD occurring during exercise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14880803\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 revised Task Force Criteria were selected based on analysis of receiver operator curves generated from data from 108 probands with newly diagnosed ARVC and data from normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"     35",
"    </a>",
"    ]. Both the original and revised criteria are divided into minor and major criteria and are classified into six categories (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Global",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      regional dysfunction and structural alterations",
"     </li>",
"     <li>",
"      Tissue characterization of wall",
"     </li>",
"     <li>",
"      Repolarization abnormalities on the electrocardiogram (ECG)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Depolarization/conduction",
"      </span>",
"      abnormalities on the ECG",
"     </li>",
"     <li>",
"      Arrhythmias",
"     </li>",
"     <li>",
"      Family history",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Definite",
"    </strong>",
"    diagnosis of ARVC using the 2010 revised Task Force criteria requires the presence of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two major criteria OR",
"     </li>",
"     <li>",
"      One major and two minor criteria OR",
"     </li>",
"     <li>",
"      Four minor criteria from different categories",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Borderline",
"    </strong>",
"    diagnosis of ARVC using the 2010 revised Task Force criteria requires the presence of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One major and one minor criteria OR",
"     </li>",
"     <li>",
"      Three minor criteria from different categories",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Possible",
"    </strong>",
"    diagnosis of ARVC using the 2010 revised Task Force criteria requires the presence of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One major criteria OR",
"     </li>",
"     <li>",
"      Two minor criteria from different categories",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2010 revised criteria (",
"    <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52639 \" href=\"mobipreview.htm?27/26/28077\">",
"     table 2",
"    </a>",
"    ) included quantitative measures for improved diagnostic sensitivity with preserved specificity compared with the 1994 Task Force Criteria, which were based upon clinical experience with severe disease so they are highly specific but lack sensitivity for early and familial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/63,76,77\">",
"     63,76,77",
"    </a>",
"    ]. The improved sensitivity and preserved or improved specificity have been demonstrated in cohort studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. As an example, in a cohort of 103 known carriers of a desmosome mutation and 102 mutation-negative relatives, abnormalities in ECG, SAECG, ambulatory ECG, and echocardiography with met 2010 criteria lead to an additional 16 carriers being diagnosed with ARVC, increasing the sensitivity from 57 to 71 percent with improved specificity from 92 to 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS FOR ARVC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for ARVC includes causes of generalized cardiomyopathy with involvement of the RV. A rare alternate diagnosis is Uhl's anomaly, a partial or complete congenital absence of the RV myocardium. In addition, the EKG characteristics of VT seen in ARVC may be indistinguishable from an idiopathic RV tachycardia, which arises from the RV outflow tract and is seen in patients with a normal heart.",
"   </p>",
"   <p>",
"    Any localized, inflammatory process in the right ventricle, most commonly myocarditis or sarcoidosis, may exhibit clinical features similar to ARVC. An endomyocardial biopsy may be helpful in distinguishing these entities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. One distinguishing feature is conduction disease, which is a common early manifestation of cardiac sarcoidosis, but uncommon in ARVC. The recognition of LV involvement in the majority of patients with ARVC, however, has removed LV systolic dysfunction as a potential distinguishing feature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Endomyocardial biopsy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1492647\">",
"     'Left ventricular involvement'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, right ventricular enlargement and distorted right ventricular anatomy can occur in a number of other conditions, such as congenital heart disease and pulmonary hypertension. As a result, these disorders must be excluded in patients suspected of having ARVC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36119?source=see_link\">",
"     \"Cor pulmonale\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cardiomyopathy with involvement of the RV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In classic ARVC, the clinical presentation is with right ventricular arrhythmia and electrocardiographic changes, usually in association with structural and functional changes in the right ventricle that are demonstrable on imaging studies. With disease progression, there is left ventricular involvement, and in an autopsy series the majority of hearts had significant left ventricular involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/31\">",
"     31",
"    </a>",
"    ]. This correlated with clinical markers of progression, such as T wave changes extending to V4-V6, ventricular arrhythmia of right bundle branch block as well as left bundle branch block morphology, and decreased left ventricular ejection fraction (LVEF). (See",
"    <a class=\"local\" href=\"#H1492647\">",
"     'Left ventricular involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The distinction between ARVC and dilated cardiomyopathy (DCM) with predominant RV dysfunction may be difficult if the LVEF is less than 50 percent. However, it is rare in ARVC to have marked and progressive left ventricular dilatation. On the other hand, it is uncommon to have sustained ventricular tachyarrhythmia or sudden cardiac arrest as the initial presentation of DCM. Therefore, when a patient presents with sustained VT or sudden cardiac arrest, ARVC should be suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients who fulfill the diagnostic criteria for ARVC but have no family history of this disorder may have myocarditis. The potential frequency with which this might occur and the role of electroanatomic mapping in making this distinction were illustrated in a study of 31 patients with a clinical diagnosis of ARVC; on electroanatomic mapping, 20 patients had regions of low voltage electrograms and 11 did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/82\">",
"     82",
"    </a>",
"    ]. The group with abnormal electrograms had significantly higher rates of myocyte loss and fibrofatty replacement on endomyocardial biopsy, and 65 percent had a family history of ARVC. In contrast, the patients with normal electrograms had inflammatory abnormalities on biopsy specimens, and none had a family history of ARVC. The patients with normal electrograms also had better arrhythmic outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Uhl's anomaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uhl's anomaly (also called parchment right ventricle) is a rare disorder characterized by deficiency of RV myocardium. It is a separate entity from ARVC with differing pathologic features and clinical presentation (",
"    <a class=\"graphic graphic_table graphicRef66378 \" href=\"mobipreview.htm?26/1/26651\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The RV is paper-thin and almost devoid of muscle fibers.",
"     </li>",
"     <li>",
"      The finding of only a portion of the RV that is completely devoid of ventricular musculature, with apposition of endocardium and epicardium, should be classified as Uhl's anomaly rather than partial ARVC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226098\">",
"    <span class=\"h2\">",
"     Brugada syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brugada syndrome, which is manifested by a specific ECG pattern consisting of a pseudo-right bundle branch block and persistent ST segment elevation in leads V1 to V3 (",
"    <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"mobipreview.htm?8/35/8762\">",
"     waveform 3",
"    </a>",
"    ), may resemble ARVC. This was illustrated in a report of 96 Italian victims of SCD who were &le;35 years of age and had a baseline ECG available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/85\">",
"     85",
"    </a>",
"    ]. Right precordial ST segment elevation with or without right bundle branch block was present in 13 (14 percent); at autopsy, all but one had ARVC, though the typical coved Brugada Type I pattern is rare in ARVC and should suggest the possibility of two diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     RVOT tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;VT with LBBB morphology and an inferior axis may originate from the RV outflow tract in patients without structural heart disease. This idiopathic VT, which is a form of repetitive monomorphic VT, generally has a much more benign prognosis than ARVC and can be successfully treated with radiofrequency ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/86\">",
"     86",
"    </a>",
"    ]. In addition, it is not genetically determined, and thus other family members are not at risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link&amp;anchor=H13#H13\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'RVOT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to distinguish RVOT tachycardia from VT due to ARVC. A potential source of confusion is that RVOT tachycardia, like ARVC, may be associated with right ventricular outflow dilatation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following tests may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The resting ECG in sinus rhythm is typically normal in patients with RVOT tachycardia. The ECG is also normal in 40 to 50 percent of patients with ARVC at presentation, but in almost no patient after six years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       '12-lead ECG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with RVOT tachycardia have a normal SAECG when in sinus rhythm and normal imaging studies of RV size and function. Abnormalities in the SAECG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RV imaging studies are present in most patients with ARVC. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The response during electrophysiologic testing is also helpful as illustrated by the following findings in 56 patients with right ventricular tachycardia, including 41 with RVOT tachycardia and 15 with ARVC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/75\">",
"       75",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Programmed premature stimulation induced VT in all but 1 of the 15 patients with ARVC compared to only two patients with RVOT tachycardia (93 versus 3 percent).",
"     </li>",
"     <li>",
"      Fractionated diastolic electrograms recorded during VT or sinus rhythm at the VT site of origin or other RV sites were present in all but one patient with ARVC but were not seen in any patient with RVOT tachycardia.",
"     </li>",
"     <li>",
"      The induction of VTs with different QRS morphologies was seen only in ARVC (73 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     Isoproterenol",
"    </a>",
"    infusion can induce VT in patients with ARVC and may have a similar effect in RVOT tachycardia; as a result, it does not help distinguish between these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/22/32106/abstract/21,87\">",
"     21,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a clinical entity characterized by ventricular arrhythmias and a specific ventricular pathology. The incidence of ARVC is unknown, but the prevalence in the general adult population is estimated to be approximately 1 in 2000 to 1 in 5000. (See",
"      <a class=\"local\" href=\"#H1492591\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principle symptoms of ARVC are dizziness, palpitations, and syncope. Other symptoms include atypical chest pain and dyspnea. As many as 40 percent of patients with ARVC are asymptomatic. (See",
"      <a class=\"local\" href=\"#H1492605\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of ventricular arrhythmias varies with the severity of ARVC. The most common arrhythmia is monomorphic VT (sustained or nonsustained) with an LBBB pattern. Sudden cardiac death occurs in patients with ARVC and can be the first presentation of the disease. Although most sudden cardiac death in ARVC occurs during routine activity, VT and SCD can be exercise-induced. (See",
"      <a class=\"local\" href=\"#H1492612\">",
"       'Ventricular arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Left ventricular involvement is more common in patients with ARVC than initially appreciated. Many patients have similar degrees of involvement of both left and right ventricles, some have predominantly or solely RV involvement, and relatively few have predominantly LV disease. (See",
"      <a class=\"local\" href=\"#H1492647\">",
"       'Left ventricular involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ARVC should be considered in patients who present with symptomatic or asymptomatic VT of LBBB configuration, particularly in those without apparent heart disease. The diagnosis is made by applying the 2010 revised Task Force Criteria to the clinical scenario and the results of a variety of diagnostic tests (",
"      <a class=\"graphic graphic_table graphicRef58452 \" href=\"mobipreview.htm?32/6/32878\">",
"       table 1",
"      </a>",
"      ). The general approach to making the diagnosis includes a thorough history and physical examination, 12-lead electrocardiogram (ECG), and transthoracic echocardiography in all patients, with additional testing directed by the clinical presentation and the results of the initial tests. (See",
"      <a class=\"local\" href=\"#H14880771\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients in whom ARVC is being considered should have a resting 12-lead electrocardiogram (ECG) performed. As many as 40 to 50 percent of patients with ARVC have a normal ECG at presentation. However, by six years, virtually all patients with ARVC have one or more of the following ECG findings during normal sinus rhythm: prolongation of S-wave upstroke by &ge;10 msec, QRS prolongation by &ge;10 msec, new T-wave inversion in &ge;1 precordial lead, or new bundle branch block. (See",
"      <a class=\"local\" href=\"#H10\">",
"       '12-lead ECG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When feasible (ie, the technology is available to perform the test), we suggest performing a signal-averaged ECG as abnormalities in the signal-averaged electrocardiogram are frequently detected in patients with ARVC and are a minor criterion on the 2010 task force criteria. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Signal-averaged ECG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients in whom the diagnosis of ARVC is being considered should have a transthoracic echocardiogram performed. Echocardiographic findings suggestive of ARVC include enlargement of the right ventricular outflow tract with reduced RV function and areas of akinesis, dyskinesis, or aneurysm. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not routinely perform cardiovascular magnetic resonance (CMR) imaging or right ventriculography in all patients with suspected ARVC, particularly in those patients whose other test results and clinical features have led to a definite diagnosis of ARVC based on the 2010 revised task force criteria. However, in patients with suspected ARVC and non-diagnostic results of other imaging modalities, CMR should be performed, ideally in a center with expertise in the evaluation of CMR for abnormalities suggestive of ARVC. Alternatively, in patients in whom right ventricular endomyocardial biopsy is planned, right ventriculography may be performed. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cardiovascular magnetic resonance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1226485\">",
"       'Right ventriculography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrophysiological (EP) testing in ARVC is rarely indicated as part of diagnostic or prognostic evaluation. In patients with refractory ventricular arrhythmias, however, EP testing along with ablation of the arrhythmia may be performed. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Electrophysiologic testing and electroanatomic mapping'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although mutation analysis frequently identifies mutations in patients with ARVC, their clinical utility is limited because of difficulty interpreting whether they are pathogenetic, disease modifying, or normal variants. We do not recommend genetic testing in all patients with suspected ARVC but rather proceed with genetic testing in selected patients. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis for ARVC includes various forms of congenital heart disease, particularly those involving left to right shunts, other cardiomyopathies with RV involvement, Uhl's anomaly, idiopathic RV tachycardia, myocarditis, and sarcoidosis. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Differential diagnosis for ARVC'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/1\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/2\">",
"      Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2001; 38:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/3\">",
"      Sen-Chowdhry S, Lowe MD, Sporton SC, McKenna WJ. Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. Am J Med 2004; 117:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/4\">",
"      Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/5\">",
"      Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation 2006; 113:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/6\">",
"      Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation 2000; 101:E101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/7\">",
"      Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/8\">",
"      Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation 2005; 112:3823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/9\">",
"      Nava A, Bauce B, Basso C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000; 36:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/10\">",
"      Angelini A, Basso C, Nava A, Thiene G. Endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy. Am Heart J 1996; 132:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/11\">",
"      Basso C, Ronco F, Marcus F, et al. Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria. Eur Heart J 2008; 29:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/12\">",
"      Hulot JS, Jouven X, Empana JP, et al. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2004; 110:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/13\">",
"      Hermida JS, Minassian A, Jarry G, et al. Familial incidence of late ventricular potentials and electrocardiographic abnormalities in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1997; 79:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/14\">",
"      Protonotarios N, Tsatsopoulou A, Anastasakis A, et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. J Am Coll Cardiol 2001; 38:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/15\">",
"      Antoniades L, Tsatsopoulou A, Anastasakis A, et al. Arrhythmogenic right ventricular cardiomyopathy caused by deletions in plakophilin-2 and plakoglobin (Naxos disease) in families from Greece and Cyprus: genotype-phenotype relations, diagnostic features and prognosis. Eur Heart J 2006; 27:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/16\">",
"      Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 2003; 108:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/17\">",
"      Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/18\">",
"      Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988; 318:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/19\">",
"      Douglas PS, O'Toole ML, Hiller WD, Reichek N. Different effects of prolonged exercise on the right and left ventricles. J Am Coll Cardiol 1990; 15:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/20\">",
"      Kirchhof P, Fabritz L, Zwiener M, et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 2006; 114:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/21\">",
"      Haissaguerre M, Le M&eacute;tayer P, D'Ivernois C, et al. Distinctive response of arrhythmogenic right ventricular disease to high dose isoproterenol. Pacing Clin Electrophysiol 1990; 13:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/22\">",
"      Leclercq JF, Potenza S, Maison-Blanche P, et al. Determinants of spontaneous occurrence of sustained monomorphic ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol 1996; 28:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/23\">",
"      Wichter T, Hindricks G, Lerch H, et al. Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy. An analysis using 123I-meta-iodobenzylguanidine scintigraphy. Circulation 1994; 89:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/24\">",
"      Wichter T, Sch&auml;fers M, Rhodes CG, et al. Abnormalities of cardiac sympathetic innervation in arrhythmogenic right ventricular cardiomyopathy : quantitative assessment of presynaptic norepinephrine reuptake and postsynaptic beta-adrenergic receptor density with positron emission tomography. Circulation 2000; 101:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/25\">",
"      Maron BJ, Ackerman MJ, Nishimura RA, et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005; 45:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/26\">",
"      Tonet JL, Castro-Miranda R, Iwa T, et al. Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1991; 67:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/27\">",
"      Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007; 115:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/28\">",
"      Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 2005; 45:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/29\">",
"      Sen-Chowdhry S, Prasad SK, Syrris P, et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. J Am Coll Cardiol 2006; 48:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/30\">",
"      Pinamonti B, Sinagra G, Salvi A, et al. Left ventricular involvement in right ventricular dysplasia. Am Heart J 1992; 123:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/31\">",
"      Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997; 30:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/32\">",
"      Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol 2008; 52:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/33\">",
"      Manyari DE, Duff HJ, Kostuk WJ, et al. Usefulness of noninvasive studies for diagnosis of right ventricular dysplasia. Am J Cardiol 1986; 57:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/34\">",
"      Jaoude SA, Leclercq JF, Coumel P. Progressive ECG changes in arrhythmogenic right ventricular disease. Evidence for an evolving disease. Eur Heart J 1996; 17:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/35\">",
"      Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/36\">",
"      Marcus FI, Zareba W. The electrocardiogram in right ventricular cardiomyopathy/dysplasia. How can the electrocardiogram assist in understanding the pathologic and functional changes of the heart in this disease? J Electrocardiol 2009; 42:136.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/37\">",
"      Fontaine G, Umemura J, Di Donna P, et al. [Duration of QRS complexes in arrhythmogenic right ventricular dysplasia. A new non-invasive diagnostic marker]. Ann Cardiol Angeiol (Paris) 1993; 42:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/38\">",
"      Cox MG, Nelen MR, Wilde AA, et al. Activation delay and VT parameters in arrhythmogenic right ventricular dysplasia/cardiomyopathy: toward improvement of diagnostic ECG criteria. J Cardiovasc Electrophysiol 2008; 19:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/39\">",
"      Fontaine G, Frank R, Guiraudon G, et al. [Significance of intraventricular conduction disorders observed in arrhythmogenic right ventricular dysplasia]. Arch Mal Coeur Vaiss 1984; 77:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/40\">",
"      Nasir K, Bomma C, Tandri H, et al. Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity: a need to broaden diagnostic criteria. Circulation 2004; 110:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/41\">",
"      Nava A, Canciani B, Buja G, et al. Electrovectorcardiographic study of negative T waves on precordial leads in arrhythmogenic right ventricular dysplasia: relationship with right ventricular volumes. J Electrocardiol 1988; 21:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/42\">",
"      Piccini JP, Nasir K, Bomma C, et al. Electrocardiographic findings over time in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Cardiol 2005; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/43\">",
"      Quarta G, Ward D, Tom&eacute; Esteban MT, et al. Dynamic electrocardiographic changes in patients with arrhythmogenic right ventricular cardiomyopathy. Heart 2010; 96:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/44\">",
"      Leclercq JF, Coumel P. Late potentials in arrhythmogenic right ventricular dysplasia. Prevalence, diagnostic and prognostic values. Eur Heart J 1993; 14 Suppl E:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/45\">",
"      Kinoshita O, Fontaine G, Rosas F, et al. Time- and frequency-domain analyses of the signal-averaged ECG in patients with arrhythmogenic right ventricular dysplasia. Circulation 1995; 91:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/46\">",
"      Mehta D, Goldman M, David O, Gomes JA. Value of quantitative measurement of signal-averaged electrocardiographic variables in arrhythmogenic right ventricular dysplasia: correlation with echocardiographic right ventricular cavity dimensions. J Am Coll Cardiol 1996; 28:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/47\">",
"      Turrini P, Angelini A, Thiene G, et al. Late potentials and ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 1999; 83:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/48\">",
"      Blomstr&ouml;m-Lundqvist C, Hirsch I, Olsson SB, Edvardsson N. Quantitative analysis of the signal-averaged QRS in patients with arrhythmogenic right ventricular dysplasia. Eur Heart J 1988; 9:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/49\">",
"      Kamath GS, Zareba W, Delaney J, et al. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2011; 8:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/50\">",
"      Yoerger DM, Marcus F, Sherrill D, et al. Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol 2005; 45:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/51\">",
"      Scheinman MM, Crawford MH. Echocardiographic findings and the search for a gold standard in patients with arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol 2005; 45:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/52\">",
"      Boxt LM, Rozenshtein A. MR imaging of arrhythmogenic right ventricular dysplasia. Magn Reson Imaging Clin N Am 2003; 11:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/53\">",
"      Midiri M, Finazzo M, Brancato M, et al. Arrhythmogenic right ventricular dysplasia: MR features. Eur Radiol 1997; 7:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/54\">",
"      Bluemke DA, Krupinski EA, Ovitt T, et al. MR Imaging of arrhythmogenic right ventricular cardiomyopathy: morphologic findings and interobserver reliability. Cardiology 2003; 99:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/55\">",
"      Tandri H, Castillo E, Ferrari VA, et al. Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia: sensitivity, specificity, and observer variability of fat detection versus functional analysis of the right ventricle. J Am Coll Cardiol 2006; 48:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/56\">",
"      Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 2005; 112:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/57\">",
"      Kaplan SR, Gard JJ, Protonotarios N, et al. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm 2004; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/58\">",
"      Tandri H, Calkins H, Marcus FI. Controversial role of magnetic resonance imaging in the diagnosis of arrhythmogenic right ventricular dysplasia. Am J Cardiol 2003; 92:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/59\">",
"      Fogel MA, Weinberg PM, Harris M, Rhodes L. Usefulness of magnetic resonance imaging for the diagnosis of right ventricular dysplasia in children. Am J Cardiol 2006; 97:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/60\">",
"      Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation 2011; 123:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/61\">",
"      Daliento L, Rizzoli G, Thiene G, et al. Diagnostic accuracy of right ventriculography in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 1990; 66:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/62\">",
"      Daubert C, Descaves C, Foulgoc JL, et al. Critical analysis of cineangiographic criteria for diagnosis of arrhythmogenic right ventricular dysplasia. Am Heart J 1988; 115:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/63\">",
"      McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994; 71:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/64\">",
"      Le Guludec D, Slama MS, Frank R, et al. Evaluation of radionuclide angiography in diagnosis of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 1995; 26:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/65\">",
"      Mariano-Goulart D, D&eacute;chaux L, Rouzet F, et al. Diagnosis of diffuse and localized arrhythmogenic right ventricular dysplasia by gated blood-pool SPECT. J Nucl Med 2007; 48:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/66\">",
"      Bomma C, Dalal D, Tandri H, et al. Evolving role of multidetector computed tomography in evaluation of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Cardiol 2007; 100:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/67\">",
"      Boulos M, Lashevsky I, Reisner S, Gepstein L. Electroanatomic mapping of arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol 2001; 38:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/68\">",
"      Marra MP, Leoni L, Bauce B, et al. Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy: comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol 2012; 5:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/69\">",
"      Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/70\">",
"      Paul M, Stypmann J, Gerss J, et al. Safety of endomyocardial biopsy in patients with arrhythmogenic right ventricular cardiomyopathy: a study analyzing 161 diagnostic procedures. JACC Cardiovasc Interv 2011; 4:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/71\">",
"      Kitzman DW, Scholz DG, Hagen PT, et al. Age-related changes in normal human hearts during the first 10 decades of life. Part II (Maturity): A quantitative anatomic study of 765 specimens from subjects 20 to 99 years old. Mayo Clin Proc 1988; 63:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/72\">",
"      Avella A, d'Amati G, Pappalardo A, et al. Diagnostic value of endomyocardial biopsy guided by electroanatomic voltage mapping in arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Electrophysiol 2008; 19:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/73\">",
"      Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2009; 360:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/74\">",
"      Munkholm J, Christensen AH, Svendsen JH, Andersen CB. Usefulness of immunostaining for plakoglobin as a diagnostic marker of arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2012; 109:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/75\">",
"      Niroomand F, Carbucicchio C, Tondo C, et al. Electrophysiological characteristics and outcome in patients with idiopathic right ventricular arrhythmia compared with arrhythmogenic right ventricular dysplasia. Heart 2002; 87:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/76\">",
"      Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol 2002; 40:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/77\">",
"      Syrris P, Ward D, Asimaki A, et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation 2006; 113:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/78\">",
"      Protonotarios N, Anastasakis A, Antoniades L, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmosomal mutations. Eur Heart J 2011; 32:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/79\">",
"      Cox MG, van der Zwaag PA, van der Werf C, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up study. Circulation 2011; 123:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/80\">",
"      Chimenti C, Pieroni M, Maseri A, Frustaci A. Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol 2004; 43:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/81\">",
"      Vasaiwala SC, Finn C, Delpriore J, et al. Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 2009; 20:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/82\">",
"      Corrado D, Basso C, Leoni L, et al. Three-dimensional electroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2005; 111:3042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/83\">",
"      UHL HS. A previously undescribed congenital malformation of the heart: almost total absence of the myocardium of the right ventricle. Bull Johns Hopkins Hosp 1952; 91:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/84\">",
"      Gerlis LM, Schmidt-Ott SC, Ho SY, Anderson RH. Dysplastic conditions of the right ventricular myocardium: Uhl's anomaly vs arrhythmogenic right ventricular dysplasia. Br Heart J 1993; 69:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/85\">",
"      Corrado D, Basso C, Buja G, et al. Right bundle branch block, right precordial st-segment elevation, and sudden death in young people. Circulation 2001; 103:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/86\">",
"      Le Guludec D, Gauthier H, Porcher R, et al. Prognostic value of radionuclide angiography in patients with right ventricular arrhythmias. Circulation 2001; 103:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/22/32106/abstract/87\">",
"      Ritchie AH, Kerr CR, Qi A, Yeung-Lai-Wah JA. Nonsustained ventricular tachycardia arising from the right ventricular outflow tract. Am J Cardiol 1989; 64:594.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4931 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32106=[""].join("\n");
var outline_f31_22_32106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1492591\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1492598\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1492605\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1492612\">",
"      Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1492619\">",
"      - Sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1492626\">",
"      - Risk of ventricular arrhythmias during exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1492633\">",
"      Supraventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1492640\">",
"      Noncardiac manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1492647\">",
"      Left ventricular involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1492714\">",
"      - Disease patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1492721\">",
"      - Left-dominant arrhythmogenic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226212\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - 12-lead ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ECG evolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Signal-averaged ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226346\">",
"      Cardiac imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5514062\">",
"      Concerns with CMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CMR use in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1226485\">",
"      - Right ventriculography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7299579\">",
"      - Radionuclide ventriculography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7299586\">",
"      - Multidetector computed tomography (MDCT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Electrophysiologic testing and electroanatomic mapping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14880771\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14880803\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIFFERENTIAL DIAGNOSIS FOR ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cardiomyopathy with involvement of the RV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Uhl's anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226098\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RVOT tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4931\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4931|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/11/6322\" title=\"diagnostic image 1\">",
"      Echocardiogram apical 4-chamber in ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/19/5428\" title=\"diagnostic image 2\">",
"      MRI arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4931|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/42/42670\" title=\"figure 1\">",
"      Late potentials in ARVC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4931|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/6/32878\" title=\"table 1\">",
"      2010 revised criteria for diagnosis of ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/26/28077\" title=\"table 2\">",
"      Sensitivity and specificity of proposed RV imaging criteria ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/1/26651\" title=\"table 3\">",
"      Differentiation of Uhl anomaly from ARVC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4931|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?36/55/37754\" title=\"waveform 1\">",
"      12-lead ECG ventricular tachycardia in ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/5/42078\" title=\"waveform 2\">",
"      12-lead ECG epsilon wave and T wave inversions in ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?8/35/8762\" title=\"waveform 3\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/18/4391?source=related_link\">",
"      Clinical applications of the signal-averaged electrocardiogram: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36119?source=related_link\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13271?source=related_link\">",
"      General principles of asynchronous activation and preexcitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23528?source=related_link\">",
"      Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13093?source=related_link\">",
"      Technical aspects of the signal-averaged electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10872?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_22_32107="Spetzler Martin grading scale";
var content_f31_22_32107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spetzler-Martin Intracranial AVM grading scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 3 cm",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.1 to 6.0 cm",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;6 cm",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noneloquent brain area",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eloquent brain area*",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Deep venous drainage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Present",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Score = sum of all categories, with lesions graded I to V based upon total sum (eg, grade I = 1 point).",
"    <div class=\"footnotes\">",
"     * Associated with significant neurologic impairment (eg, language area, motor cortex, others).",
"    </div>",
"    <div class=\"reference\">",
"     From: Spetzler RF, Martin NA, J Neurosurg 1986; 65:476.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32107=[""].join("\n");
var outline_f31_22_32107=null;
var title_f31_22_32108="Vasculitic periph neuropathy";
var content_f31_22_32108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of vasculitic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Granulomatosis with polyangiitis (Wegener's) (GPA)",
"        </strong>",
"       </td>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Polyarteritis nodosa (PAN)",
"        </strong>",
"       </td>",
"       <td>",
"        Mononeuritis multiplex",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Churg Strauss syndrome (CSS)",
"        </strong>",
"       </td>",
"       <td>",
"        Paranasal granulomas may infiltrate cranial nerves II, VI, VII via extension in WG or CSS",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Rheumatoid arthritis",
"        </strong>",
"       </td>",
"       <td>",
"        Neuropathy seen in long standing, usually rheumatoid factor positive, cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence for vasculitis includes non-healing leg ulcers and nailfold infarcts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Sj&ouml;gren's syndrome",
"        </strong>",
"       </td>",
"       <td>",
"        May present as stocking-glove sensorimotor neuropathy, trigeminal neuropathy or ataxic large fiber neuronopathy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Systemic lupus erythematosus",
"        </strong>",
"       </td>",
"       <td>",
"        Associated with central nervous system involvement: seizures and psychiatric symptoms",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Human immunodeficiency virus",
"        </strong>",
"       </td>",
"       <td>",
"        CD4+ count &gt;200: isolated vasculitic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4+ count &lt;50: more extensive neuropathy and rapidly progressive; also consider CMV, toxoplasmosis, HZV, lymphoma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Lyme disease",
"        </strong>",
"       </td>",
"       <td>",
"        Meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facial nerve commonly involved",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Essential mixed cryoglubulinemia",
"        </strong>",
"       </td>",
"       <td>",
"        80 percent of patients have antibodies to hepatitis C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        False positive RF",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <strong>",
"         Temporal arteritis",
"        </strong>",
"       </td>",
"       <td>",
"        12 percent of patients have a peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaw claudication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated ESR, C reactive protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemic optic neuropathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CMV: cytomegalovirus; HZV: herpes zoster (varicella zoster) virus; ESR: erythrocyte sedimentation rate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32108=[""].join("\n");
var outline_f31_22_32108=null;
var title_f31_22_32109="Exercise diastolic dysfunction";
var content_f31_22_32109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PCWP increases during exercise in patients with diastolic heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During symptom-limited upright exercise, normal subjects have an increase in left ventricular end diastolic volume (LVEDV), associated with a modest increase in pulmonary capillary wedge pressure (PCWP) which remains within a normal range (red arrow). In contrast, patients with normal systolic function who have left ventricular hypertrophy, diastolic dysfunction, and a stiff, nondistensible left ventricle have a marked increase in PCWP with exercise, often to levels associated with pulmonary edema (blue arrow), but no change in LVEDV. This is consistent with exercise-induced ischemia and an exaggerated impairment of diastolic relaxation of the hypertrophied myocardium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kitzman DW, Higginbotham MB, Cobb FR, et al, J Am Coll Cardiol 1991; 17:1065.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32109=[""].join("\n");
var outline_f31_22_32109=null;
var title_f31_22_32110="Length time bias a";
var content_f31_22_32110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship between length-time bias and speed of tumor growth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 263px; background-image: url(data:image/gif;base64,R0lGODlhuAEHAeYAAP///4CAgAAAAP8QEP/w8MDAwEBAQP8wMP/Q0P9gYP+goP8gIP+AgP/g4P/AwP9AQP8AAP9wcP+QkP+wsP9QUBAQEKCgoDAwMNDQ0ODg4LCwsPDw8GBgYFBQUCAgIHBwcJCQkH9/fz8/P7+/v5+fn29vby8vL+/v7w8PD8/Pz19fX6+vr09PTx8fH4+Pj89wcICZ/9/f3wAZf38gILDA/38AAAAjrwADD1Bz/6CjsD8AAPDz/7+QkIBwcM8QEAAz/4AwMHCN/wAv748wMIBgYIBAQIAQEBBA/x8AAHB8rwAPTxAwr79wcODQ0M+AgD8wMAAcjy8AAH9QUO8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAC4AQcBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHihRoa4+fo6aQcHOru7/CUFRXx9fb3gxgCAhj4/v/nPuz7sKlAAYAIE/q6sO/CpgABFEqcSCvDvn0ZNEGkyLHjKhAXBYDQGNGjyZOhOoTsQBKly5eYNoTctyHTRpg4c0a62VKnz5+IeNosCbQoUKGYkBpd+lKpJadMo3aESomq1KsJrUrSirXrPa6QwHod606sI7Nk04pDy4it2rfc/9wqkgu3rjW6QYna3btWb1K/fAPHBfyUsODDdw1XVYy4MTS8hyA7nvxLciHLzwwaPKX5YKfOlHthHjS6WcgKFkqdTr1pdWhdpQHEXrYPQAaGnkXVvi0gN6bduF/jij1bWW0AFgSwHHU8+fJMzZULv0WccbfjBQQYIIVde2sBgrJvn16rurro7ZiDRy4gPfT1yd1jw6C5piALBvqFwq//EYYOBrC2i3np7FOABfNkpN6BCX7HYAUKZmNASAQBUEAAEX5yYYaNeFBBAAVMOKB1O5G4zUr96XZRByn+tmKL10xYwAYcCBDRhgB8YIABHOinAY8bXagBBwaYA4AGAI4kCP8IO36QAY5I8uhbAQAaMFJyHoDogY0HUWnABzVZgCEIHKJCIHn1yGibAPQE0BsAWX5QgQdHCnBBAFvKxuaEAmSggXICEVTjBwFccGFvzgXQgV4BcBDAhBYIVEGAFWhnwZ8dCMTShJX6lsqZaMKjJgC1udmljpUCMGFGIpqaY28q1XQBPSotepCpIN0poCAbgNABQxF5p+p6KkGU54T2tUKcARA16+yz0E4J7bTTSkvttRBZiy21uU3gxLbXanvtCy9ES8iF4D5LrrjpNstuuyCeay4palpEp6mYasDQsIK0+qapIvJLI0MCaODqowMRMisIIAU7XsATOsvvK8vC++z/u+1inK7G4HpGwABMWOwsxxBJMUW5F8tr8RADvMDujhurLHK8g6A7cikTgqBvwXoeGoAGeQr0c54H99YwpgBwAEIBAoGA6wcHSjeIAB4wbSOpDxeMAUgdFDDkxK6AGg4FFJSCwAAKdMLAAAi0ZSIzfNpppKkbMORBnhtMeDd4RR8kp3I1BVBpBQThuyXghCSn3dXCalDpSHjus+l6Yb99luXVTDAAAaScnTYnCSzQttvxZGABgw69I7Y3H09ACgEHJMAJARQcwHkjxTWDQaXKwXjO6t2Q/Xrssx/wwO24Yx5qKJs9pHw0miMPCuyyb4IA8WE9vzwvuQvTOikJ2G79/wARbKX99rCd34zwo4Qv/SWaf75UwCh1D0z07YuviQIQyJ8NgBjyD5E6YAEMxOtCGMjAz4iEgR9VKAAWYNKNthQvDBAJTLZZYH4cKAgLGoCA6rCfLz7mgFEogG2bkAAKK7GCEITASME4nHLKZAiL3IkDHbAIS1TypH1wam+pYdMHVAICBFkqAxW4UxIt5EM2AdGGjXoOMTDgu0uIsBcUKJ8oTji6TCRghZM4gQkEIIIxqq8VpqsRm2CICH144AMgqMmqpJOdiIiojlgDgEy2EzCQmEMg9LnaHW3kRjgmixg78sQVd6GABbyvE1zUBAHcZ4kQCKAEHWRjMDLApyoO4v9HlXJIchhiDjwO0mGC8E7A+mZK8OARlHY6hr4UecZjNGAAJQyF5yR5AP1VggT7EEEIPPmLGnngkIUoAAc0UIB56HFw4RGkKxlnqBqNZEIaoKJyCuAhJtpxmiBaZjPpYYy4Cesv3XiAFkGxy0w0AHuUmIDrABACFFxkV8PYAAUTwRs76WdQ0fymN0k1DwFUyHEiQc6WLtCPVnqznww9ho529KWeaEMCjtQl2jRxtupRIgIDcN0JBJGCEpyzGFiKBENoaIiT5mSRt7hlLj9BPU04YKOUIMADDtAAQYRABCQYgQquhozjOEIf42GES8fBpA5osjDbUGcoapoJ/vkvEh3/Rd4IRLCPFtRyFsEpikAu8tTFXDSjNIXnJVTYRUlIoH/VCCtQrrYBAFnUGjINBSUx8cW2QoJ2oovMV2th1LkaSUd3rYZUQbHXS4Svp5O4HgUeKQiYoqKwP1GJARiiJHReA6OUvUVoGXFCBiiiebShHFDqKkTnXSOv0vjiTK1hEXKSx7KxWGwhRsDbEYz0ESUQQSFIIIIUlAKxhHgnT7UhnqV4qUmJjQZoDzGTFTyCBCEohCVHEAph0Q8AN11nNpprFN75MLrPgG1LwQNM4cZABSIQQQlGit2tqoC+2QVAClgQXwFwdxAngK8LuRsCEqQguycIrgqMO4IQGFdMeoQg/5YwhM0OdOAFON0G15ZCOFoqVryFqI0LBKACAGw1BEMtMVdVYFIWAICrAIgBClDwU/8SYowlGGp2BWBP8JiAxj+OQQouCSd+/AkEksqP3hiCBL8uArXJcNNg/4EfzRAze9SYLiJCYoLfkgC+ZHzxesYoZgCMmAT0tLEgRkBiEwtgxyYgKZFXIAAXAKAFJhjynQSSEe8KAAELiIJqk8cMKS9FjecdyjTUS91LCqAFIzVpCdgsXBiXGcbbTfN/3ZxdNu9YuJwO9VBLcIEPXODUqcwaBCTwXUIvQyX49ImdmhVrs0rjAaZVRG246mKurqC9Yh7BiHsNHjazYKtqBsAJHv89ApN+ehAoaMEIWCAA49JZJNkxaCqr1oQn/Bls3BhVUSraCdyuQgIHUCp4ZCwAA9uTq5V+NBlHammTomCMmwYACd79ZlKBWr9jbAGaBWHPflRKP24SgA90sJ5Wa0PcQOHApKCraGjc0smUsHQkgjptAVgXfgPItSVa+MJkYGR+IUmqFad8iwOIHBMiaiwj1JglQZzt5Y8A6TwrIUYymrGogxaOuVHBgHR3QuaSOOFVGwG75V7CkpgEQAOBzhQx0Rq9yEAABDBuiUhW4oQ7f8RNPRpP1wGTjMNERm2ZYk6VQ9UZLockGCcBUq4rQoVL/ysFQurTHgug1sAgr1HoYxD/1GDdGEWXu90bEb7FHwKwjl+E5iYriN+WdKnBEHxUPnh4Ymg98pBo5yR06ktHAJryOd172H8a1KGynBWaB4rVBeL2SgydFHEfX94dATvUP+KEErDE5N+H7Ee/HvaY14k5yzqJ24si8bqvBKDJznTZVoJ2fKdG7H9C+AKwtPnHd8XnN0HVyJIvEsodLSOGnwjng+JPtffJ6QRRjs4HI/eZKL8k4hcJzYFY79nXfuFnQrNFCG5SIUbBLIKAXJ6FDNCXf2oVCUoXCWsTdv1HPupXWQNIUwywAAtQgIPgHEaRbSthf74wfpqAdI+wNqA3CKTXgoYAWCCYF7zQAGvzADNY/zPJBxMYYABzsiMsYoK9gH98VXqQEDowCABZRQkqFAEZaIAbqAkNkAAQkACRt33y5ykVh3hG50VGyHu184SE8Fa7xwgN8AAfWCK44AAPQD6QxQhYGBruZz1btz9z9wiwczx4SAGBNQlNKIaXEYVfdwALwACAGE3xJ4eCWApE2HV3aHoRuAjXo4eScIZpOAlQ9goEgFELUIaKYBFBlwob4H2sQB96RIqD8CTIlAkzAgpzmAkPeAleh1UDQH2LUFpMiIHIYIMDgIOWQBOKMFFf8n0Q5gjFiEercEoG+Cad0BsfAHhvNwxn84aWIHqQcFOeaAgglYOLYInc+AtTWIVJiP8IcnUIE8IBclIB/UEf9vFd7EgI7+hwp1gmqGgIVASPvjGKuaGPyWQjT1JZzDiKV+YIyuEBzAIR0KiGxHAAwYcJ1vh7cOUIykWNj/CHmUByzCcKbOiGmlAjjKEm8KdHcSMmFxEAeXNPUidDKrEPIHI1itMe28Y7bOQmfNIOdbMP6ggAIHEROhkS/JIdBHMBG+AqRmQnqxgJY5VyQngLEfAAmfCQjsBWYnd+lYiG3/gIPVdGRFUKCkCIhsgJo6QIo1IbgKRPHsAb3leWdzMs/aAzuNFDJukdbmIOVKMBIKFybpIaqyIQM7JEVJMBGxBEZxmYPwmTeUk30gESCXlUF8D/AVa2lLVwUxQ5epHIeI+YCGuTjYhgkZkAdZn0OpyomZMAit83luBhTqfZcDORR4MQMHWER3gkLCfVNxADHogmKBdBEMpYR6ZCgiyZC6+YUwvQkJagf7yngohAOwcwjgDgjVVldsGUdqLAi74YChGTCGoCEu1QI/rBKuvBnYKQEXdTEwnkmv4Ik8kRROMxm2/CQzUinnRSABhgAbghn/TZG8qomKaiQ6mYCazVYZA5C02JCcbJdL0EiKd3iIPAmZbAhgswT/WEkp8QjlZICtlRAUc5LKdmlFJXKZtlm3YCArujHfuCJTJSIxewNFdTIz4olKzJnhvaDrvjAQwhmC0q/xMGmUQnyUQGaZSuYkw+OFgT8qFTFpySIJlFqKDNWZmIwD/E+QjOeQlTGHIARlImlYgN2oYRMJnWKTWGYHU/QwiBCRH90CsBUKZW151OkxpmmkA0YzAWYB8QVFm7ImVzGp5Oox8GBEHkiZBhEhEK5DRxZCEBJHV+Ch2HhaUKOULDmaS0aIvJ2VdupYvFyQBVKD2sJ1RbWVVeqaSYMKLywT3MKAwfokcWFqCwMKCO9YWLgI2QSIlQulNX2Qgq9ACTWXxeJUmh2QqKcwFx2gs4MgxJyTNbyAtI6ojjaFWO4H+TinOT4AALcACzKoU3OK2joEYRpRNNlZHmw6hPOgmz6P8IJ2StOodVO8WchYAAaJiNmEGh6OoJ+gCTyTSQqGCKIbSIm6CqX3eZiiCpjEB6XKoIluqs6PdFX7kIkrGRWzoLQ0pdiqoK8hgORtoIx0oJULkIj0Wxtaig17OclVqLAWsIeNGVheipopAcEOKwo5ihhfAkKZKJqViPUteK58JS/5gP9PoME7sIBNCo0pdhBsqqhoB3FAgBBAsJJ/QASegWm+iBoqkKwLJlHsImDaRtAsFGK+kdRVkB2fEr25GUNjmSpDK1POMvQSkIiDaqicEL+mp+TysI1POEkBd6vfSuguAAhGitUAgJ1Km3qRCvGWqU2dEOcwIndKKDHbABfrL/AXOyARsANbN2KQnFQ2pJJ3V5l/xygAWAGyLoKriAAbjhAZ21crtQsZJQoIrQUY2QoJAwsJZwhgPwrY8gFu6qCwIRqoQgm18rEpt6k2xyOluJjAl3ESGymrqbuf/SG32TC7PCtQxIurnQs7KLh0yKCGczvYaAi4/QsXY7SUZrshrICBuZACE7C1uSkd6hDzJ6ERmSAU8CApXCn0eCjMmhJI4LnrbxonzEN8lbAIrZM7lQMAZwIQ87u/hqCW0bCaibCMrKCNa3gkZrCWtDvtDbpAcQcuCbCqCoa5MyD/rBEG4HlOeYNHaCG0R1kxcgIyP6ofqLvLfSG0g0KQaSCxXA/yRAg7u2dgumGwnI2aS4ZIYHur11+3ULUJ0VTAhN24nAkByKGgBOU6gkHGsGE6YdlC0K5BtTbCRjeqaywRpzCmE4giOBir/UERJamMO10LMWeIRCewj+qgjMCsFHS7Hr6lrJdYNrzAtCEwmMa1u0MCkMkTq5sK12bAsRUDaU0MNu7LGLUIFCzMiVuHdznMMU6re0gE2RoEDcyqsQscmPccD7tzmUEK6KQHoZ+IJynFOW6oQeNr7lywvxi3IrwbIGbAvfA678GoMH4HvWuwAJgKBD7Ie9+Mq2VwQXfLDGgFk/sVk7kkSbisaywD5Jl8vp6suM8FbYewhrM8lwHK2WjP+HCjADM/C2u+BGTFE1C8gOBUw6tIA/knCxh3BzPIuEr0rM8VzHHNiLPHDGxBCHOQGTdcUs64ywoMx7ARh6QKsIE5i6xiOGBLA22awIU4rMnFDJzuDPOJG2UdSAsSDNCP20YHeLVEqxRWzPhfDQIPsJDrB3FJwZO4gTQ7kjI5FAHP0K7vxX1VsIdbcI5fqvIBXRDNyLdqvQbUjRF/3SjrGzt4zTkLrIi9d09gyttnqkeesJBNBISqx9SP0SRbnVlxPNiMzUTLdT6jd2TPfTVRm7Vo3Hp8XPw4DRMLE3PojD4BcLN/0IiuyCDS2wCY0IUm3SLkiFRo0JFk3QywDXL1H/MODxAXTdrZp40I6Q1zaX08oZeQSA1hSY0pyw0prNzjWoAN+I2C7RG3diV8XKCh4d2W08CGfzf4TAuq1a0hJYxN98i0WtoDubCAhQdBBAAaHt1SjRmAmHgEe8CnfdCKR8CPzHwKvm02p9jfgsSVhNzqRR0P0XOr6cx4Yg2jDBMIW8CkstrtQsCAv9eA+sCH/Nt5I8O2wNza/QAApAARDgckm4dkvxjEtSpNZtCKlNWuMNACyYCO8Eq8mJ2by3yhlsCIVte/ttvbxNAQoA2CEWijC9uY7pJajKCcctiX1tCPSMCHHcC5zd0sWdChOA3Qmg3ZCgzDnhm/vQ2IuaCuHN/wjw7IJhmAg93Qu3/d2mAN/yTd+bEMtAoUAGCRGDetqnkEUfzbNB/Hg7FbAkZ10pAFSwQN3PK1insNsH0NsSIOGOAHHclxE0neGZMAFoZaBNPQjvlOZLaAhZOUYh4GnASlQRW92kcOILUIsTkOCLAOY+wSN/wg9kfgkkRL1pbnO1mAhkmAieqV8rIOdmJgIsYF0xEALW1WAxYGYI9lOTbmIOFlSEEGDCFOf0ZGAIFlw9ghwm2cWGqkza8U1IEoQiu4E+Pt8RMNSPYE1LIcA0CuNYlgq69a85DV4dDgBzmwhnJ0wM1m+SRm3WdW8AMFQusGwu9mMhMEYHxmP9Ngg4pv9jpNJjAGDts5IBfrR2gGQ3+0ujVIPlnKDlXO7lVvTMstZMjjLQnm0KWsZ4q93AhiBZTxih+xBU/Qbt1B7tAnAC9yYCdGZgaKdjlvRxg8BmJSbnAhBn+kVkR2YRcIQbFxCfdL4e+zLrmoDnes7nVSHvOtHxIkEkg04JjIaxqy2Vh6C9yVk2lmdSIkDxoBZmwGRSwDRUJ0BpLhTnmUYIcq7za9ZveESjX9KY2oaMtcnuORXfA3AAt/4KITmCSYREoxuNpRDsMK9+b1wI563cA1A2mapjcu7slmRnyyYALrYPFj9jQeUC2JVslcdszuZv0CZtKtEPY2VA+1BKymEOUS//8u+Mbu8uC9wdGLiV7yJtd5PEqhOZCNg3T7jaaf12AtSGAlEHANRmZ6FPUtT2aC2E94Kwb2TUb2FGUmPkAayhD/Qg+63JJhMjj2gxARGQ5ylu8p8B3B3hyQze4z+M3LncdJQVXnB89r7/S7zl7GZCIle9d1aP66Jg3z9BNVDM46EA9kFtd2uOCJlp+apHxw8qizuOtvtQc9Gv24pPAV3eCywOE0giOYsZ46EA+bpd7EoICAMJAISFAAQPBwiGjBMDFASMkgANFAMMk5mTBAoLCwqRmqKjpJkBAZITEQuCE6GlsLGyhgICs7e4ubq7uhkBHgIVHxm8hKfFpA0DDqUI/wMKms4SkwgLCa+MBJYTpAQREBHYswQMAw/QyOnGqIcKlgcRi+rzpLX09/j5uAUctQXFx/QRehCh2TNNCiCgYyQBwrRMjiCRkvCoga4GCSBQYCZQVwEeEg5olGCxo8AMwUyqXJlvAwgMANnpk7BA3KYDgzIpWCaJQIIB8npuIzVhwQGOuBxQgJCgJMtYqlglcPVUnwYBBqpq3VpqQwGvG9IFzKcMqSYCODX9DFoIwYEHNglFjGvIwYNPuiY8uESXKyFO7+L5zdfvw+DDfi34u2AY2Vh8BLulzZTggNNCjjBtGioKI99cnT715Yog5MjLiNVtqCBAQ+rXLD1c8FAgQP9WxzLv0RxNqHJctAdsRhjAbZKjcKLICeKdSfk52HJXtWIO/VYAAR6qa88noICBAh9uxyTLc5Tvm9eyHbC8eYHZSTsfsI3leSNswAPgzTdU4N/2WxjUYsF/BKbjAQcXBCCMWLnNE5l5wVEjiCQOTDgJRchp4oAn78HiQEZNvVaaSBSQRMpjBYqygYICcJDii7pcVUsFxOCGT0i87bQfANJIQtFChjRwV4dB7gUkVHsxQJ1JUQkCSiwopuiABEh1wFotHIQF45azYBAACDXaSI8yOxqiI3wKZUPBAjti2JdPECh5S2hPDobfAhEQeWKD2k1ZGQQ4IVWLABcMyOWhsFj/4BoABRg6Hj0PaIYQUPARx0g1EjEipHtnlROiLM4dqdWIEDxgoi5RIuanSDhROUkG/iEqKykGCDCgbQzSw8ABozgjKgDDzbfTQwwNkCF8Czygpyb1LatSkwnUyUuqWq0KaAKuzqotLwawdop40/K5CwIQlEmIr5NUxpZP5RXJaSZ2LVBcLB8yhRpLd+ZJD7UmWduqs9sGHIsBpwQD7i784nKApBKKikiEhTSwnk1uZlLJAMTCotdnWjUgwQOlnnpPwvMQ4AADFLCKLcACtzwwKoodjKq4ueya3GSGoJWpXMZKsqme3oCzJCF0Dq2OA9JFazQuJO9iMsoLXJuty1Qj/2OBfxo4Gm465JqLVk6GVAM2IeXMW0jFk5RDwb2dmvOrQJz8hCfL6jQN6slrSk131XyX8hUG/fUHk5jFLHwWzm1dknMi8/0MUbJ7U/KTfSx5DLKpbHdkd3J4R/1v36Cr012tg8qcy+aj2KwWxIXsBKQz6RmCNiPxvj1JvZ+qhLRU0mqFeiFP5/156MTXnYEFp5yiNcI0y9L16uLsZHZDRzru809ylrJx9h3FPcDcqdkdfNQEKRB58ejfAus8v2diOGWsExIs8GvONzvwDDC1ZNEmWR5y5lyh1vhKFQEFmCt9CNQFCLqDAdZcQEuP0oXqKjWfBLCpLW/BhpCOUqkHAP8wZ+V4Tkd256SlrWQsAyzfARPIQl10oAMA6McFBACCXOnieRTMWcpesROGAYAiPiTEht41imbBTQFy01eBAkAEqBHQgC2MYj4IBgBgbCA8NszF+yRxJuBlsBDDMQsCGCeJMR6EFLj7IC/8hzkCja8GMyjgCqVIx128ECUXAACuCHeLCV7qjOfCmcTYU4j8BZFd3NPE9kzooaT17j6deyIC2lfHSsZCMbVAxQVcxEfnlathYeuZEEUZSEVkw1NqBAD/6OE98FUnhXJkBCUtSctR9MMAXrFVFmexxVACyRELKQeQDMlFyI1COQew3UU+9j/owBKKmphlLaepif6wr3n/ovCjF8fmur+kLChuMWVdDiCvIv5EWfQgodJe04AJMGAvkoQSNqlJT1hI0xTzlNB+vmaIcsgDU68gZpAskbHbgSiVsWhlBMzml3a+cwDx3Ees6knRWdxzEpQ8QEEPgbi1EM0hGBTnX75xLOMkCaGl8J9G59gRh8JThRWN6VYuKon2vTNdEPNJhNgVFIEWsiKiCI0EGEkh6VDgkU9xKURhKtOmzjSfsvidM+51Ho5GyC1wKSVbioLO5pQjmcVQKEMr586XxtKpaA0gVOWZ0AVstKoSy8lxChmnutzFdp7p6jJBttKOlXUA5mDABFCa1sLmg6ayXCuwHsBFSvHIQsMp/044g+KZRIbtoOOKwAEegVSBKDWwg/WLNQ1rWMQaYnMVQk0XKwSNh5XEp+TQH7xOmgsCTCCJY9XHZyMV2vAplrS0NG0hxOdWRnQxIdCoUHom2zpzZE6ojPTYUvrav7+ClrBPES5w0addPUI1Aoz1JSEosogfkU1xQuTQJhhgFGVGQ7OcJSp9rMtb7Kp1u2ntbtNSK14ArEUbF8RqScz4qwYMR6+wsC1uPUtfwdoXMd3FL+j0O08CFDdxrfUNQJXzEETaBAGYpY8EpisBluJitw4OWIQlzDcKjwK8OUsLcDihuA158BCopBBtYYEA+B5VvtFocG9dtmIWU83FGhqAU//4+TV2OcAbGCNasvYD3VIo+HsLpQcCFABeCFyXeEU2csuQvIkLc3QQsBukyZJlEQeQk6HkaG9KRwyoEqtjy13+MgLDLGYV/3ZPmoBxITSMseNAeRpCinKQDsyyHm/2x8jAM8j0HEU+91lbZKadkgcdHOSWzcYNCFoiQWyv5NwWy7mdhaS9XN9aWvrSsso08MzsG+klAmlRVttl7HIJAEq3zibOxKqTleJ6vhrWh5K1/MKrSqD8pBNTYXMnEFxlavi4s83gMsgWQAEGPNmpx0b2lpTN32aDGB5xGg6V7oo/Offk1HhKda+0DQFuexvIlf6zuMGsb1GgyMIP2Ymbue3/VshhL2KM9hmdFxbsc9Hb3t+WcLj3nSJZR4AC58LYeoyCvfzFjtS5O5dmNaIAwg672xHv88QpTqBMVygSzhgOq5N14JLwmgFLhvdUePxwlOM7pitn+XbIbGFuxByi9X6EUThS7V8znBQnv7fQT9vvqRO56vgsBAUwjhYvQ+Dr3ztInMHKo5Ef9YNRT7nVqb52OiLZEQTo+tfBzhcDm4MZt/XEzuElgS5D/OdGDnrbfXvNQxBH7nO3F8gd4A5AMWBH1vr74O2J9cnHuvI1RcXW/Zv4UiGA1xT409lpJ4E/Sd7yshgt6tNHYbhnZO7y6gTYrWG2yPt89bgHN9Z9EQBH/wWgB8R5vZcZwN6vPx0Atpd67pev+1woRjaECksAanDUuYceomf3VwKUz/zuN1992AnLAl0UACM0JPEJiEDpVTY177sfrbNcYGM2kJIeAKHzEB3e+/Gh+v2Pud/XIRP2MH3GtzL+ZxKCd4D50H+xcBUwBAABkkcBoAMzkDwWeIEYmIEauIEc2IEe+IEgGIIiOIIkSIIGQDAlmIIbOFEK+BQzFAAaMEOuURsqWIM2eIM4mIM6uIM8+IEs2IIrsQEc4ECLAoRGeIRImIRKuISMkAM5wIRQSHGrsQQ7EIVWeGkdIAA2gANX2IUSJiM3IAQ04IVkWFirMShKcARVWIZsGP9TWTgoWsiFbTiH1KQBNyADeIiHUPADY0iHflhJGpAEMDCIhBgEffiHiJiIiriIjNiIjviIkBiJkjiJlFiJlngPvLc8jqgBp1CE92AAjXGJ6fB8M/RAulArS7gBM2QAL3hYmiiKuYASHiB+LQIAyKMBLzQ4IHCCw2CLJ1hDBQAMAfCDCngdjYEBrpEB4dEBGuALBZA1AJABHGAAHDA4FvCLxmABu5glejQgtaEB07goGPBCpxAmsDgJ8kcI9FcBAFAr0JcdhREAFwAeAvABWQgCFsAaBvCKB4hJBAMTq1EBATCNBRAMWJEBFZAgFcCOH1CP9wgAtTAbtYgVemQwtZD/AQgpkLVCjOdoDAIggLaAigAwQwCQhR0wjABQAR5QMFkhkkrIIgKyQIYCK/VICONnG92hkiwJkVlBf1lBkdfxDw1ZG7oUlB2ZCQ5ICBHYjrbAlAAghDPUGtiRPAPikkioJRjQkATTHYVQkOxwHRyQPLJIlTxJCBQJlFwZlEZplEc5CS8Yg63hlE7JASBAjyCQhcOIPEypAYNzhLZxNf0QABHYKB3glUpJKBoAHuP4kY2CChRZlmj5D0HpgN7BlW0pCUJIhIQgkqjIIguSmcGAChrAGjWEhJU5lYQAl4z5kYWgmheQAaApkGUJmVmxllzZkAlpmZe5m35Rl3AJQbwZ/5xPAQyIKZzGeZzImZzKuZzM2ZzO+ZzQGZ3SOZ3UWZ3WeZ3YmZ3auX+AEzgFgAHX2JfbCZ2kUzq1YY5GhhUoOZ4JBDj9wAHfeZ62CIOgKIQGMDgF0AH1KVNwqJ4cmZw02IMCWoMcGYAe+Q/uCAwV4I4A4IAN+YCEEKADOqE92J9wSDD/GZwSSqEc6oEFypoViaC2YJioiJe/0JQR2qEqioMWWjrryZ59Y6Ah6pQkGpIfmTz8eaEvCqOhI6NGiYo1CgALVJjgyJ8YyqMJ5KNcCaSsKZInKgAQiqRSOqVUWqVWeqVYmqVauqVc2qVe+qVgGqZiOqZkWqZmeqZomqZSFAEIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rapidly growing tumors come to medical attention before screening is performed, whereas more slowly growing tumors allow time for detection.",
"    <div class=\"footnotes\">",
"     D: diagnosis after symptoms; S: detection after screening.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher RF, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32110=[""].join("\n");
var outline_f31_22_32110=null;
var title_f31_22_32111="Large vestibular aqueduct";
var content_f31_22_32111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patent vestibular aqueduct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This child with an enlarged vestibular aqueduct (*) developed progressive sensory-neural hearing loss after mild head trauma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_22_32111=[""].join("\n");
var outline_f31_22_32111=null;
